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PROPOSITIONS
1. Physiologically based kinetic (PBK) modelling facilitates read-across from
compounds for which in vivo toxicity studies on tumor formation are available to
compounds for which these data are unavailable.
(this thesis)
2. Consumption of parsley and dill based teas or plant food supplements (PFS) is of
concern if consumed for longer periods of time.
(this thesis)
3. The use of the retrospective data on specific disease outbreaks in addition to
forecasting models will help preventing a new outbreak.
4. The use of wireless devices to collect the lost energy of surrounding waves and
converting it into electricity will provide a novel alternative source of energy.
5. Smart phones affect the creativity of children.
6. When traveling the same roads, turtles acquire more knowledge about road quality
than rabbits.
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Short description and aim of the thesis
Apiol and myristicin are two compounds that belong to the group of alkenylbenzenes found
in several herbs and spices including for example parsley, dill, and nutmeg (Semenov et al.,
2007). The presence of apiol in parsley gives this herb its characteristics odor (Shamina and
Parthasarathy, 2008). Alkenylbenzenes also occur in the essential oils of these herbs and
spices.
Alkenylbenzenes containing herbs and spices as well as their essential oils are used as food
flavoring agents in many food types such as sauces, soups, stuffing, rissoles, minces, and
many others. In addition, parsley derived preparations are also sprinkled over vegetables or
salads.  Apiol and myristicin are alkenylbenzenes with a molecular structure that resembles
that of other alkenylbenzenes including safrole, methyleugenol and estragole (Figure 1).
Figure 1: Structures of alkenylbenzenes.
Methyleugenol, estragole and safrole were shown to induce liver tumors at high dose levels
in rodents via a mode of action that includes formation of DNA adducts (Boberg et al.,
1986, Boberg et al., 1983, Phillips et al., 1984, Randerath et al., 1984, Wiseman et al.,
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1985, Wislocki et al., 1976, Miller et al., 1983). For methyleugenol, formation of DNA
adducts was also detected in 29 out of 30 human liver samples at levels that amounted for
the median to maximum levels from 13 to 37 adducts per 108 nucleosides respectively
(Herrmann et al., 2013), indicating that at current levels of intake DNA adducts in human
liver can actually be detected. Given that DNA adducts are generally considered a marker of
exposure rather than of risk the actual risk that the presence of these DNA adducts would
pose to human health remains to be established. This also holds for exposure to other
alkenylbenzenes including apiol and myristicin.
The currently preferred risk assessment approach used to assess the risk of exposure to
compounds that are both genotoxic and carcinogenic is the so-called margin of exposure
(MOE) approach (EFSA, 2005). The MOE is calculated as the ratio between a dose level
derived from human epidemiological data or from in vivo carcinogenicity data obtained in
experimental animals and the estimated daily intake (EDI). The preferred point of departure
derived from the in vivo data to calculate the MOE is the lower confidence of the dose level
that results in 10% extra cancer incidence above background levels the so-called BMDL10
(O'Brien et al., 2006, EFSA, 2005). For some alkenylbenzenes, including estragole,
methyleugenol and safrole, tumor data from rodent bioassays enabling definition of a
BMDL10 are available, while for the two related alkenylbenzenes of the present thesis, apiol
and myristicin, such data do not exist.
The aim of the present PhD project was to perform a mode of action based risk assessment
of exposure to low doses of apiol and myristicin by using physiologically based kinetic
(PBK) modelling based read-across from other alkenylbenzenes and to use the results
obtained for risk assessment of consumption of plant food supplements (PFS) and other
botanical products containing parsley and dill.
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Apiol and myristicin; chemical and physical properties.
Apiol (C12H14O4) and myristicin (C11H12O3) are alkenylbenzenes with a molecular weight of
222.23 g/mol and 192.21 g/mol respectively. They are soluble in most organic solvents like
ethanol, ethyl ether, and chloroform and relatively insoluble in water. Apiol has a boiling
point of 294 °C and myristicin has a boiling point of 173 °C (NTP, 2000), which indicates
that these two molecules even though they are hydrophobic are not real volatiles.
Apiol, myristicin and structurally related alkenylbenzenes.
Alkenylbenzene compounds have common structural features consisting of an allylbenzene
nucleus containing one or more alkoxy ring substituents. Safrole, myristicin and apiol contain
a 3,4-methylenedioxy substituent with one additional methoxy substituent in case of
myristicin and two in case of apiol (Figure 1). Estragole, methyleugenol and elemicin contain
only methoxy substituents with estragole containing one, methyleugenol two and elemicin
three of these moieties (Figure 1). Because these compounds have similar structures it can be
foreseen that they may share similar metabolism, mode of action and biological effects
(WHO, 2009, Van den Berg et al., 2012). This similarity provides the basis for the mode of
action based read-across and risk assessments of the present thesis.
Human exposure to apiol and myristicin.
As already stated above, alkenylbenzenes can be found in many herbs and spices such as
anise, basil, fennel, nutmeg, dill, parsley and tarragon (National Toxicoloy Program, 1999,
WHO, 2009, Kreydiyyeh and Usta, 2002, Simon and Quinn, 1988, Stavri and Gibbons,
2005). Human exposure to apiol and myristicin mainly occurs through the consumption of
different forms of parsley and dill preparations such as teas, spices and/or PFS. The EDI of
safrole, estragole, methyleugenol, and myristicin (Gavin et al., 2007) due to daily
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consumption of spice has been estimated to be within the range of 400-600 ug/person per day
(Gavin et al., 2007). The maximum dietary intake for myristicin and safrole based on EU
import data for nutmeg and mace in the USA is 684 and 879 μg/person/day respectively
(Gavin et al., 2007). For methyleugenol the average daily human intake from all sources,
including use as a food flavor, has been estimated to be 217 µg/kg bw/day for a 60 kg person
(SCF, 2001a) and for estragole this daily human intake from all sources has been estimated
to be 72 µg/kg bw/day for a 60 kg person (SCF, 2001b). Since these estimates have been
reported by the SCF, the use of methyleugenol and estragole as pure substance in foodstuff
has been prohibited in the EU from September 2008 onwards (European Commission (EC),
2008) and as a consequence these EDIs from all sources will at present likely be lower.
In general, human exposure to apiol is considered as the lowest among the alkenylbenzenes.
In the USA, the mean intake of apiol from spice and spice oils per capita is estimated to
amount to 2.84 ug/person/day while for other alkenylbenzenes, including myristicin, exposure
may be at least 10 times higher (Gavin et al., 2007). Given that several of the related
alkenylbenzenes cause liver carcinogenicity by a genotoxic mode of action, the possible risks
associated with exposure may need further investigation in line with the WHO
recommendation stating that: “Further research is needed to assess the potential risk to human
health from low-level dietary exposure to alkoxy-substituted allylbenzenes present in foods
and essential oils and used as flavoring agents”. (WHO, 2009).
Absorption, distribution, metabolism, and excretion of alkenylbenzenes.
Following exposure, alkenylbenzenes are rapidly absorbed, metabolized, and excreted (Lee et
al., 1998, Benedetti et al., 1977, Kamienski and Casida, 1970, WHO, 2009). In human,
safrole, estragole or methyleugenol, are completely absorbed, metabolized and eliminated
within 24 h (WHO, 2009).
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In general, in rodents the distribution and metabolism of alkenylbenzenes follow a dose-
dependent trend in which increasing the dose level will lead to an increase in the plasma
concentration of the alkenylbenzenes and their metabolites (Benedetti et al., 1977).
In a study performed by the National Toxicology Program (NTP, 2000), different groups of
male and female mice were given 25, 50 or 75 mg/kg bw of methyleugenol by gavage. AUCs
were 4.91–48.4 μg/ml per minute for males and 3.27–60.5 μg/ml per minute for females. In
the same study groups of rat that were given 37, 75 or 150 mg/kg bw of methyleugenol by
gavage showed AUC values amounting to 33.50–459.5 μg/ml per minute for males and 27–
307.9 μg/ml per minute for females. Based on those results it was concluded that
methyleugenol was eliminated more rapidly in mice than in rats (NTP, 2000).
The metabolic pathways of methoxy-substituted alkenylbenzenes and methylenedioxy-
substituted alkenylbenzenes involve three processes (O-demethyl(en)ation, epoxidation and 1′-
hydroxylation of the alkene side chain) (Figure 2) (WHO, 2009). O-demethyl(en)ation is
catalysed by liver cytochrome P450 enzymes and involves oxidation and cleavage of a
methoxy substituent or of the methylenedioxy substituent in an O-dealkylation reaction. This
is considered the predominant pathway, yielding polar hydroxy- or dihydroxyallylbenzene
metabolites that are readily excreted either free or as sulfate or glucuronic acid conjugates. In
rodents, at high dose levels O-demethyl(en)ation becomes saturated, and 1ʹ-hydroxylation and
epoxidation of the allyl side-chain (Figure 2) compete to a larger extent. 1ʹ-
Hydroxyalkenylbenzene metabolites can subsequently be conjugated with glucuronic acid or
sulfate groups (Benedetti et al., 1977, Miller et al., 1983, Drinkwater et al., 1976). The sulfate
conjugate of the 1ʹ-hydroxyalkenylbenzenes is unstable, leading to formation of a putative
carbocation that reacts with cellular macromolecules including DNA (Drinkwater et al., 1976,
Miller et al., 1983, Swanson et al., 1981, Gardner et al., 1996, Smith et al., 2002). The relative
importance of the above three biotransformation processes is dose dependent, in which O-
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demethyl(en)ation is dominant at all concentrations (Anthony et al., 1987, Sangster et al.,
1987, Beyer et al., 2006), while the relative percentage of epoxide and 1′-hydroxy formation
increases at higher doses (Anthony et al., 1987, Zangouras et al., 1981). For example, in a
study with mice and rats given doses of 0.05, 5, 50, 500, and 1000 mg/kg bw, the percentage
of formation of the 1ʹ-hydroxy metabolite amounted to 1.3, 2.1, 5.2, 7.8, and 9.4%,
respectively (Anthony et al., 1987, Zangouras et al., 1981). In line with this the results of
estragole bioactivation and detoxification in male rat obtained using PBK models showed the
same shifting (Punt et al., 2008).   However, the dose levels at which this metabolic switch
may occur may be higher than the dose levels causing carcinogenicity and are higher than
estimated daily intake levels (Rietjens et al., 2014).
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Figure 2: Metabolic pathways of apiol with the bioactivation route highlighted with solid
arrows.
Alkenylbenzenes toxicity and carcinogenicity.
The metabolic pathways of the alkenylbenzenes described above reveal the ability of these
compounds to form DNA adducts, and this has been confirmed in experimental studies and is
considered an important part of the mode of action underlying the formation of liver tumors
(Borchert et al., 1973, Drinkwater et al., 1976, Miller et al., 1983, Phillips et al., 1984,
Wiseman et al., 1985, Wiseman et al., 1987). Randerath et al. 1984, using 32P-postlabeling
indicated that estragole, safrole, methyleugenol, myristicin, elemicin, and apiol can produce
DNA adducts in adult mouse liver. Estragole, methyleugenol and safrole showed the highest
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activity of the alkenylbenzenes tested (Randerath et al., 1984). Similar results were shown by
Phillips et al. 1984, who reported that in neonatal mice the ability to form DNA adducts
decreased as follows: methyleugenol > estragole > safrole > myristicin > apiol (Phillips et al.,
1984). Zhou et al. used cultured human HepG2 cells to study the DNA adduct formation of
alkenylbenzenes and concluded that at low concentration (50 μmol/l), high level of DNA
adduct formation by estragole, methyleugenol and safrole can be detected while for myristicin
at a concentration of 450 μmol/l the level of adduct formation was increased and as high as
that of safrole and methyleugenol (Zhou et al., 2007).
In addition to studies reporting DNA adduct formation several studies reported formation of
liver tumors upon exposure to alkenylbenzenes.
Borchert et al.  reported that, upon administration of safrole at a dose of 1265 mg/kg bw per
day, liver tumors were induced in 65% of the males and 100% of the females (Borchert et al.,
1973). Miller et al. reported a study in mice dosed with 370 mg safrole / kg bw twice a week
by gavage up to 35 days, in which 62 % of the males and 12% of females developed
hepatomas (Miller et al., 1983). Within the same study groups of 50 male and females’ CD-1
mice were injected intraperitoneally with safrole, estragole, methyleugenol, elemicin,
myristicin, and apiol. The results showed increased incidences of hepatocellular carcinoma
especially with safrole, estragole and methyleugenol. Together these studies indicate that the
related alkenylbenzenes are compounds that are genotoxic and carcinogenic, while the may
differ in relative potency.
Approaches for risk assessment.
Since alkenylbenzenes are considered as compounds that are both genotoxic and carcinogenic
(Borchert et al., 1973, Miller et al., 1983, Phillips et al., 1984, Wislocki et al., 1977), the
Chapter 1
16
suitable approach for risk assessment of these compounds is the MOE approach (EFSA, 2005,
O'Brien et al., 2006). As already indicated above, the MOE is the dimensionless ratio between
a reference point based on epidemiologic data or experimental data on tumor incidence which
is divided by the EDI in humans (Barlow et al., 2006, EFSA, 2005). The reference point used
to calculate the MOE is the BMDL10. When using an MOE value based on a BMDL10 value
obtained from animal data, a value of 10000 was suggested to be the value based on which to
make the risk management decision (i.e an MOE value lower than 10000 would be of concern
for human health and is considered as a priority for risk management) (EFSA, 2005).  The
value of 10000 was considered to include all possible uncertainties that may be involved and
affect the risk assessment. The value of 10000 includes a factor of 100 for kinetic and
dynamic differences between species and within humans, a factor of 10 that presents the
variability in cell cycle control and DNA repair within humans, and a factor of 10 that takes
into account that the BMDL10 is not a no effect level but represents a 10% Bench Mark
Response (BMR).  Besides the BMDL10, human exposure data reflected by the EDIs for the
relevant population groups are needed to calculate the MOE value (EFSA, 2005). The MOE is
a useful approach to compare the possible human risk from exposure to different carcinogenic
compounds, but it requires that a BMDL10 value and thus carcinogenicity data for the
compound under consideration are available. However, this may not always be the case. For
myristicin and apiol, the model compounds of the present thesis, such data that enable
definition of a BMDL10 and calculation of MOE values are not available. In the present thesis,
we tested whether in such situations a mode of action based approach using physiologically
based kinetic (PBK) modelling and read-across from compounds for which such data are
available can be applied. In order to apply such a read-across approach for a group of
compounds, the chemical and physical properties of these compounds should be defined and
similar, enabling definition the structural-activity relationships (SARs) among these
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compounds enabling to read-across from the compounds with available in vivo data to those
with no data (EPA 2005). In the present thesis, the relevant relationships that enabled the
read-across were defined using so-called PBK modelling. In the next section, some
background information on this PBK modelling and how it could be used to define BMDL10
values for compounds for which carcinogenicity data are lacking is presented.
PBK modelling
PBK models are models based on different parameters including physiological parameters,
physico-chemical parameters, and metabolic parameters in order to build up mathematical
equations that describe the kinetic processes of the compound of interest in the organ and
species of interest. The models include absorption, distribution, metabolism and excretion
(ADME) (Krewski et al., 1994, Chiu et al., 2007, Rietjens et al., 2011). The use of PBK
models allows the study of possible time- and dose-dependent variations in metabolism,
predicting the concentrations of the chemical and its metabolites within tissues and blood
(Rietjens et al., 2011), and the study of interspecies differences through use of parameters of
the species of interest (Andersen and Krishnan, 1994). Development of PBK models involves
several steps including i) definition of the conceptual model, ii) translation into a
mathematical model, iii) setting parameter values, iv) solving the model equations, v) model
evaluation and vi) making predictions. Definition of the conceptual model means describing
the structure of the model including organs and tissues that are of importance for the kinetic
processes and the toxicity of the compound of interest. A conceptual model will include
separate tissue compartments for the tissues that are relevant for the kinetics and toxicity of
the compound and the remaining organs and tissues can be pooled in compartments
representing slowly or richly perfused tissues. If the compound is lipophilic the fat tissue can
be represented by a separate compartment. All compartments are mutually connected through
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the systemic circulation. Following that, describing the kinetic processes of the compound of
interest will be done through definition of the mathematical equations for each compartment.
In a subsequent step the relevant parameters, including physiological, anatomical, physico-
chemical and kinetic values need to be defined for each equation. This can be done based on
available literature data, computer models, and/or using in vitro or in vivo experiments. Once
the mathematical model is established and the relevant parameters have been defined, the
equations can be solved using specific software in order to obtain concentrations of the
compound of interest and its metabolite(s) in relevant compartments of the body, at certain
dose levels and points in time. Then, the validity of the model needs to be evaluated through
comparison of its output with available in vivo data. In addition, a sensitivity analysis can be
performed to study how the input parameters of the model influence the model output. When
evaluated and shown to be adequate, the model can be used to make predictions.
Objectives and outline of the thesis
The aim of the present PhD project was to perform a mode of action based risk assessment of
exposure to low doses of apiol and myristicin by using PBK modelling based read-across to
other alkenylbenzenes and to use the results obtained for risk assessment of consumption of
PFS and other botanical products containing parsley and dill.
Chapter 1, the current chapter, starts with a short introduction and definition of the
aim of the thesis, followed by a description of the chemical, ADME and toxicity
characteristics of apiol and myristicin and other structurally related alkenylbenzenes, as well
as a brief outline of the method used for their risk assessment and a short introduction to PBK
modelling.
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Chapter 2 defines PBK models for apiol in male rat and human, enabling prediction
of dose-dependent effects in bioactivation and detoxification of apiol. In addition to that the
outcomes of the rat and human model were compared to evaluate the occurrence of species
differences in metabolic activation and detoxification of apiol. The PBK model based
predictions were subsequently compared to those for safrole enabling estimation of a BMDL10
for apiol from read-across from the BMDL10 available for safrole, thereby enabling risk
assessment of current dietary exposure to apiol.
Chapter 3 defines a PBK model for the related alkenylbenzene myristicin in male rat
and human, enabling prediction of dose-dependent effects in bioactivation and detoxification
of myristicin. In addition to that, the outcomes of the rat and human model were compared to
evaluate the occurrence of species differences in metabolic activation and detoxification of
myristicin. The PBK model based predictions were subsequently compared to those for
safrole enabling estimation of a BMDL10 for myristicin from read-across to the BMDL10
available for safrole, thereby enabling risk assessment of current dietary exposure to
myristicin.
Chapter 4 evaluates the risk of exposure to apiol and related alkenylbenzenes through
drinking of parsley and dill based herbal teas. Chemical analyses of hot water extracts of the
various teas were performed and the amount of alkenylbenzenes that would be consumed
through consumption of a cup of tea where quantified. MOE values where calculated for the
individual alkenylbenzenes as well as taking into account the presence of more than one
alkenylbenzenes within selected herbal teas.
Chapter 5 describes the chemical analysis of parsley and dill based PFS and a
subsequent risk assessment of exposure to alkenylbenzenes upon ingestion of recommended
doses of these supplements.
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Finally, chapter 6 summarizes the results obtained in the thesis, compiles the overall
discussion and presents the future perspectives that follow from the results obtained.
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Abstract
The present study developed physiologically-based kinetic (PBK) models for the
alkenylbenzene apiol in order to facilitate risk assessment based on read-across from the
related alkenylbenzene safrole. Model predictions indicate that in rat liver the formation of
the 1ʹ-sulfoxy metabolite is about 3 times lower for apiol than for safrole. These data support
that the lower confidence limit of the benchmark dose resulting in a 10% extra cancer
incidence (BMDL10) that would be obtained in a rodent carcinogenicity study with apiol may
be 3-fold higher for apiol than for safrole. These results enable a preliminary risk assessment
for apiol, for which tumor data are not available, using a BMDL10 value of 3 times the
BMDL10 for safrole. Based on an estimated BMDL10 for apiol of 5.7-15.3 mg/kg body wt per
day and an estimated daily intake of 4×10-5 mg/kg body wt per day, the margin of exposure
(MOE) would amount to 140000-385000. This indicates a low priority for risk management.
The present study shows how PBK modelling can contribute to the development of
alternatives for animal testing, facilitating read-across from compounds for which in vivo
toxicity studies on tumor formation are available to compounds for which these data are
unavailable.
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Introduction
Apiol (1-allyl-2,5-dimethoxy-3,4-methylenedioxybenzene) is one of alkenylbenzene
compounds found in herbs and other botanicals like parsley, fennel, nutmeg and elemi tree.
High levels of apiol are especially present in parsley and apiol gives parsley its characteristics
odor (Miller et al., 1983, Parthasarathy, 2008, Tunali et al., 1999). Parsley parts (leaves, stems,
roots and seeds) are used as food flavoring agent in many food types such as sauces, soups,
stuffing, rissoles, and minces, and are also sprinkled over vegetables or salads. Beside the use
of parsley in food, medicinal uses of apiol extracted from the Triple Moss curled variety of
parsley have been reported (Parthasarathy, 2008). The structure of apiol is closely related to
Figure 1: The structural formulas of the alkenylbenzenes estragole, methyleugenol,
elemicin, safrole, myristicin and apiol.
These alkenylbenzenes are of concern because they can be converted to DNA reactive 1ʹ-
sulfoxy metabolites that readily form DNA adducts that may contribute to the formation of
hepatomas in rodent bioassays upon exposure to these alkenylbenzenes at high dose levels
(Miller et al., 1983, Randerath et al., 1984, SCF, 2001b, SCF, 2001a, SCF, 2002, Wiseman et
al., 1987). DNA adduct formation results from bioactivation of apiol following the metabolic
pathways presented in figure 2 (WHO, 2009). Apiol however is less well studied than its
that of safrole, myristicin, estragole, methyleugenol, and elemicin (Figure 1).
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related alkenylbenzene safrole and rodent carcinogenicity studies on apiol are not available
hampering its risk assessment.
Figure 2: Suggested metabolic pathways of apiol.
The structural similarity of apiol to safrole raises a concern and provides a rationale for an
updated risk assessment of exposure to apiol via food including food supplements. Several
studies have reported on the DNA adduct formation by apiol in animal in vivo studies or in
human in vitro models as compared to the related alkenylbenzenes and found apiol to be less
potent than its structural analogues (Miller et al., 1983, Phillips et al., 1984, Randerath et al.,
1984, Zhou et al., 2007).
The safety of human exposure to apiol has been assessed by the WHO in 2009 concluding that
the structural similarities to safrole with available experimental data give evidence that apiol
Mode of action based risk assessment of the botanical food-borne alkenylbenzene apiol
29
may cause toxicity and carcinogenicity in rodents exposed to high dose levels (WHO, 2009).
Because rodent bioassays characterizing the possible carcinogenicity of apiol are not
available, the aim of the present study was to perform a risk assessment for apiol based on
PBK-modelling based read-across from safrole for which rodent tumor data are available
(Miller et al., 1983, Phillips et al., 1984, Randerath et al., 1984).
Materials and methods
Caution: Apiol and 1ʹ-hydroxyapiol are possible carcinogens and should be handled with
care.
Chemicals and Reagents:
Apiol, uridine 5ʹ-diphosphoglucuronic acid trisodium salt (UDPGA), reduced L-glutathione
(GSH), alamethicin (from Trichoderma viride), and 3′-phosphoadenosine-5′-phosphosulfate
(PAPS) were obtained from Sigma Aldrich (Zwijndrecht, Netherlands). Reduced β-
nicotinamide adenine dinucleotide phosphate (NADPH) and nicotinamide adenine
dinucleotide (NAD+) were from Roche Diagnostic (Mannheim, Germany), and dimethyl
sulfoxide (DMSO) was obtained from Acros Organics (Geel, Belgium). Chromatographic
grade trifluoroacetic acid (TFA) was obtained from Merck (Darmstadt, Germany). Potassium
dihydrogen phosphate, dipotassium hydrogen phosphate trihydrate, acetic acid, and
magnesium chloride were provided by VWR International (Darmstadt, Germany). Acetonitrile
(ACN) (ULC/MS grade) was purchased from Biosolve BV (Valkenswaard, The Netherlands).
Pooled male rat liver microsomes and S9 from Sprague−Dawley and mixed gender pooled
human liver microsomes and S9 were from BD Gentest (Woburn, United States). Pooled male
Sprague−Dawley rat lung, kidney, and small intestinal microsomes and pooled gender human
lung, kidney, and intestinal microsomes were purchased from BioPredic International (Rennes,
France).
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Synthesis of 1ʹ-hydroxyapiol and 1ʹ-oxoapiol
The synthesis of 1ʹ-hydroxyapiol from apiol was done as described previously for the synthesis
of 1ʹ-hydroxysafrole from safrole by Jeurissen et al., (2004) and 1ʹ-oxoapiol was synthesized
from 1ʹ-hydroxyapiol according to the method used for synthesis of 1ʹ-oxoestragole from 1ʹ-
hydroxyestragole (Wislocki et al., 1976).
In vitro incubations.
Microsomal metabolism of apiol by rat and human microsomes:
Liver, kidney, lung and small intestine microsomes from male Sprague Dawley rat and from
human were used to determine tissue-specificity of the microsomal biotransformation of apiol
in rat and human. Incubations were performed by adding 1 mg/ml of the microsomal protein
preparation to an incubation mixture containing (final concentrations) 3 mM NADPH in 0.2 M
Tris-HCl (pH 7.4). After a 1 minute pre-incubation at 37°C, apiol (final concentration 1000
µM) was added from a 100 times concentrated stock solution in DMSO so that the final DMSO
content was 1% (v/v). After 120 minutes incubation at 37oC for rat and human microsomes the
reactions were terminated by adding 25 µl ice-cold acetonitrile. All samples were centrifuged
for 5 minutes at 16,000 g and the supernatant was stored at -20˚C until Ultra Performance
Liquid Chromatography (UPLC) analysis.
For both male rat and human, metabolism of apiol was only observed in incubations with liver
microsomes (See the Results section) and hence kinetic constants for the formation of
microsomal metabolites were determined only for liver microsomes. To determine the kinetic
constants incubations following the conditions described above were done using final
concentrations of apiol from 25 to 1000 µM for rat and human liver while keeping the DMSO
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content at 1% (v/v). Blank incubations were performed in the absence of the cofactor NADPH.
All incubations were performed in triplicate.
Glucuronidation of 1ʹ-hydroxyapiol to 1ʹ-hydroxyapiol glucuronide by rat and human liver
S9
The kinetic constants for the metabolic conversion of 1ʹ-hydroxyapiol to 1ʹ-hydroxyapiol
glucuronide in incubations with both male rat and human liver fractions were determined as
described previously for related 1ʹ-hydroxyalkenylbenzenes (Al-Subeihi et al., 2012, Al-
Subeihi et al., 2011, Martati et al., 2011, Martati et al., 2012, Punt et al., 2008, Punt et al., 2009,
Van den Berg et al., 2012). In short, incubations were performed using (final concentrations)
10 mM UDPGA and 0.5 mg/ml male Sprague−Dawley rat or pooled gender human S9 protein
in 0.2 M Tris-HCl (pH 7.4) containing 10 mM MgCl2. First the incubations were pre-treated
on ice for 15 minutes with 0.025 mg/ml alamethicin added from a 200 times concentrated stock
solution in methanol to overcome enzyme latency and to obtain maximal glucuronidation
activity. After the pre-treatment on ice and pre-incubation at 37 °C for 1 minute, the reactions
were subsequently started by adding 1ʹ-hydroxyapiol in final concentrations of 10 to 2000 μM.
1ʹ-Hydroxyapiol was added from 100 times concentrated stock solutions dissolved in DMSO.
The reaction was incubated for 30 and 120 minutes for rat and human S9, respectively, and
terminated by adding 25 μL of ice-cold acetonitrile. Blank incubations were carried out in the
absence of the cofactor UDPGA. Experiments were performed in triplicate.  All samples were
centrifuged for 5 minutes at 16000g, and the supernatant was stored at −20 °C until UPLC
analysis.
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Oxidation of 1ʹ-hydroxyapiol to 1ʹ-oxoapiol by rat and human liver microsomes
The kinetic constants for the enzymatic conversion of 1ʹ-hydroxyapiol to 1ʹ-oxoapiol were
determined using incubation mixtures containing (final concentrations) 3 mM NAD+, 2 mM
GSH, and 1 mg/mL rat or human liver microsomes in 0.2 M Tris-HCl (pH 7.4). GSH was added
to the incubation mixtures to trap the reactive 1ʹ-oxometabolite formed after oxidation of 1ʹ-
hydroxyapiol.  To determine the kinetic constants incubations following the conditions
described above were done using final concentrations of 1ʹ-hydroxyapiol from 50 to 2000 μM
added to the incubation mixture from 100 times concentrated stock solutions in DMSO. After
pre-incubation for 1 minute at 37 °C the reactions were started by adding the 1ʹ-hydroxyapiol
and were terminated after 60 minutes of incubation at 37oC by adding 25 μL of ice-cold
acetonitrile. The formation of the GSH conjugate of 1ʹ-oxoapiol, GS-1ʹ-oxoapiol, was linear
with time and microsomal protein under the experimental conditions used. Blank incubations
were performed without the cofactor NAD+. Incubations were performed in triplicate. All
samples were centrifuged for 5 minutes at 16000g, and the supernatant was stored at −20 °C
until UPLC analysis.
Sulfonation of 1ʹ-hydroxyapiol to 1ʹ-sulfoxyapiol by rat and human liver S9
The kinetic constants for the enzymatic conversion of 1ʹ-hydroxyapiol to 1ʹ-sulfoxyapiol were
determined using incubation mixtures containing (final concentrations) 10 mM GSH, 0.2 mM
PAPS, and 3 mg/ml Sprague−Dawley rat or mixed gender pooled human liver S9 proteins in
0.1 M potassium phosphate buffer (pH 8.0). GSH was used as a scavenger of the reactive
carbocation formed due to the unstable nature of the 1′-sulfoxy metabolite in an aqueous
environment. After pre-incubation for 1 minute at 37 °C 1ʹ- hydroxyapiol dissolved in
the final DMSO content at 1% (v/v). The reaction was terminated after 360 minutes
DMSO was added in final concentrations ranging between 50 and 2000 μM, while keeping
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by adding 25 μL of ice-cold acetonitrile. The formation of the GSH conjugate of 1ʹ-
sulfoxyapiol was linear with time and S9 protein concentration under the experimental
conditions used. The scavenging may either be chemically or catalysed by the glutathione S-
transferases present in the S9 incubations in which the sulfonation of 1ʹ-hydroxyapiol was
measured. Blank incubations were performed in the absence of PAPS. Incubations were
performed in triplicate. All samples were centrifuged for 5 minutes at 16000g, and the
supernatant was stored at −20 °C until UPLC analysis.
Identification and quantification of apiol metabolites
Apiol metabolites formed in microsomal incubations were identified using a photodiode array
detection (UPLC-PDA) composed of a Waters (Waters, Milford, MA) Acquity solvent
manager, sample manager, and diode array detector, equipped with a Water Acquity UPLC
BEH C18 column. The gradient was made with a mixture of ACN and ultrapure water
containing 0.1% (v/v) TFA. The flow rate was 0.6 ml/min. After equilibrating the column at
the starting condition of 10% ACN, ACN increased to 50% over 4 minutes, was further
increased to 80% over 0.5 minutes, decreased to 10% over 0.5 minutes and was finally kept at
10% for 1 minutes. Metabolites were identified as described in the Result section.
Quantification of microsomal apiol metabolites was done by comparison of the peak areas
obtained at a wavelength of 208 nm to the calibration curve of synthesized 1ʹ-hydroxyapiol
because UV spectra of all metabolites were similar.
The concentration of 1ʹ-hydroxyapiol glucuronide was determined using the same UPLC-PDA
system as described above. The gradient was made with acetonitrile and ultrapure water
containing 0.1% (v/v) TFA. The flow rate was 0.6 ml/min. In a mixture of ACN and ultrapure
water containing 0.1% (v/v) TFA, the gradient started at 10% ACN, increased to 60% ACN
over 3.5 minutes, further increased to 80% over 0.5 minutes, kept at 80% ACN for 0.5 minutes
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and then decreased to 10% ACN over 0.5 minutes. 1ʹ-hydroxyapiol glucuronide was identified
as described in the Result section. Quantification of 1ʹ-hydroxyapiol glucuronide was done by
comparison of the peak areas obtained at a wavelength of 208 nm to the calibration curve of
synthesized 1ʹ-hydroxyapiol.
The concentration of the glutathione conjugate of 1ʹ-oxoapiol was determined using the same
UPLC-PDA system as described above. The gradient was made with acetonitrile and ultrapure
water containing 0.1% (v/v) TFA. The flow rate was 0.6 ml/min. In a mixture of ACN and
ultrapure water containing 0.1% (v/v) TFA, the gradient started at 10% ACN, increased to 30%
ACN over 2.5 minutes, was further increased to 80% ACN over 0.5 minutes, kept at 80% ACN
for 0.5 minutes and finally decreased to 10% ACN over 0.5 minutes, and kept at 10% ACN for
0.5 minutes. Quantification of the GSH adduct of the metabolite was done by comparison of
the peak areas obtained at a wavelength of 280 nm to the calibration curve of the GSH adduct
of the synthesized 1ʹ-oxoapiol.
The concentration of the glutathione conjugate of 1ʹ-sulfoxyapiol was determined using the
same UPLC-PDA system described above. The flow rate was 0.6 ml/min. In a mixture of ACN
and ultrapure water containing 0.1% (v/v) TFA, the gradient started at 0% ACN, increased to
20% ACN over 0.2 minutes, further increased to 30% ACN over 4.3 minutes, and again
increased to 100% ACN over 0.3 minutes, kept at 100% ACN for 0.2 minutes, and finally
decreased to 0% ACN over 0.2 minutes and kept at 0% ACN for 0.8 minutes. The GSH adduct
of 1ʹ-sulfoxyapiol formed was identified by LC-MS using a microOTOF MS (Bruker) coupled
to an Agilent LC (1200 Series) equipped with an Altima C18 column (150 x 4.6 mm, 3 µm).
The mobile phase used consisted of nanopure water with 0.1 % formic acid and ACN with 0.1
% formic acid. Elution was at a flow rate of 0.8 ml/min, starting at 22 % ACN with a linear
increase to 100 % ACN in 30 minutes. Subsequently, the gradient returned linearly to the initial
condition in 2 minutes and remained 13 minutes at this condition prior to the next injection.
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Quantification of the GSH adduct of 1ʹ-sulfoxyapiol was done by comparison of the peak areas
obtained at a wavelength of 280 nm to the calibration curve of the GSH adduct of synthesized
1ʹ-oxoapiol since their UV spectra are comparable. Mass spectrometric analysis was in the
negative electrospray mode using a spray capillary voltage of 4500 V, a capillary temperature
of 200°C and nitrogen as nebulizer gas at 8.0 L/min.
Determination of kinetic constants of apiol and 1ʹ-hydroxyapiol metabolic conversions
Kinetic constants for the metabolic conversions of apiol and 1ʹ-hydroxyapiol were calculated
by two equations depending on the dose-dependency of the kinetics of the conversion. If the
reaction reached saturation with increasing substrate concentration, the kinetic constants were
derived by fitting the data to the standard Michaelis-Menten equation; v = Vmax × [S]/(Km +
[S]), in which [S] represents the substrate concentration, Vmax the maximum velocity and Km
the Michaelis-Menten constant for the formation of the different metabolites of apiol or 1ʹ-
hydroxyapiol. Data analysis was accomplished using GraphPad Prism, version 5.04 (GraphPad
Software, San Diego, California, USA). When the reaction did not reach saturation and rather
displayed a linear increase in the rate of conversion with increasing substrate concentration,
the kinetic rate constant for a first order reaction was derived by using the following equation;
v = k·[S], with k being the first order rate constant and [S] representing the substrate
concentration.
Apiol PBK models in rat and human
PBK models were developed describing the dose-dependent bioactivation and detoxification
of apiol in respectively rat and human. The apiol models were based on the PBK models
previously defined for the metabolism of estragole, methyleugenol, elemicin and safrole in rat
(Al-Subeihi et al., 2011, Martati et al., 2011, Punt et al., 2008, Van den Berg et al., 2012) and
Chapter 2
36
human (Al-Subeihi et al., 2012, Martati et al., 2012, Punt et al., 2009, Van den Berg et al.,
2012). Figure 3 presents an overview of the developed PBK models for apiol metabolism in rat
and human.
Figure 3: Overview of the PBK model for apiol.
The models consist of several compartments representing different organs and tissues (i.e. liver,
fat tissue, rapidly perfused tissues and slowly perfused tissues) which are connected through
the systemic circulation. First order kinetics was used to describe the uptake of apiol from the
gastrointestinal tract assuming a direct and complete uptake by the liver with an absorption rate
constant (ka) of 1.0 h-1 which is based on the fast and complete absorption of the structurally
related alkenylbenzene estragole from the gastrointestinal tract (WHO, 2009).
For both rat and human, only the liver microsomes were able to convert apiol to different
microsomal metabolites (see Result section) and this is why no other tissue compartments were
described as separate compartments in the model. In liver microsomal incubations 2ʹ,3ʹ-
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dihydroxyapiol (DHA), 1ʹ-hydroxyapiol (HA), and 4-allyl-3,6-dimethoxybenzene-1,2-diol
(ADD) were formed and their formation was included. Since 2ʹ,3ʹ-dihydroxyapiol is formed
after hydrolysis of apiol-2ʹ,3ʹ-oxide, data for both metabolites that result from epoxidation of
apiol were combined and referred to as 2ʹ,3ʹ-dihydroxyapiol. Accordingly, a mass balance
equation for apiol in rat and human liver is as follows:
Where uptakeA (μmol) is the amount of apiol taken up from the gastrointestinal tract, AGIA
(μmol) is the amount of apiol remaining in the gastrointestinal tract, ALA (μmol) is the amount
of apiol in liver. CLA is the apiol concentration in the liver (μmol/L). CAA is the apiol
concentrations in the arterial blood (in μmol/L), QL is the blood flow rate to liver (L/h), VL is
the volume of the liver (L), PLA is the liver/blood partition coefficient of apiol, and Vmax, and
Km, are the values representing the maximum rate of formation and Michaelis-Menten constant,
respectively, for the formation of 1ʹ-hydroxyapiol (HA), 2ʹ,3ʹ-dihydroxyapiol (DHA), and 4-
allyl-3,6-dimethoxybenzene-1,2-diol (ADD).
In both models, the conversion of apiol to 2ʹ,3ʹ-dihydroxyapiol and 4-allyl-3,6-
dimethoxybenzene-1,2-diol are described, but further reactions with these metabolites were not
included in the model. It was assumed that these metabolites and/or their possible conjugates
were completely excreted into the urine. Since the liver is the major target organ for
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alkenylbenzene-induced carcinogenicity in rats and mice, the present study focused primarily
on metabolic conversion of 1ʹ-hydroxyapiol by glucuronidation, oxidation and sulfonation in
the liver only. The mass balance equation for 1ʹ-hydroxyapiol in rat and human liver is as
follows:
where ALHA is the amount of 1ʹ-hydroxyapiol in the liver (μmol), CLHA is the 1ʹ-hydroxyapiol
concentration in the liver (μmol/L), PLHA is the liver/blood partition coefficient of 1ʹ-
hydroxyapiol, Vmax, and Km, are the maximum rate of formation and Michaelis-Menten
constant, respectively, for the formation of the different apiol  metabolites, including 1ʹ-
hydroxyapiol glucuronide (HAG) in the rat and human liver and  1ʹ-oxoapiol (HAO) in human,
and k is the first order rate constant for formation of 1ʹ-oxoapiol in rat, and 1ʹ-sulfoxyapiol
(HAS) in rat and human liver.
Vmax and Km values and first order rate constants k in case of absence of saturation (for
oxidation in rat and sulfonation of 1ʹ-hydroxyapiol) for the different metabolic pathways of
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apiol and 1ʹ-hydroxyapiol were derived in vitro in the present study. Vmax values that were
derived in vitro expressed as nmol min-1 (mg liver microsomal or S9 protein)-1 were scaled to
values representing the Vmax per µmol h-1 (g liver)-1 using microsomal yields of 35 mg/g liver
in rat and 32 mg/g liver in human and S9 protein yields of  143 mg/g liver as defined by Punt
et al.(Punt et al., 2008, Punt et al., 2009) based on Medinsky et al.(Medinsky et al., 1994) First
order rate constants k expressed in ml min-1 (mg liver microsomal or S9 protein)-1 were scaled
to values expressed in ml h-1 per g liver using the same conversion factor for microsomal and
S9 protein yield.
Tables 1 and 2 summarize the physiological parameters (i.e. tissue volumes, cardiac output and
tissue blood flows) for rat and human respectively which were derived from literature (Brown
et al., 1997). Partition coefficients were derived in silico based on a method described by
DeJongh et al. (DeJongh et al., 1997) using the log Kow. Log Kow values for apiol (ClogP 3.12)
and 1ʹ-hydroxyapiol (ClogP 1.56) were estimated using ChemBio3D 2010 (CambrigeSoft,
USA). Mass balance equations were coded and numerically integrated in Berkely Madonna
8.3.18 (Macey and Oster, UC Berkeley, CA, USA) using the Rosenbrockʹs algorithm for stiff
systems. The PBK models were run during 720 hours after the dosing to allow full conversion
of the parent compound.
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Table 1: Parameters used in the physiologically based biokinetic model for apiol in male rat.
Physiological parameters Tissue: blood partition
coefficientsBody wt (kg) 0.25
Percentage of body wt apiol
liver 3.4 liver 2.40
fat 7.0 fat 75.93
rapidly perfused 5.1 rapidly perfused 2.40
slowly perfused 60.2 slowly perfused 0.80
arterial blood 1.85
venous blood 5.55
Cardiac output (L/h) 5.4 1ʹ-hydroxyapiol
Percentage of cardiac output liver 1.10
liver 25.0
fat 7.0
rapidly perfused 51.0
slowly perfused 17.0
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Table 2: Parameters used in the physiologically based biokinetic model for apiol in human.
Physiological parameters Tissue: blood partition
coefficientsBody wt (kg) 60
Percentage of body wt apiol
liver 2.6 liver 6.45
fat 21.4 fat 104.74
rapidly perfused 5.0 rapidly perfused 6.45
slowly perfused 51.7 slowly perfused 4.08
blood 7.9
1ʹ-hydroxyapiol
Cardiac output (L/h) 310 liver 1.55
Percentage of cardiac output
liver 22.7
fat 5.2
rapidly perfused 47.3
slowly perfused 24.8
Model sensitivity analysis using normalized sensitivity coefficients
A sensitivity analysis was used to determine which parameters have the greatest influence on
model predictions, and performed as described previously (Al-Subeihi et al., 2012, Al-Subeihi
et al., 2011, Martati et al., 2011, Martati et al., 2012, Punt et al., 2008, Punt et al., 2009, Van
den Berg et al., 2012). For this purpose, normalized sensitivity coefficients (SC) were
determined using the following equation: SC = (Cʹ – C)/(Pʹ – P)·(P/C), with C being the initial
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value of model output, Cʹ the modified value of the model output resulting from an increase in
parameter value, P being the initial parameter value and Pʹ representing the modified parameter
value. An increase of 5% in parameter values was used to analyse the effect of a change in
parameter on the formation of 1ʹ-hydroxyapiol and 1ʹ-sulfoxyapiol (expressed as a percentage
of the dose over 720 hours). Each parameter was analysed individually while the other
parameters were kept at their initial value.
Comparison of the newly developed apiol PBK models based predictions with PBK model
predictions for the structurally related compound safrole.
The PBK model-based predictions for the formation of 1ʹ-hydroxyapiol and 1ʹ-sulfoxyapiol
were compared to the PBK model-based predictions for the dose-dependent formation of the
1ʹ-hydroxy and 1ʹ-sulfoxy metabolites of the structurally related alkenylbenzene safrole. For
this purpose, the previously defined PBK models for safrole in rat and human described by
Martati et al. (Martati et al., 2011b, Martati et al., 2012b) were used. For comparison with
apiol, the models describing the metabolism of safrole were also run for 720 hours.
Results
To identify the organs involved in the metabolism of apiol in both male rat and human,
incubations were performed using microsomal protein preparations from liver, kidney, lung
and small intestine. UPLC analysis of these incubations revealed that for both rat and human
conversion of apiol was detected only in incubations with liver microsomes. An example of a
chromatogram of an incubation of apiol with male rat liver microsomes and NADPH as the
cofactor was shown in figure 4.
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The metabolites formed in incubations with both rat and human liver microsomes were 2ʹ,3ʹ-
dihydroxyapiol (RT 1.5 minutes), 1ʹ-hydroxyapiol (RT 2.4 minutes), and 4-allyl-3,6-
dimethoxybenzene-1,2-diol (RT 2.2 minutes). Identification of 1ʹ-hydroxyapiol was done
based on comparison of the UV-spectrum and retention time of the formed 1ʹ-hydroxyapiol
with those of the specific synthesized reference compound. Tentative identification of 4-allyl-
3,6-dimethoxybenzene-1,2-diol, resulting from the O-demethylenation of apiol(Benedetti et
al., 1977, Beyer et al., 2006, Lee et al., 1998), and 2ʹ,3ʹ-dihydroxyapiol was based on analogy
to UPLC chromatograms of metabolic conversions of safrole and the fact that apiol-2ʹ,3ʹ-oxide,
formed following incubation of apiol with liver microsomes and NADPH, would be hydrolysed
by epoxide hydrolase to 2ʹ,3ʹ-dihydroxyapiol as was previously demonstrated for the
structurally related alkenylbenzenes(Al-Subeihi et al., 2011, Martati et al., 2011b, Punt et al.,
2008, Luo et al., 1992, Luo and Guenthner, 1996, Guenthner and Luo, 2001). Furthermore, the
formation of these three major metabolites is in line with the overview presented by JECFA of
the three primary biotransformation pathways for methylenedioxy-substituted alkenylbenzenes
including safrole, myristicin and apiol (WHO, 2009). Safrole, myristicin and apiol were
Figure 4: Chromatogram showing the different metabolites of apiol formed in incubations
with male rat liver microsomes.
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reported to be converted primarily by 1,2 ring-O-demethenylation yielding diphenolic
derivatives(Benedetti et al., 1977, Beyer et al., 2006, Lee et al., 1998),  by epoxidation of the
double bond in the allyl side-chain yielding the 2′,3′-epoxide(Luo and Guenthner, 1996, Luo
et al., 1992), and by hydroxylation  of the alkene side-chain to yield the 1′-hydroxy
metabolite(Benedetti et al., 1977, Miller et al., 1983, Zangouras et al., 1981).Apiol
concentration-dependent formation of the various microsomal metabolites was also
characterised and the kinetic constants derived from these data on the concentration-dependent
microsomal metabolite formation of apiol in incubations with both male rat and human liver
samples are presented in Table 3. .
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Glucuronidation of 1ʹ-hydroxyapiol to 1ʹ-hydroxyapiol glucuronide by rat and human liver
S9
UPLC analysis of incubations with male rat liver S9 or mixed gender pooled human liver S9,
UDPGA as cofactor and 1ʹ-hydroxyapiol as substrate revealed a peak at 1.5 minutes,
representing 1ʹ-hydroxyapiol glucuronide since this peak was increased with increasing apiol
concentration. Chromatographic analysis of blank incubations performed in the absence of the
cofactor UDPGA did not show this peak at a retention time of 1.50 minutes, and the formation
and elution behaviour of the metabolite was in analogous to results from similar incubations
with safrole (Martati et al., 2011, Martati et al., 2012).
The 1ʹ-hydroxyapiol concentration-dependent increase in glucuronidation of 1ʹ-hydroxyapiol
to 1ʹ-hydroxyapiol glucuronide in incubations with both male rat and human liver fractions is
presented in figures 5A and 5D respectively. The kinetic constants derived from these data are
presented in Table 3.
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Figure 5: Concentration-dependent rate of (A) glucuronidation of 1ʹ-hydroxyapiol in
incubations with pooled male rat liver S9 or (D) pooled human mixed gender liver S9, (B)
oxidation of 1ʹ-hydroxyapiol in incubations with pooled male rat liver microsomes or (E)
pooled human mixed gender liver S9, and (C) sulfonation of 1ʹ-hydroxyapiol in pooled male
rat liver S9 or (F) pooled human mixed gender liver S9. Data points represent mean values +/-
SD of three or four individual experiments.
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Oxidation of 1ʹ-hydroxyapiol to 1ʹ-oxoapiol   by rat and human liver microsomes
UPLC analysis of incubations with male rat liver microsomes or mixed gender pooled human
liver microsomes, NAD+ as cofactor and 1ʹ-hydroxyapiol as substrate revealed a peak at 2.0
minutes. In this incubation GSH was also added to trap the reactive oxidation metabolite 1ʹ-
oxoapiol. The peak at 2.0 minutes was identified as the GSH conjugate of 1ʹ-oxoapiol, GS-1ʹ-
oxoapiol. Identification of GS-1ʹ-oxoapiol was done based on comparison of the UV-spectrum
and retention time of the formed GS-1ʹ-oxoapiol with those of the synthesized reference
compound.
The rate of oxidation of 1ʹ-hydroxyapiol in male rat liver microsomes and pooled human liver
microsomes with increasing concentrations of 1ʹ-hydroxyapiol is presented in figures 5B and
5E respectively. Table 3 presents the kinetic constants derived from these data.
Sulfonation of 1ʹ-hydroxyapiol to 1ʹ-sulfoxyapiol by rat and human liver S9
The reactive 1ʹ-sulfoxyapiol formed upon sulfonation of the proximate carcinogenic metabolite
1ʹ-hydroxyapiol was trapped by using GSH. The scavenging may be either chemically or
catalysed by the glutathione S-transferases present in the S9 incubations in which the
sulfonation of 1ʹ-hydroxyapiol was measured.
UPLC analysis of incubations with male rat liver S9 or mixed gender pooled human liver S9,
1ʹ-hydroxyapiol, PAPS and GSH revealed a peak at 1.3 minutes. The LC-MS analysis showed
increased signal of m/z 526 with negative ion mode. The ion at m/z 526 corresponds to the
theoretically expected [M-H]- mass of a GSH adduct of 1ʹ-sulfoxyapiol. Figures 5C and 5F
present the 1ʹ-hydroxyapiol concentration dependent rate of formation of 1ʹ-sulfoxyapiol in
incubations with male rat liver S9 or mixed gender pooled human liver S9. The kinetic
constants for the conversion of 1ʹ-hydroxyapiol to 1ʹ-sulfoxyapiol in rat and human liver
derived from these data are presented in Table 3.
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Comparison of the kinetic constants for conversion of apiol and 1ʹ-hydroxyapiol by male rat
and mixed gender pooled human tissue fractions
In order to allow a comparison between the kinetic constants for metabolism of apiol and 1ʹ-
hydroxyapiol  by male rat and mixed gender pooled human tissue fractions, Vmax values that
were derived in vitro expressed as nmol min-1 (mg microsomal or S9 protein)-1 were scaled to
values representing the Vmax per µmol h-1 (g tissue)-1 using microsomal and S9 protein yields
as described in literature(Medinsky et al., 1994) and previously used by Punt et al.,(Punt et al.,
2009, Punt et al., 2008) Al-Subeihi et al.(Al-Subeihi et al., 2012, Al-Subeihi et al., 2011) and
Martati et al.(Martati et al., 2012b, Martati et al., 2011b). The in vivo Vmax values derived
accordingly, were used to calculate a scaled catalytic efficiency (scaled Vmax in vivo/ Km) for
the formation of apiol metabolites (Table 4). These values revealed that the catalytic efficiency
for formation of the proximate carcinogenic metabolite of apiol, 1ʹ-hydroxyapiol, is 3.3 times
higher in male rat liver than in human liver. The difference in the formation rate is mainly due
to the 3-fold difference in the maximum velocity (Vmax) for the conversion of apiol to 1ʹ-
hydroxyapiol (see Table 3).
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The formation of 1ʹ-hydroxyapiol glucuronide was found to represent the main metabolic
reaction for detoxification of 1ʹ-hydroxyapiol in rat and human liver while in rat liver the
catalytic efficiency for this conjugation was found to be 11.2-fold higher than in human.
For 1ʹ-hydroxyapiol oxidation, the scaled k for rat liver was found to be 3.1 times lower than
the scaled in vivo catalytic efficiency for human liver. While for sulfonation the scaled k was
1.3-fold higher in rat liver than in human liver.
Altogether, the results revealed that glucuronidation of 1ʹ-hydroxyapiol, representing a
detoxification pathway, is the most important pathway in rat and in human for conversion of
1ʹ-hydroxyapiol, and bioactivation of 1ʹ-hydroxyapiol by sulfonation was found to represent
only a minor pathway in both rat and human.
Evaluation of apiol PBK model performance
Since there are no available quantitative experimental data on the excretion of the apiol
metabolites formed after metabolism in both rat and human exposed to apiol, the performance
of the newly developed PBK models for apiol could not be evaluated against in vivo data.
Therefore, the evaluation of the PBK models for apiol was based on the evaluation of the similar
PBK models for safrole and the other alkenylbenzenes, for which more in vivo data allowing
evaluation of the models were available. The performance of the rat PBK model developed for
safrole was evaluated by Martati et al. (Martati et al., 2011) where the predicted and observed
levels of a variety of safrole metabolites in plasma or the urine of rats were compared. The
predicted and observed safrole metabolite levels were found to be similar (Martati et al., 2011).
Besides that, a comparison could be made between the predictions of the developed human
PBK model for safrole (Martati et al., 2012) and the known in vivo data for human plasma
concentrations or the urinary excretion of selected safrole metabolites. Furthermore, a
comparison of the predictions of the developed PBK models for other alkenylbenzenes
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(estragole and methyleugenol) (Al-Subeihi et al., 2012, Al-Subeihi et al., 2011, Punt et al.,
2008, Punt et al., 2009) and the reported plasma and urine levels of their metabolites could be
done to support the validity of developed PBK models for the alkenylbenzenes, thus indirectly
supporting the validity of the apiol models. Based on the above considerations showing the
validity of developed PBK models for all other alkenylbenzenes, it was concluded that it is a
reasonable assumption that these models also adequately describe the metabolite levels formed
in vivo in both rat and human after ingestion of different oral doses of apiol.
Apiol PBK model predictions for rat and human
Figure 6A shows the PBK model-based predictions for the dose-dependent formation of the
different microsomal metabolites of apiol in rat liver. 4-Allyl-3,6-dimethoxybenzene-1,2-diol
appears to be the major metabolite formed amounting to 91.5-85% of the dose with the
percentage somewhat decreasing with increasing dose. The percentage of the dose converted to
1ʹ-hydroxyapiol was predicted to increase in a dose-dependent manner from 4% to about 7% of
the dose at low and high dose levels respectively. Concurrent with the increase in the percentage
of the dose that undergoes 1ʹ-hydroxylation of the alkene side chain, a dose-dependent increase
from about 4% to 8% of the dose converted by epoxidation was observed.  Figure 6B shows
the PBK model-based predictions for the dose-dependent increase in the formation of the
metabolites of 1ʹ-hydroxyapiol in rat liver. The percentage of the dose of apiol converted to 1′-
sulfoxyapiol varies with the dose amounting to 0.0032 % at a low dose of 0.05 mg/kg bw to
0.0050 % of the dose at a relatively high dose of 300 mg/kg bw, while these percentages amount
to 0.017 % at low dose and 0.026 % at high dose for 1ʹ-oxoapiol. Glucuronidation appears to
be the major metabolic route for 1ʹ-hydroxyapiol at all dose levels as 1ʹ-hydroxyapiol
glucuronide amounts to about 4.38 % of the dose at low dose levels and to 6.80% of the dose
at high dose levels.
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Figure 7A shows the PBK model-based predictions for the dose-dependent formation of the
different microsomal metabolites of apiol in human liver. In human liver 4-allyl-3,6-
dimethoxybenzene-1,2-diol was predicted to be the major microsomal metabolite amounting to
about 82.6-83.5% of the dose. In human liver, the percentage of the dose converted to 1ʹ-
hydroxyapiol was only slightly decreased with the dose amounting to 6.7-6.3 % of the dose.
The decrease in the formation of 1ʹ-hydroxyapiol with increasing dose, is predicted to be
accompanied by a decrease in the formation of apiol-2ʹ,3ʹ-oxide. Figure 7B shows the dose-
dependent decrease in the relative formation of 1ʹ-hydroxyapiol glucuronide and 1ʹ-oxoapiol
and the dose-dependent decrease of the relative formation of 1ʹ-sulfoxyapiol in human liver.
There were only limited changes in the relative percentage of the different metabolites with the
dose. 1ʹ-Hydroxyapiol glucuronide appears to be the major 1ʹ-hydroxyapiol metabolite
amounting to about 5.9-5.5% of the dose, while 1ʹ-oxoapiol amounts to about 0.75% of the dose
and 1ʹsulfoxyapiol to 0.035% of the dose.
Figure 6: PBK-predicted dose-dependent changes in overall formation of (A) microsomal
metabolites of apiol in rat liver and (B) metabolites of 1ʹ-hydoxyapiol in rat liver. The lines
correspond to (A)  4-allyl-3,6-dimethoxybenzene-1,2-diol (●●●●), 1ʹ-hydroxyapiol (▬▬),
and 2ʹ,3ʹ-dihydroxyapiol (▬  ▬), and (B) 1ʹ-hydroxyapiol glucuronide (▬  ▬), 1ʹ-
sulfoxyapiol (▬▬), and 1ʹ-oxoapiol (●●●●).
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Figure 8 shows a comparison of the relative extent of bioactivation of apiol by rat and human
liver. There are species differences in the formation of 1ʹ-hydroxyapiol (Figure 8A) and 1ʹ-
sulfoxyapiol (Figure 8B) (expressed as nmol/g liver). In rat liver, the formation of 1ʹ-
hydroxyapiol at low dose was almost 2 times lower than in human liver and gradually increased
with increasing the dose to reach almost the same relative level as in human at high dose.
Human liver was predicted to be more efficient in formation of 1ʹ-sulfoxyapiol being 15-fold
higher at low dose and 8-fold higher at high dose than 1ʹ-sulfoxyapiol formation by rat liver
(Figure 8B). This higher relative formation of 1ʹ-sulfoxyapiol in human than rat liver in spite
of the almost equal rate of formation of its metabolic precursor 1ʹ-hydroxyapiol in rat and
human liver is due to the fact that the glucuronidation of 1ʹ-hydroxyapiol in rat liver is around
10 times more efficient than that in human liver providing increased opportunity for the
competing sulfonation. The difference in overall formation of the 1ʹ-sulfoxyapiol formation
between rat and human is not due to a marked difference in the kinetics for sulfonation of the
Figure 7: PBK-predicted dose-dependent changes in overall formation of (A) microsomal
metabolites of apiol in human liver and (B) metabolites of 1ʹ-hydoxyapiol in human liver.
The lines correspond to (A)  4-allyl-3,6-dimethoxybenzene-1,2diol (●●●●), 1ʹ-hydroxyapiol
(▬▬), and 2ʹ,3ʹ-dihydroxyapiol (▬  ▬), and (B) 1ʹ-hydroxyapiol glucoronide (▬  ▬), 1ʹ-
sulfoxyapiol (▬▬), and 1ʹ-oxoapiol  (●●●●) .
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1ʹ-hydroxyapiol since this difference appeared limited with an only 1.35-fold higher first order
rate constant for sulfonation in rat than human liver (see Table 3).
Sensitivity analysis
In order to know the model parameters that have the highest impact on the formation of 1′-
hydroxyapiol and 1ʹ-sulfoxyapiol in rat and human liver, a sensitivity analysis was performed.
The analysis was done at an apiol dose of 0.05 mg/kg body wt per day to calculate the
normalized sensitivity coefficients for all model parameters. Normalized sensitivity coefficient
values higher than 0.1, affecting the formation of 1ʹ-hydroxyapiol and 1ʹ-sulfoxyapiol in rat and
human liver, are shown in figures 9A and 9B. Figure 9 shows that in both rat and human the
parameters that influence the formation of both metabolites to the highest extent are the same.
1ʹ-Hydroxyapiol formation is mainly influenced by the kinetic constants for formation of 1ʹ-
hydroxyapiol (Vmax,HA, km,HA) and the kinetic constants for formation of 4-allyl-3,6-
dimethoxybenzene-1,2-diol (Vmax,ADD, km,ADD). Besides the above parameters, 1ʹ-sulfoxyapiol
formation was influenced by kinetic constants for formation of 1ʹ-hydroxyapiol glucuronide
(Vmax,HAG, km,HAG) and of 1ʹ-sulfoxyapiol (k,HAS).
Figure 8: PBK-predicted dose-dependent formation of (A) 1ʹ-hydroxyapiol and (B) 1ʹ-
sulfoxyapiol in rat and human liver.
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Figure 9: Normalized sensitivity coefficients for the formation of 1ʹ-hydroxy apiol (black)
and 1ʹ-sulfoxyapiol (grey) in the liver of rat and human. S9PL = S9 protein yield of the liver,
MPL = microsomal protein yield of the liver, Vmax the maximum velocity and Km the
Michaelis-Menten constant for the formation of the different metabolites, k = the kinetic rate
constant for a first order reaction, ADD = 4-allyl-3,6-dimethoxybenzene-1,2-diol,  DHA, =
2ʹ,3ʹ-di hydroxyapiol ,  HA = 1′-hydroxyapiol,  HAG  = 1ʹ-hydroxyapiol glucuronide,  HAO =
1′-oxoapiol; HES = 1′-sulfoxyapiol.
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Comparison of the PBK model-based prediction of bioactivation of apiol by rat and human to
the PBK model predictions for bioactivation of the structurally related compound safrole.
The PBK model-based predictions for bioactivation of apiol in rat and human, were compared
to the PBK model-based predictions for bioactivation of safrole to facilitate a read-across-based
risk assessment. Figure 10 shows the dose-dependent formation of the 1ʹ-hydroxy and 1ʹ-
sulfoxy metabolites in rat liver as predicted by the respective PBK models from dose levels
representing estimated human daily intakes up to dose levels causing liver tumors in rodent
bioassays with safrole. In rat liver, the PBK model-based predicted formation of the proximate
carcinogenic 1ʹ-hydroxy metabolite was found to be 2.8-fold lower for apiol than for safrole at
low dose and 2.0-fold lower at the highest dose (Fig. 10A). Figure 10B shows the predicted
model outcomes for the formation of the ultimate carcinogenic 1ʹsulfooxy metabolites of apiol
and safrole. In rat liver, the formation of the 1ʹ-sulfoxy metabolite is predicted to be about 3-
fold lower for apiol than for safrole. For both alkenylbenzenes the formation of their 1ʹ-sulfoxy
metabolite increases linearly with increase of the dose.
Figure 10: PBK-predicted dose-dependent formation (nmol / g liver) of (A) 1ʹ-hydroxy
metabolites and (B) 1ʹ-sulfoxy metabolites of apiol (▬▬) and safrole (▬ ▬) in male rat
liver.
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Figure 11 shows the predicted dose-dependent formation of the 1ʹ-hydroxymetabolites and 1ʹ-
sulfoxy metabolites of apiol and safrole in human liver. The predicted formation of the 1ʹ-
hydroxy metabolite is predicted to be about 8-fold lower for apiol than for safrole at low dose
and about 6-fold lower at high dose levels. In human liver, the formation of the 1ʹ-sulfoxy
Implications for risk assessment
In order to evaluate the possible human health hazards due to daily consumption of apiol, the
margin of exposure (MOE) approach can be used. The MOE is the preferred approach to assess
the safety of a compound that is carcinogenic and genotoxic (EFSA, 2005).
Carcinogenicity data for apiol from which a BMDL10 can be derived are absent, hampering the
application of the MOE approach in the risk assessment of apiol. On the other hand, the results
of the PBK model predictions presented above indicate that at dose levels in the range at which
safrole exposed rodents develop tumors (10-100 mg/kg body wt per day) (Long et al., 1963),
the formation of 1′-sulfoxy metabolites of apiol in rat liver is about 3-fold lower than that of
safrole.  Based on this result it can be assumed that the PBK modelling supports use of the
BMDL10 for tumor formation by safrole for risk assessment of the related compound apiol
metabolites of apiol is predicted to be 2 times lower for apiol than for safrole.
Figure 11: PBK-predicted dose-dependent formation (nmol / g liver) of (A) 1ʹ-
hydroxymetabolites and (B) 1ʹ-sulfoxy metabolites of apiol (▬▬) and safrole (▬ ▬) in
human liver.
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making a correction for the expected 3-fold lower formation of the ultimate carcinogenic 1ʹ-
sulfoxy metabolite assuming the same mode of action for these two analogues.  Depending on
the differences of formation of ultimate carcinogen of apiol and safrole in rat liver at dose levels
that induce liver tumor formation in rodents exposed to safrole, the BMDL10 of safrole which
amounts to 1.9-5.1 mg/kg body wt per day (van den Berg et al., 2011) was multiplied by factor
of 3 resulting in a BMDL10 of 5.7-15.3 mg/kg body wt per day. The estimated mean daily intake
of apiol from spice and spice oil in the USA was reported to amount to 4×10-5 mg/kg body wt
per day (WHO, 2009).  Using a BMDL10 of 5.7-15.3 mg/kg body wt per day and an estimated
daily intake of apiol of 4×10-5mg/kg body wt per day the MOE for apiol would amount to
140000 -385000. This indicates that there would be a low concern and a low priority for risk
management of the current levels of exposure to apiol. For comparison, the MOE values of
safrole can be given, obtained at the estimated daily intake of safrole from spice and spice oil
in USA that amounts to 1×10-3 mg/kg body wt per day (WHO, 2009), and using a BMDL10 of
safrole of 1.9-5.1 mg/kg body wt per day. These data result in an MOE for safrole of 1900-5100
indicating a priority for risk management that is higher than for apiol.
Discussion:
The present paper describes the definition of mode of action-based PBK models for
detoxification and bioactivation of the alkenylbenzene apiol in rat and human and the use of
predictions made by these models to facilitate a read-across-based risk assessment to the
structurally related alkenylbenzene safrole (Martati et al., 2011, Martati et al., 2012), for which
in vivo carcinogenicity data are available. Previously, using a similar approach and read-across
to estragole and methyleugenol, the risks of exposure to elemicin for which also no in vivo
rodent tumor data were available could be evaluated (Van den Berg et al., 2012). The approach
enables a preliminary risk assessment of apiol for which in vivo toxicity data are limited
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without the need for additional animal studies. The physiological parameters for rat and human
and the biochemical and physiochemical parameters for apiol were defined to develop the apiol
PBK models.
The newly developed PBK models for apiol provide insight into the species-differences in the
relative extent of bioactivation and detoxification, and could also be used to compare the level
of metabolic activation of apiol to that of safrole in male rat and human liver (Martati et al.,
2011, Martati et al., 2012). Comparing the apiol and safrole model-based predictions showed
that the formation of the proximate and ultimate carcinogenic metabolites of the two
alkenylbenzenes in rat is predicted to be comparable within an order of magnitude. The PBK
models predict the formation of the ultimate carcinogenic 1ʹ-sulfoxy metabolite at a dose level
of 100 mg/kg body wt, at which safrole is causing liver tumors in rodent animal (Long et al.,
1963, WHO, 2009), to be 3-fold lower for apiol than for safrole in rat liver.  In line with these
differences, Randerath et al. (Randerath et al., 1984), using 32P-postlabeling reported that the
number of DNA adducts formed by apiol in adult mouse liver was lower than for safrole. In a
parallel study, Phillips et al. (Phillips et al., 1984) reported that in preweaning male mice the
level of DNA adducts formed after neonatal apiol exposure was about 12-fold lower than after
neonatal safrole exposure (Phillips et al., 1984). In addition, the ability of apiol to form DNA
adducts in cultured human (HepG2) cells was reported to be 3-5 times lower than that of safrole
(Zhou et al., 2007).
It is important to note that the PBK model-based predictions quantify the amount of the ultimate
carcinogenic metabolite formed and not the ability of these compounds to bind to DNA or other
macromolecules. One could argue that this reactivity may differ between the different
alkenylbenzene compounds and that an increasing number of methoxy groups may reduce the
electrophilicity of the 1ʹ-sulfoxy metabolite or its carbocation decreasing its ability to bind to
DNA (Miller et al., 1983, Randerath et al., 1984). However, given that the PBK model-based
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predicted differences are in line with the currently available data from in vivo and cellular in
vitro studies on DNA adduct formation by apiol and safrole it is concluded that these possible
differences in electrophilicity of the two 1ʹ-sulfoxy metabolites does not affect the predictions
to an extent that it would modify the conclusions of the current MOE based preliminary risk
assessment.
Based on the rat PBK model predictions for formation of the related 1ʹ-sulfoxy metabolite,
being 3-fold lower for apiol than for safrole at dose levels that are known to induce tumors in
safrole-exposed rodent models, it was concluded that the BMDL10 that would be expected in a
rodent animal bioassay for apiol could be 3-fold higher than that of safrole. Based on these
considerations a preliminary risk assessment was performed for apiol using the MOE approach
and an estimated BMDL10 for apiol, of 3 times the BMDL10 for safrole (1.9-5.1 mg/kg body wt
per day) (van den Berg et al., 2011) and the MOE for apiol was calculated to amount to 140000
-385000. It is of interest to note that the PBK model of the present study predicted that the
formation of the ultimate carcinogenic 1ʹ-sulfoxy metabolite of apiol in human liver would be
about 10 times higher than its formation in rat liver. This difference is included in the MOE of
10 000 which was defined to include a factor of 10 for interspecies differences (EFSA, 2005).
Given that the MOE values actually obtained for apiole are 14-38-fold higher than 10 000 they
could accommodate an even larger species difference than the 10-fold difference now included
in the MOE of 10000 without leading to a different conclusion. Furthermore, comparison of the
MOE values obtained in the present study for apiol and safrole, indicate a priority for risk
management of safrole that is higher than for apiol, due to its 3 times lower BMDL10 and its
25-fold higher estimated daily intake.
In conclusion, the present study reports the development of apiol PBK models for rat and human
providing insight into the occurrence of species differences in the metabolic activation of this
food-borne compound that is genotoxic and carcinogenic. In addition, the PBK model
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predictions were applied to support read-across from safrole for which tumor data are available
facilitating a preliminary risk assessment for apiol for which limited in vivo data are available.
This example illustrates how PBK modelling can be used to contribute to risk assessment
eliminating the need for animal bioassays thereby contributing to the 3Rs of animal testing in
human safety assessments.
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Abstract
The present study describes physiologically based kinetic (PBK) models for the alkenylbenzene
myristicin that were developed by extension of the PBK models for the structurally related
alkenylbenzene safrole in rat and human. The newly developed myristicin models revealed that
the difference between rat and human in the formation of the proximate carcinogenic metabolite
1′-hydroxymyristicin in liver is 1.8-fold higher in rat at most, and limited for the ultimate
carcinogenic metabolite 1′-sulfoxymyristicin to (2.8-4.0)-fold higher in human. In addition, a
comparison was made between the relative importance of bioactivation for myristicin and
safrole. Model predictions indicate that for these related compounds the formation of the 1′-
sulfoxy metabolites in rat and human liver are comparable with a difference of less than 2.2-fold
over a wide dose range. The results from this PBK analysis support that risk assessment of
myristicin may be based on the BMDL10 derived for safrole of 1.9-5.1 mg/kg bw per day. Using
an estimated daily intake of myristicin of 0.0019 mg/kg bw per day resulting from use of herbs
and spices, this results in MOE values for myristicin that amount to 1000-2700 indicating a
priority for risk management. The results obtained illustrate that PBK modelling provides insight
in possible species differences in the metabolic activation of myristicin. Moreover, they provide
an example of how PBK modelling can facilitate a read-across in risk assessment from a
compound for which in vivo toxicity studies are available to a related compound for which tumor
data are not reported, thus contributing to alternatives in animal testing.
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Introduction
Myristicin (1-allyl-5-methoxy-3,4 methylene-dioxybenzene or methoxysafrole) is naturally
occurring and present in several spices including nutmeg and mace of trees of Myristica species,
principally Myristicafragrans Hout, and their essential oils (Forrest and Heacock, 1972,
Matthews and Pickering, 1974, Sammy and W.W., 1968). There is a potential for human
exposure to myristicin through foods, beverages, food supplements and traditional medicines.
Myristicin belongs to the group of alkenylbenzenes, that contains structural analogues like
methyleugenol, estragole, elemicin, safrole and apiol (Figure. 1), compounds that are all
naturally occurring in herbs and spices like basil, nutmeg, and their essential oils (Barceloux,
2009). Safrole, estragole, and methyleugenol have been shown to induce hepatic tumors in rats
or mice upon chronic oral exposure to high doses and upon administration to male CD-1 mice
during the preweaning period (Borchert et al., 1973, Drinkwater et al., 1976, Ioannides et al.,
1981, Wislocki et al., 1977, 1973, Innes, 1969, National Toxicology, 2000). Tumors were found
especially in the liver at frequencies that amounted to for example 2/50, 3/50, 14/50 and 25/50
at 0, 37 75 and 150 mg methyleugenol/kg bw per day in male rats (NTP, 2000). A summary of
further incidences of malignant tumor formation in mice and rats after administration of
estragole, methyleugenol or safrole can be found in our previous paper (van den Berg SJPL,
2011). However, myristicin is less well studied than its structurally related analogues, and only
myristicin is mutagenic and capable of inducing the formation of DNA adducts (EFSA, 2009,
Zhou et al., 2007b), no 2-year carcinogenicity studies of myristicin in experimental animals are
available hampering its risk assessment.
limited toxicological data are available. While in vitro genotoxicity studies indicate that
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Figure 1: The structural formulas of the alkenylbenzenes estragole, methyleugenol, elemicin,
safrole, myristicin and apiol.
Some short-term studies were conducted on the induction of hepatic tumors, in which male
B6C3F1-mice were given myristicin during the preweaning period in 2 separate experiments. In
the first experiment myristicin was injected at a total dose of 3.75 µmoles to 33 male B6C3F1-
mice over a period of 22 days, and the total duration of the experiment was 12 months. In a
second experiment 45 male B6C3F1-mice were each injected a total dose of 4.75 µmoles
myristicin over a period of 22 days, and the total duration of the experiment was 18 months. In
these short term exposure experiments, myristicin had no detectable activity for the initiation of
hepatic tumours (Miller et al., 1983).
In agreement with hepatocarcinogenicity in mice (Miller et al., 1983), DNA adduct formation
upon exposure to myristicin was generally lower and less persistent than DNA adduct formation
upon exposure to methyleugenol, estragole and appeared to be about 2-fold lower than DNA
adduct formation upon exposure to safrole, both in in vitro study (Zhou et al., 2007a) as well as
in in vivo studies (Table. 1) (Phillips et al., 1984, Randerath et al., 1984).
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myristicin safrole
Model Sex
Route
of
admin.
Dose
or
conc.
pmol
adduct/
mg DNA
Dose
or
conc.
pmol
adduct/
mg
DNA
DNA adducts
identified Duration of
Exposure
DNA isolation
and persistence
study
Analysis
technique of
DNA adduct
Ref.
Cultured
Human
HepG2
cells
50# 0.017 50#
N2-(trans-
propenylbenzene-3’-
yl) deoxyguanosine
(major)  and N2-
(allylbenzene-1’-yl)
deoxyguanosine
(minor).
The cells
were treated
with
different
doses,
incubated,
and then
harvested
after 24 h
32P-
Postlabeling,
studying
DNA binding
ability in
vitro
(Zhou et
al., 2007b)
150# 0.049 150# 0.083
450# 0.165 450# 0.102
Mouse
liver CD-
1
Femal
e
i.p
400* 49.5 400* 203.4
N2-(trans -
propenylbenzene-3’-
yl) deoxyguanosine
and N2-
(allylbenzene-1’-yl)
deoxyguanosine
(both major), N6--
(trans -
propenylbenzene-3’-
yl) deoxyadenosine
(minor)
livers were
collected 24
h after
treatment
after admin.
Of dose 400
mg/Kg.bw
safrole, livers
were taken
after 24 h, 28,
58, 98, & 140
days after each
treatment, after
140 days
adduct was 21
pmol/mg DNA
32P-
Postlabeling,
studying
DNA binding
ability in vivo (Randerat
h et al.,
1984)
80* 16.8 80* 45.9
New
born
mice
B6C3F1
Male i.p 36.5* 7.8 30.8* 17.5
N2-(trans & cis-
propenylbenzene-3’-
yl) deoxyguanosine
and N2-
(allylbenzene-1’-yl)
deoxyguanosine
(both major)  (both
major). N6--(trans -
propenylbenzene-3’-
yl) deoxyadenosine
(minor)
22 days after
birth (1, 8,
15, & 22
days of
injection)
days 23, 29, &
43.  Adducts
were still
available after
43 days
32P-
Postlabeling,
studying
DNA binding
ability in vivo (Phillips
et al.,
1984)
*for dose in mg/kg bw, # for concentration in uM.
Table 1: Comparison of data on DNA adduct formation from in vitro and rodent studies using safrole and myristicin
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N2-(trans-isomyristicin-3′-yl)-2′-deoxyguanosine was found to be the major myristicin DNA
adduct formed when mice were given cola drinks instead of water up to 8 weeks. In a parallel
experiment, pregnant ICR mice were treated by gastric intubation with a single dose of 6 mg
myristicin, level of myristicin adducts in maternal and fetal liver were 68% and 63% of the total
adducts (Randerath K, 1993). In freshly isolated rat hepatocytes in primary culture, safrole,
estragole, and methyleugenol, induced unscheduled DNA synthesis (UDS) and cytotoxicity at
concentrations of 10-6-10-3M, (Howes et al., 1990) while myristicin showed cytotoxicity. In
these studies concentrations inducing UDS were generally close to or already at concentrations
detecting cytotoxicity, hampering interpretation of the data. The data supporting a genotoxic
mode of action for the tumor induction by the alkenylbenzenes rather comes from studies
reporting DNA adduct formation. In these studies, myristicin, as well as estragole,
methyleugenol and safrole all showed positive results (Zhou et al., 2007a, Kobets et al., 2016,
Phillips et al., 1984, Randerath et al., 1984). A schematic overview of the detoxification and
bioactivation of myristicin that is similar to that of its structurally related compound safrole
(Swanson et al., 1979, Borchert et al., 1973, Drinkwater et al., 1976) is shown in (Figure. 2).
Epoxidation of the double bond in the allyl side-chain yields the 2,3-epoxide. In in vitro
experiments, the epoxide readily forms DNA adducts, but rapid detoxification by epoxide
hydrolase and glutathione S-transferases (GSTs) prevents it from forming detectable levels of
DNA adducts in vivo (Luo et al., 1992, Luo and Guenthner, 1996).
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Figure 2: Proposed metabolic pathways of the alkenylbenzene myristicin.
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The primary bioactivation pathway of myristicin is 1′-hydroxylation of the alkene side-chain to
yield the 1′-hydroxy metabolite which can be conjugated with either glucuronic acid
representing a detoxification reaction or sulfate representing the ultimate bioactivation to 1′-
sulfoxymyristicin (Drinkwater et al., 1976, Benedetti et al., 1977, Zangouras et al., 1981, Miller
et al., 1983). The 1′-sulfoxy metabolite represents the ultimate carcinogenic metabolite
(Wiseman et al., 1987, Wiseman et al., 1985, Randerath et al., 1984, Phillips et al., 1984). 1′-
Sulfoxy metabolites of alkenylbenzenes may react readily with DNA, RNA, and proteins but
can also be detoxiﬁed through reaction with H2O or conjugation with glutathione (Phillips et al.,
1984, Miller et al., 1983, Fennell, 1984, Ishii et al., 2011). Therefore, only a fraction of the 1′-
sulfoxy metabolite is expected to form DNA adducts (Rietjens et al., 2014).
Although myristicin is thus likely to also induce DNA adducts and liver tumors its risk
assessment at low realistic dietary intake levels is hampered by the fact that carcinogenicity
studies are lacking (Hallstrom and Thuvander, 1997). Therefore, the aim of the present study
was to characterise the detoxification and bioactivation of myristicin and to develop a
physiologically based kinetic (PBK) model to describe the ultimate formation of the 1′-sulfoxy
metabolite in the liver of both rat and human and subsequently perform a read-across-based risk
assessment using a similar PBK model previously described for safrole for which tumor data
from long term toxicity testing are available. Previously, using a similar approach and read-
across from estragole and methyleugenol the risk of exposure to elemicin for which also only
limited in vivo rodent tumor data were available could be evaluated (van den Berg et al., 2012).
Such a PBK modelling based read-across illustrates a novel approach for animal-free risk
assessment of a genotoxic carcinogen without the need for a long term carcinogenicity study.
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Materials and methods
Chemicals
Myristicin, tris(hydroxymethyl)aminomethane, uridine 5′-diphosphoglucuronide acid
(UDPGA), reduced L-glutathione (GSH), alamethicin (from Trichodermaviride), 3′-
phosphoadenosine- 5′-phosphosulfate (PAPS), β-nicotinamide adenine dinucleotide (NAD+),
reduced β-nicotinamide adenine dinucleotide phosphate (NADPH), were obtained from Roche
Diagnostics (Mannheim, Germany). Dimethyl sulfoxide (DMSO) was obtained from Acros
Organics (Geel, Belgium). Potassium dihydrogen phosphate, dipotassium hydrogen phosphate
trihydrate, acetic acid, and magnesium chloride were supplied by VWR International
(Darmstadt, Germany). Acetonitrile (ACN) (UPLC/MS grade) was purchased from Biosolve
BV (Valkenswaard, The Netherlands).Trifluoroacetic acid TFA was obtained from Merck
(Darmstadt, Germany). Pooled male rat liver microsomes and S9 from Sprague−Dawley and
mixed gender pooled human liver microsomes and S9 were obtained from BD Gentest (Woburn,
United States). Pooled male Sprague−Dawley rat lung, kidney, and small intestinal microsomes
and pooled gender human lung, kidney, and intestinal microsomes were purchased from
BioPredic International (Rennes, France).
Synthesis of 1ʹ-hydroxymyristicin  and 1ʹ -oxomyristicin
The synthesis of 1ʹ-hydroxymyristicinfrom myristicin was done as described previously by
Jeurissen et al. (Jeurissen et al., 2004), and 1ʹ-oxomyristicin was synthesized from 1ʹ-
hydroxymyristicin according to the method used for synthesis of 1ʹ-oxoestragole from 1ʹ-
hydroxyestragole (Wislocki et al., 1976).
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Microsomal metabolism of myristicin.
First it was determined which organs are involved in the biotransformation of myristicin in rat
and human. For this purpose, liver, kidney, lung, and small intestine microsomes from male
Sprague-Dawley rat and pooled gender human were used. Incubations were performed by adding
myristicin to incubation mixtures containing 1 mg/ml of the microsomal protein preparations and
3mM NADPH in 0.2M Tris-HCl (PH 7.4). After 1 minutes pre-incubation at 37°C, myristicin
(ﬁnal concentration, 1000 μM) was added from a 100 times concentrated stock solution in DMSO
so that the ﬁnal DMSO content was 1% (v/v). Incubations were carried out for 30 minutes after
which the reactions were terminated by adding 25μl (0.25 times the incubation volume) of  ice-
cold ACN. Samples were centrifuged for 5 minutes at 13000g, and the supernatant was stored at
−20°C until ultra-performance liquid chromatography (UPLC) analysis. As metabolism of
myristicin was observed only in incubations with liver microsomes for male rats and pooled
gender human the determination of kinetic constants for the formation of microsomal metabolites
were performed only for the liver fractions. Incubations to determine kinetic constants were
performed following the conditions described above using ﬁnal concentrations of myristicin from
25 to 1000 μM for rat and human liver. In all incubations the ﬁnal concentration of DMSO, in
which myristicin was dissolved, was kept at 1% (v/v). The formation of diﬀerent microsomal
metabolites was linear with time and microsomal protein concentration under the conditions
described. Blank incubations were performed in the absence of the cofactor NADPH. All
incubations were performed in triplicate.
Glucuronidation of 1ʹ-hydroxymyristicin to 1′-hydroxymyristicin glucuronide.
The kinetic constants for the metabolic conversion of 1ʹ-hydroxymyristicin to 1′-
hydroxymyristicin glucuronide (HMG) by both male rat and human liver fractions were
determined as described previously for the related 1′-hydroxyalkenylbenzenes (Punt et al., 2008,
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van den Berg et al., 2012, Punt et al., 2009, Martati et al., 2011, Martati et al., 2012, Al-Subeihi
et al., 2011, Al-Subeihi et al., 2012). Briefly, incubations contained (ﬁnal concentrations) 10
mM UDPGA and 0.5 mg/ml male Sprague−Dawley or pooled gender human S9 protein in 0.2
M Tris-HCl (pH 7.4) containing 10 mM MgCl2. To overcome enzyme latency and to obtain
maximal glucuronidation activity, incubations containing S9 were pretreated on ice with 0.025
mg/ml alamethicin added from a 200 times concentrated stock dissolved in methanol (Fisher et
al. 2000, Lin and win 2002). After 15 minutes of alamethicin treatment, samples were pre-
incubated at 37°C for 1 minutes, and reactions were subsequently started by adding 1′-
hydroxymyristicin at ﬁnal concentrations of 10 to 1200 μM. 1′-Hydroxymyristicin was added
from 100 times concentrated stock solutions in DMSO. The reaction mixtures were incubated
for 30 and 180 minutes for rat and human, respectively, and terminated by adding 25 μl (0.25
times the incubation volume) of ice-cold ACN. Blank incubations were carried out in the
absence of the cofactor UDPGA. Experiments were performed in triplicate. The longer
incubation time in human samples was required due to the lower rate of glucuronidation. The
formation of 1′-hydroxymyristicin glucuronide was linear with time and the S9 protein
concentration under the experimental conditions described. All samples were centrifuged for 5
minutes at 16000g, and the supernatant was stored at −20°C until UPLC analysis.
Oxidation of 1′-hydroxymyristicin to 1′-oxomyristicin.
The kinetic constants for the enzymatic conversion of 1′-hydroxymyristicin to 1′-oxomyristicin
were determined using incubation mixtures containing (ﬁnal concentrations) 3 mM NAD+, 2mM
GSH, and 1mg/ml rat or human liver microsomes in 0.2 M Tris-HCl (pH 7.4). GSH was added
to the incubation mixtures to trap the reactive 1′-oxo metabolite formed after oxidation of 1′-
hydroxymyristicin. The level of GSH in the incubations was optimized in a previous study to
obtain maximum scavenging of 1′-oxoestragole (Punt et al., 2009). To this end, incubations were
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performed in the presence of increasing concentrations of GSH, ranging from 2 to 10 mM. At a
concentration of 2 mM GSH maximum formation of GS-1′-oxoestragole was reached in the
incubations, pointing at maximum scavenging of 1′-oxoestragole at this concentration (Punt et
al., 2009). Kinetic constants for this reaction in rat and human liver were derived by performing
incubations with NAD+ as a cofactor, given that in rat and human liver, NAD+ is mainly present
in an oxidized form with levels of NAD+ being much higher than those of NADH. In a previous
study, it was shown that the highest level of 1′-hydroxy alkenylbenzene oxidation occurs in
incubations with microsomes in the presence of NAD+ as cofactor. In incubations with pooled
human liver cytosol in the presence NAD+ or NADP+, lower levels of oxidation were observed
indicating that the reaction is not primarily catalyzed by alcohol dehydrogenases (ADH) or other
enzymes present in the cytosol (Punt et al., 2010). The enzyme responsible for the oxidation
may be 17β-hydroxysteroid dehydrogenase type 2 (17β-HSD2) (Punt et al., 2010). Prior to the
addition of 1′-hydroxymyristicin at ﬁnal concentrations ranging between 10 and 4000 μM to the
incubation mixture from 100 times concentrated stock solutions in DMSO, samples were pre-
incubated for 1 minutes at 37°C. Reactions were terminated after 10 minutes of incubation at
37°C by adding 25μl (0.25 times the incubation volume) ice-cold ACN. The formation of the
GSH conjugate of 1′-oxomyristicin (GS-1′-oxomyristicin) was linear with time and microsomal
protein concentration under the experimental conditions used. Blank incubations were
performed without the cofactor NAD+. Incubations were performed in triplicate. All samples
were centrifuged for 5 minutes at 13000g, and the supernatant was stored at −20°C until UPLC
analysis.
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Sulfonation of 1ʹ-hydroxymyristicin to 1ʹ-sulfoxymyristicin.
The formation of 1′-sulfoxymyristicin was determined using incubations containing male rat
liver Sprague-Dawley or pooled gender human liver S9 proteins, PAPS as a cofactor, and GSH,
which acts as a scavenger of the reactive carbocation formed due to the unstable nature of the
1′-sulfoxy metabolite in an aqueous environment (van den Berg et al., 2012, Martati et al., 2011,
Al-Subeihi et al., 2011). Incubation mixtures containing (final concentrations) 10 mM GSH, 0.2
mM PAPS, and 3 mg/ml S9 proteins in 0.1 M potassium phosphate (pH 8.2) were pre-incubated
for 1 minutes at 37°C. After the pre-incubation 1′-hydroxymyristicin dissolved in DMSO was
added in final concentrations ranging between 10 and 6000 μM while keeping the final content
of DMSO at 1% (v/v). The reaction was terminated after 360 minutes of incubation by adding
25μl (0.25 times the incubation volume) ice-cold ACN. The formation of the GSH conjugate of
1′-sulfoxymyristicin was linear with time and S9 protein concentrations under the experimental
conditions used. Blank incubations were performed in the absence of PAPS. Incubations were
performed in triplicate. All samples were centrifuged for 5 minutes at 16000g, and the
supernatant was stored at −20°C until UPLC analysis.
Identification and quantification of metabolism of myristicin and 1′-hydroxymyristicin by
UPLC.
Microsomal incubations with myristicin only detected primary metabolites, all incubations
conditions were chosen such that substrate conversion did not exceed 10% of the initial substrate
concentration, a condition that is also essential to ascertain adequate determination of the kinetic
constants. Secondary metabolism of the relevant 1′-hydroxy metabolite of myristicin was taken
into account by determining the kinetic constants for its conversion in a) glucuronidation, b)
sulfation and c) oxidation, again under conditions that allowed adequate definition of kinetic
constants and with less than 10% substrate conversion. Incubation samples were subjected to
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UPLC analysis that was performed as described previously (Punt et al., 2008). Identiﬁcation was
achieved by comparing the UV spectra of the formed metabolites to the spectra of the
synthesized 1′-hydroxymyristicin and 1′-oxomyristicin reference standards. Quantiﬁcation of all
formed metabolites was done by comparing the peak areas to those of calibration curves of the
corresponding reference compounds, determined using UPLC with photodiode array detection
(UPLC-PDA). The UPLC system was composed of a Waters (Waters, Milford, MA) Acquity
solvent manager, sample manager, and photodiode array detector, equipped with Water Acquity
UPLC BEH C18 column.
For 2′,3′-dihydroxymyristicin, 5-allyl-2,3-dihydroxyanisole, that were found to have the same
UV spectrum as 1′-hydroxymyristicin, and for 1′-hydroxymyristicin, estimation was based on
comparison of the peak area of the formed metabolites to the calibration curve of the synthesized
1′-hydroxymyristicin at a wavelength of 210nm. For 3′-hydroxymyristicin, estimation was based
on comparison of the peak area to the calibration curve GSH adduct of the synthesized 1′-
oxymyristicin at a wavelength of 212 nm, because 3′-hydroxymyristicin was found to have the
same UV spectrum as the GSH adduct of synthetized 1′-oxymyristicin. The gradient for analysis
of microsomal metabolites was performed with 100% ACN and ultrapure water containing 0.1%
(v/v) TFA. The flow rate was 0.6 ml/min. The gradient started at 10% ACN, increased to 50 %
ACN over 4 minutes, increased  to 80% over 0.5 minutes, followed by decrease to 10 % ACN
over 0.5 minutes, and finally kept at 10% for 1 minutes.
1′-Hydroxymyristicin glucuronide was estimated based on comparison of the peak area of the
formed metabolite to the calibration curve of 1′-hydroxymyristicin at a wavelength of 210 nm.
The flow rate was 0.6 ml/min. the gradient was made using a mixture of ACN and ultrapure
water containing 0.1% (v/v) TFA. The gradient started at 10% ACN, increased to 60% over 3.5
minutes, after which ACN was increased  to 80% over 0.5 min, and kept at 80% for 0.5 min,
and finally decreased to 10 % over 0.5 min.
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Quantiﬁcation of GS-1′-oxomyristicin was based on a calibration curve of the GSH adduct of
the synthesized 1′-oxymyristicin made as previously described (van den Berg et al., 2012, Punt
et al., 2009, Martati et al., 2011, Al-Subeihi et al., 2011). In short, a 60 μM concentration of the
synthetic standard of 1′-oxomyristicin, dissolved in ACN, was incubated with different
concentrations of GSH (i.e., 0-20 μM) in 0.2 M Tris-HCl (pH 7.4) for 6 h at 37°C, resulting in
full conversion of the GSH to GS-1′-oxymyristicin. Quantification was done by comparing the
peak areas of the formed GS-1′-oxo metabolite in the incubation mixtures with peak areas of the
GS-1′-oxymyristicin calibration curve thus obtained at a wavelength of 212 nm. The gradient
for analysis of the metabolite consisted of a mixture of ACN and ultrapure water containing
0.1% (v/v) TFA. The flow rate was 0.6 ml/min, The running protocol started at 10% ACN,
increased to 30% ACN over 2.5 minutes, after which ACN was increased  to 80% over 0.5 min,
kept at 80% for 0.5 min, followed by a decrease to 10% over 0.5 min, and finally kept at 10%
for 0.5 min.
Quantification of 1′-sulfoxymyristicin was done using UPLC analysis as described for the
estimation of 1′-sulfoxysafrole (Martati et al., 2011). The UV spectrum of the GSH adduct of
1′-sulfoxymyristicin was found to be similar to the UV spectrum of the GSH conjugate of 1′-
oxomyristicin, and estimation of the GSH adduct of 1′-sulfoxymyristicin was thus accomplished
by comparing the peak area of this metabolite to the calibration curve of GS-1′-oxomyristicin at
a wavelength 305 nm. The gradient for analysis of the metabolite consisted a mixture of ACN
and ultrapure water containing 0.1% (v/v) TFA. The flow rate was 0.6 ml/min, starting at 0%
ACN and increasing the percentage of ACN to 20% over 0.2 minutes, followed by an increase
to 30% ACN over 4.3 min, then increasing to 100% over 0.3 min, and keeping at 100% for 0.2
min, and finally decreasing to 0% over 0.2 minutes and keeping at 0% for 0.8 min. Separation
and purification of the GSH adduct of 1′-sulfoxymyristicin was performed by collecting the peak
of the metabolite from the UPLC column. Then LC-MS analysis of the metabolite was
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conducted using a micro-TOF MS (Bruker) coupled to an Agilent LC (1200 Series) equipped
with Altima C18 column (150 x 4.6 mm, 3 µm). The mobile phase used consisted of (A)
nanopure water with 0.1 % formic acid and (B) HPLC-grade ACN with 0.1 % formic acid.
Elution was at a flow rate of 0.8 ml/min, starting at 22 % B with a linear increase to 100 % B in
30 min. Subsequently, the gradient returned linearly to the initial conditions in 2 minutes and
remained 13 minutes at this condition prior to the next injection. Mass spectrometric analysis
was in the negative electrospray mode using a spray capillary voltage of 4500 V, a capillary
temperature of 200°C and nitrogen as nebulizer gas at 8.0 L/min.
Determination of kinetic constants
Kinetic constants for the metabolic conversions of myristicin and 1′-hydroxymyristicin were
derived by fitting the data to the standard Michaelis−Menten equation,v = V × [S] K⁄ + [S]
For conversion of1′-hydroxymyristicin to 1′-sulfoxymyristicin, a first rate order linear equation
was used; v = k ×[S]
in which [S] represents the substrate concentration, Vmax the maximum velocity, and Km the
Michaelis−Menten constant for the formation of the different metabolites of myristicin or 1′-
hydroxymyristicin, kHMS the first order rate constant for sulfonation of 1′-hydroxymyristicin.
Data analysis was accomplished using GraphPad Prism, version 5.04 (GraphPad Software, San
Diego, CA).
Physiologically based kinetic (PBK) models.
Two PBK models were developed describing the relative importance of bioactivation and
detoxification of myristicin in rat and human at different oral dose levels. The models developed
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in this study were essentially based on the PBK models previously defined for the metabolism
of estragole (Punt et al., 2008, Punt et al., 2009), methyleugenol (Al-Subeihi et al., 2011, Al-
Subeihi et al., 2012), elemicin (van den Berg et al., 2012) , and safrole (Martati et al., 2011,
Martati et al., 2012) in rat and human. A schematic overview of the developed PBK models for
myristicin metabolism in rat and human is shown in (Figure. 3).
Figure 3: Schematic overview of the PBK model for myristicin in rat and human.
The models consist of several compartments representing different organs and tissues (i.e., liver,
fat tissue, richly perfused tissues, and slowly perfused tissues) that are mutually connected
through the systemic circulation. First-order kinetics was used to describe the uptake of
myristicin from the gastrointestinal (GI) tract assuming a direct uptake by the liver with an
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absorption rate constant (ka) of 1.0 h−1, which is based on the fast and complete absorption of
the structurally related alkenylbenzene safrole from the GI tract (Punt et al., 2008). For rat and
human, the liver was the only organ able to convert myristicin to different microsomal
metabolites. 2′,3′-Dihydroxymyristicin (DHM), 3′-hydroxymyristicin (3HM), 1′-
hydroxymyristicin (HM), 5-allyl-2,3-dihydroxyanisole (DHA) were formed in incubations with
both rat and human liver.
Accordingly, mass balance equations for Myristicin in rat liver and human were as follows:
Where UptakeM (μmol) is the amount of myristicin taken up from the GI tract, AGIM (μmol) is
the amount of myristicin remaining in the GI tract, and ALM (μmol) is the amount of myristicin
in the liver or CLM is the myristicin concentration in the liver (μmol/L). CAM and CVM are the
myristicin concentrations in the arterial and venous blood (both in μmol/L), QL is the blood flow
rate to a tissue (L/h), QC is the cardiac output (L/h), VL is the volume of liver, PLM is the
tissue/blood partition coefficient of myristicin, and Vmaxand Km are the values representing the
maximum rate of formation and Michaelis−Menten constant, respectively, for the formation of
2′,3′-dihydroxymyristicin (DHM), 3′-hydroxymyristicin (3HM), 1′-hydroxymyristicin (HM),
and 5-allyl-2,3-dihydroxyanisole (DHA).
The mass balance equation for the metabolic conversion of 1′-hydroxymyristicin by
glucuronidation, oxidation, and sulfonation in the liver in rat and human liver is as follows:
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where ALHM is the amount of 1′-hydroxymyristicin in the liver (μmol), CLHM is the 1′-
hydroxymyristicin concentration in the liver (μmol/L), PLHM is the liver/blood partition
coefficient of 1′-hydroxymyristicin, and Vmax and Km are the maximum rate of formation and
Michaelis−Menten constant, respectively, for the formation of the different 1′-
hydroxymyristicin metabolites in the liver, including 1′-hydroxymyristicin glucuronide, 1′-
oxomyristicin, and kHMS is the first order rate constant for sulfonation of 1′-hydroxymyristicin
that was used instead of Km and Vmax as sulfonation showed no saturation. Vmax and Km values
and first order rate constants k in case of absence of saturation (for sulfonation of 1ʹ-
hydroxymyristicin in rat and human) for the different metabolic pathways of myristicin and 1′-
hydroxymyristicin were derived from results from in vitro experiments in the present study. Vmax
values that were derived in vitro expressed as nmol min−1 (mg liver microsomal or S9 protein)−1
were scaled to values representing the Vmax per μmol h−1 (g liver)−1 using microsomal protein
yields of 35 mg/g for rat and 32 mg/g for human liver and S9 protein yields of 143 mg/g liver,
as defined previously (Punt et al., 2008, Punt et al., 2009), based on Medinsky et al. (Medinsky,
1994).First order rate constant k expressed in ml min-1 (mg liver S9 protein)-1 was scaled to
values expressed in ml h-1 per g liver using the same conversion factor for S9 protein yield.
(Table 2) and (Table 3) summarize the physiological parameters (i.e., tissue volumes, cardiac
output, and tissue blood flows) for rat and human, respectively, which were derived from the
literature (Brown et al. 1997).
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body weight (kg) 0.25 myristicin
percentage of body weight liver
Liver 3.4 fat 1.68
Fat 7.0 rapidly perfused 37.73
rapidly perfused 5.1 slowly perfused 1.68
slowly perfused 60.2 0.67
blood 7.4 1′-hydroxymyristicin
liver 0.94
cardiac output (l/h) 5.4
percentage of cardiac output
liver 25
fat 7.0
rapidly perfused 51.0
slowly perfused 17.0
Table 2: parameters used in the PBK model for myristicin in male rat
physiological parameters (Brown, 1997) tissue: blood partition coefficients
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Table 3: parameters used in the PBK model for myristicin in human
physiological parameters (Brown, 1997) tissue: blood partition coefficients
body weight (kg) 60 myristicin
percentage of body weight liver 4.22
liver 2.6 fat 83.45
fat 21.4 rapidly perfused 4.22
rapidly perfused 5.0 slowly perfused 2.81
slowly perfused 51.7
blood 7.9 1′-hydroxymyristicin
liver 0.93
cardiac output (l/h) 310
percentage of cardiac output
liver 22.7
fat 5.2
rapidly perfused 47.3
Partition coefficients were derived in silico based on a method described by DeJongh et al.
(DeJongh, 1997) using the log Kow. Log Kow values for myristicin (Clog P 3.1721) and 1′-
hydroxymyristicin (Clog P 1.6151) were estimated using Chemdraw professional 15
(ChemOffice® Professional 15.0 by perkin elmer).Mass balance equations were coded and
numerically integrated in Berkely Madonna 8.3.18 (Macey and Oster, UC Berkeley, CA) using
Rosenbrock's algorithm for stiff systems. PBK models in rat and human liver were run for 720
h, because that would be the time for total clearance of myristicin in human tissues after one
dose.
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Sensitivity Analysis.
To determine which parameters have the greatest influence on model predictions, a sensitivity
analysis was performed as described previously (Punt et al., 2008, van den Berg et al., 2012,
Punt et al., 2009, Martati et al., 2011, Martati et al., 2012, Al-Subeihi et al., 2011, Al-Subeihi et
al., 2012). For this purpose, normalized sensitivity coefficients (SCs) were determined using the
following equation: SC = (C − C) (P − P)×(P C⁄ )⁄
Where C is the initial value of the model output, C′ is the modified value of the model output
resulting from an increase in parameter value, P is the initial parameter value, and P′ represents
the modified parameter value. An increase of 5% in parameter values was used to analyze the
effect of a change in parameter on the formation of 1′-hydroxymyristicin and 1′-
sulfoxymyristicin (expressed as a percentage of the dose). Each parameter was analyzed
individually, while the other parameters were kept at their initial value.
Comparison of the PBK model-based prediction of bioactivation of myristicin to the PBK
model based predictions for bioactvation of the structurally related compound safrole.
The predicted model outcomes for the formation of 1′-hydroxymyristicin and 1′-
sulfoxymyristicin in the liver of rat and human were compared with the predicted dose-
dependent formation of the 1′-hydroxy- and 1′-sulfoxy metabolite of the structurally related
alkenylbenzene safrole. For this purpose, the previously defined PBK models for safrole
described by Martati et al. (Martati et al., 2011, Martati et al., 2012) for rat and human were
used. For the comparison the models describing the metabolism of myristicin and safrole were
run for a period of 720 h.
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Results
Microsomal conversion of myristicin.
To identify which organs are involved in the metabolism of myristicin in both male rat and
human, incubations were performed using microsomal protein preparations from liver, kidney,
lung, and small intestine of both species. Chromatographic analysis of these incubations
revealed that for rat and human no detectable metabolism of myristicin occurred in small
intestine, lung or kidney microsomes and metabolism was only observed for liver microsomes.
An example of a chromatogram of an incubation of myristicin with male rat liver microsomes
and NADPH as a cofactor is shown in (Figure. 4).
Figure 4: UPLC chromatogram of an incubation of myristicin (1000 µM) with male rat liver
microsomes. The peak marked with an asterisk (*) was also found in the blank incubation
without NADPH.
In incubations with rat liver microsomes2′,3′-dihydroxymyristicin (Rt = 1.19 min), 3′-
hydroxymyristicin (Rt = 2.01 min), 1′-hydroxymyristicin (Rt = 2.04 min), and 5-allyl-2,3-
dihydroxyanisole (Rt = 2.11 min) were formed. In incubations with human liver microsomes,
the same four metabolites were found. Identification was done based on comparison of the UV
spectra and retention times of the formed metabolites with those of the specific synthesized or
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commercially available reference compounds. However, tentative identification of 2′,3′-
dihydroxymyrsticin was based on the fact that the epoxidation of the double bond in the allyl
side-chain of estragole, methyleugenol, and safrole yields the 2′,3′-epoxid, found to be
hydrolyzed by epoxide hydrolase to 2′,3′-dihydroxy metabolite (Luo et al., 1992, Luo and
Guenthner, 1996, Guenthner, 2001). The hydrolysis product of the epoxide,2′,3′-dihydroxy
metabolite of myristicin, safrole or elemicin was detected in the urine of rats administered high
doses (100 mg/kg bw) of each substance individually or a high dose of nutmeg (500 mg/kg bw)
(Beyer et al., 2006). Data revealed that 3′-hydroxymyristicin was formed directly from
myristicin rather than from isomerization of 1′-hydroxymyristicin since the formation of 3′-
hydroxymyristicin was not observed in incubations of 1′-hydroxymyristicin with liver
microsomes and NADPH (data not shown). The kinetic constants (i.e., Vmax and Km) were
derived from plots of the rates of formation of different microsomal metabolites in incubations
with male rat liver microsomes, and human liver microsomes from myristicin at concentrations
ranging from 25 to 1000 μM (for details, see Figure. S1 in the supplementary materials). The
values obtained are shown in (Table 4), together with the catalytic efficiencies, calculated as
Vmax/Km. Analysis of incubations that were performed with male rat liver microsomal
preparations revealed that the metabolite arising from O-demethylenation of myristicin, namely,
5-allyl-2,3-dihydroxyanisole, was formed with the highest Vmax value.
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Moreover, 2′,3′-dihydroxymyristicin and 5-allyl-2,3-dihydroxyanisole were abundantly formed
in incubations with male rat microsomal liver preparations with a high affinity. In incubations
performed with male rat liver microsomes, 1′-hydroxymyristicin and 3′-hydroxymyristicin were
the least important metabolites formed upon conversion of myristicin. In general, the catalytic
efficiency for the formation of 5-allyl-2,3-dihydroxyanisole by male rat liver microsomes had
the highest value, followed by the catalytic efficiency for the formation of 2′,3′-
dihydroxymyristicin, 1′-hydroxymyristicin and 3′-hydroxymyristicin, respectively. The
catalytic efficiency for the formation of 5-allyl-2,3-dihydroxyanisole was found to be
approximately 7-fold higher than that for the formation of 3′-hydroxymyristicin. In incubations
with human liver fractions, 5-allyl-2,3-dihydroxyanisole was found to be the most abundant
metabolite formed followed by 2′,3′-dihydroxymyristicin, 1′-hydroxymyristicin and 3′-
hydroxymyristicin, respectively. Analysis of the catalytic efficiencies for the formation of the
different microsomal metabolites of myristicin, obtained with pooled human liver microsomes,
showed that the formations of 2′,3′-dihydroxymyristicin, 1′-hydroxymyristicin and 3′-
hydroxymyristicin were the least important routes of myristicin metabolism, whereas the
formation of 5-allyl-2,3-dihydroxyanisole represents the major pathway for the human liver
microsomal conversion of myristicin.
Glucuronidation of 1′-hydroxymyristicin.
Chromatographic analysis of incubations with male rat and mixed gender pooled human liver
S9, UDPGA as cofactor and 1′-hydroxymyristicin as substrate, revealed a peak at 1.36 minutes
(chromatogram not shown). Moreover, chromatographic analysis of incubations performed in
the absence of the cofactor UDPGA did not show a peak at a retention time of 1.36 min.
Together, these data indicate that the compound eluting at 1.36 minutes can be assumed to be
1′-hydroxymyristicin glucuronide. The rate of the metabolic conversion of 1′-hydroxymyristicin
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to 1′-hydroxymyristicin glucuronide in incubations with both male rat and human liver fractions
with increasing concentrations of 1′-hydroxymyristicin are presented in (Figure. 5A and 5D),
respectively. The kinetic constants derived from these plots are presented in (Table 4).
Figure 5: Concentration-dependent rate of (A) glucuronidation of 1ʹ-hydroxymyristicin in
incubations with male rat liver S9 or (D) pooled human mixed gender liver S9, (B) oxidation of
1ʹ-hydroxymyristicin in incubations with pooled male rat liver microsomes or (E) pooled human
mixed gender liver S9, and (C) sulfonation of 1ʹ-hydroxymyristicin in pooled male rat liver S9
or (F) pooled human mixed gender liver S9. Data points represent mean values +/- SD of three
or four individual experiments.
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Oxidation of 1′-hydroxymyristicin.
The rate of oxidation of 1′-hydroxymyristicin with increasing concentrations of 1′-
hydroxymyristicin in incubations with male rat and pooled human liver microsomes, are shown
in (Figure. 5B and 5E) respectively, the kinetic constants derived from these data are presented
in (Table 4).
Sulfonation of 1′-hydroxymyristicin.
In the present study, GSH was used to trap the reactive 1′-sulfoxymyristicin formed upon
sulfonation of the proximate carcinogenic metabolite of myristicin, 1′-hydroxymyristicin. The
scavenging is based on a chemical reaction but can also be catalyzed by the GST present in the
S9 incubations in which the sulfonation of 1′-hydroxymyristicin was measured.
Chromatographic analysis of incubations with male rat or mixed gender pooled human liver S9,
increasing concentration of 1′-hydroxymyristicin, PAPS, and GSH revealed a peak at 1.05 min,
which was identified as the GSH adduct of the carbocation of 1′-sulfoxymyristicin.
Identification was achieved based on the chromatographic analysis of incubations performed in
the absence of GSH and the presence of PAPS and liver S9 proteins since in these incubations
no peak was found at 1.05 min. The identity was verified by LC-MS analysis, which revealed a
deprotonated molecule at m/z 496, that corresponds to the expected [M-H]- mass of a GSH
adduct of 1′-sulfoxymyristicin. The rate of formation of 1′-sulfoxymyristicin in incubations with
male rat and mixed gender pooled human liver S9 are presented in (Figure. 5C and 5F),
respectively. The kinetic constants for the conversion of 1′-hydroxymyristicin to 1′-
sulfoxymyristicin in rat and human liver are presented in (Table 4).
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Comparison of the kinetic constants for conversion of myristicin and 1′-hydroxymyristicin by
male rat and mixed gender pooled human tissue fractions.
To allow a comparison between the kinetic constants for metabolism of myristicin and 1′-
hydroxymyristicin by male rat and mixed gender pooled human tissue fractions, Vmax values that
values representing the Vmax per μmol h−1 (g tissue)−1 using microsomal and S9 protein yields
as described in literature (Medinsky, 1994) and previously used (Martati et al., 2012, van den
Berg et al., 2012, Punt et al., 2009, Martati et al., 2011, Al-Subeihi et al., 2011, Al-Subeihi et
al., 2012). Making use of the in vivo Vmax values derived accordingly, a scaled catalytic
efficiency (scaled V in vivo⁄ ) for the formation of myristicin metabolites could be
calculated (Table 5).
were derived in vitro expressed in nmol min−1 (mg microsomal or S9 protein)−1 were scaled to
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For sulfonation, the rate constants for product formation (ml/min/mg protien) were scaled based
on S9 protein yield of 143 mg/g liver. These values show that the catalytic efficiency for the
formation of the proximate carcinogenic metabolite of myristicin, 1′-hydroxymyristicin, was
found to be 13-fold higher in male rat liver as compared to human liver. This difference in
catalytic efficiency for the formation of 1′-hydroxymyristicin is predominantly caused by the
high affinity (expressed as Km) and high activity (expressed as Vmax) for its formation from
myristicin in male rat liver, since the Km value in rat liver incubations was 2-fold lower than
that in human liver incubations and Vmax in rat liver incubations was 5-fold higher than that in
human liver incubations. The detoxification of 1′-hydroxymyristicin by formation of 1′-
hydroxymyristicin glucuronide was found to be the main metabolic reaction with 1′-
hydroxymyristicin in rat. Glucuronidation of 1′-hydroxymyristicin occurs in male rat with
higher affinity than in human (i.e., Km 836 μM, whereas in human the Km was 3140 μM),
analysis of the data revealed a high Vmax value for 1′-hydroxymyristicin glucuronidation
resulting in a catalytic efficiency that was 400-fold higher in male rats as compared to human.
Oxidation of 1′-hydroxymyristicin was found to be 1.2 times more efficient in human liver as
compared to male rat liver resulting from a 1.8-fold lower affinity in rat. Sulfonation was found
to be the least efficient metabolic pathway for 1′-hydroxymyristicin in both rats and human. For
rat, the in vivo scaled k was 0.15 ml h−1 (g tissue) −1, and for human, it was 0.14 ml h−1 (g tissue)
−1
, indicating that sulfonation of 1′-hydroxymyristicin is equally efficient in male rat liver and
human liver. Altogether, it can be concluded that glucuronidation of 1′-hydroxymyristicin,
representing a detoxification pathway, is the most important pathway in rat and the oxidation
is the most important pathway for conversion of 1′-hydroxymyristicin in human. Moreover, on
the basis of the kinetic data obtained, bioactivation of 1′-hydroxymyristicin following
sulfonation was found to represent only a minor pathway in both rat and human.
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Evaluation of PBK model performance.
The performance of the newly developed PBK models for myristicin could not be evaluated
against in vivo data because quantitative data on the formation or excretion of the different
metabolites in rat or humans exposed to myristicin are not available. However, Beyer et al.
(Beyer et al., 2006) reported that in rats and humans myristicin and safrole were O-
demethylenated. In the urine of the human nutmeg abuser, who had taken 5 nutmegs, the
acetylated metabolites of 5-allyl-2,3-dihydroxyanisole, and 2′,3′-dihydroxymyristicin, could be
identified. In the same study, O-demethylenation of myristicin to generate 5-allyl-2,3-
dihydroxyanisole seems to result in the main metabolite of myristicin detected in rat urine
samples collected over a 24 h period after administration of a single oral dose of 100 mg/kg bw
myristicin, with a percentage of 67% of the total dose (Beyer et al., 2006). In line with these
results, the developed PBK model predicted 5-allyl-2,3-dihydroxyanisole to be the major
metabolite formed at a dose of 100 mg/kg bw myristicin in rat after 24 h, with a percentage of
73% of the total dose. This predicted value of 73% of the dose matches well with the 67%
observed in the in vivo rat study.
Important to note is that the PBK models for myristicin were based on the proposed
biotransformation in (Figure. 2) and comparable with the PBK models for estragole,
methyleugenol, and safrole, for which more data allowing evaluation of the models were
available. The performance of the rat PBK models developed for estragole, methyleugenol, and
safrole, was reported before (Punt et al., 2008, Martati et al., 2011, Al-Subeihi et al., 2011).
Evaluation was done by comparing the predicted levels of a variety of metabolites in plasma or
excreted in the urine of rats. Data revealed that the predicted PBK model values and the levels
of these metabolites derived from in vivo studies adequately matched (Punt et al., 2008, Martati
et al., 2011, Al-Subeihi et al., 2011). Furthermore, also for the developed human PBK models
for estragole (Punt et al., 2009), methyleugenol (Al-Subeihi et al., 2012) and safrole (Martati et
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al., 2012), a comparison could be made between the model predictions and the reported in vivo
data for blood concentrations or the urinary excretion of some of the metabolites, thereby
further supporting the validity of the models. Considering these data, it was concluded that the
developed PBK models for myristicin will also adequately describe the in vivo levels of
metabolites formed in rat and human after conversion of myristicin and 1′-hydroxymyristicin
at different oral dose levels of myristicin.
PBK model predictions.
PBK modelling was performed at dose levels of 0.05 and 300 mg/kg bw to allow comparison
with the PBK model outcomes previously reported for safrole (Martati et al., 2011, Martati et
al., 2012). Following an exposure to 0.05 mg/kg bw myristicin, both myristicin and its
proximate carcinogenic metabolite 1′-hydroxymyristicin were predicted and observed to be
almost completely metabolized within a 720 h period in rat and human. At a higher oral dose
level of 300mg/kg bw myristicin, both myristicin and 1′-hydroxymyristicin were also predicted
to be fully metabolized within 720 h. Therefore, for all further modelling, values were
calculated at 720 h after dosing. (Figure. 6A) shows the PBK model-based predictions for the
dose-dependent formation of the different microsomal metabolites of myristicin in rat. The
percentage of the dose converted to 1′-hydroxymyristicin is predicted to increase in a dose-
dependent manner. Concurrent with the increased percentage of the dose that undergoes 1′-
hydroxylation of the alkene side chain, a 1.6-fold dose-dependent decrease in the percentage of
the dose that underwent epoxidation to give 2′,3′-dihydroxymyristicin was observed comparing
the levels at 0.05 and 300mg/kg bw. At the same time a less than 1.6-fold increase in the
formation of 3′-hydroxymyristicin was observed. The formation of 5-allyl-2,3-
dihydroxyanisole did not change with increasing dose levels and was equal to 48% of the
administered dose. (Figure. 6B) shows the dose-dependent increase in the formation of the
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metabolites of 1′-hydroxymyristicin in rat. This reveals a 1.8-fold increase in the percentage of
the dose ultimately converted into 1′-hydroxymyristicin glucuronide, 1′-oxomyristicin, and 1′-
sulfoxymyristicin, going from a dose of 0.05 to 300mg/kg bw. This dose-dependent increase in
the formation of the different 1′-hydroxymyristicin metabolites can be explained by the 1.8-
fold increase of the formation of 1′-hydroxymyristicin with increasing dose levels.
Figure 6: PBK-predicted dose-dependent changes in overall formation of (A) microsomal
metabolites of myristicin in rat liver and (B) metabolites of 1ʹ-hydroxymyristicin in rat liver.
The lines correspond to (A) 5-allyl-2,3-dihydroxyanisole (●●●●), 3′-hydroxymyristicin (▬ ●
▬ ), 1′-hydroxymyristicin (▬▬), and 2′,3′-dihydroxymyristicin (▬  ▬),and (B) 1′-
hydroxymyristicin glucuronide (▬  ▬), 1′-sulfoxymyristicin (▬▬), and 1′-oxomyristicin
(●●●●).
Figure. 7A reveals that in human the percentage of the dose converted to 1′-hydroxymyristicin
equaled 6.5% at a dose of 0.05mg/kg bw and increased to 8.0% at a dose of 300 mg/kg bw.
Accompanying the increase in the formation of 1′-hydroxymyristicin, were a 1.4-fold decrease
in the formation of 2′,3′-dihydroxymyristicin and a steady formation of 5-allyl-2,3-
dihydroxyanisole. Formation of 3′-hydroxymyristicin was predicted to increase 1.8-fold with
increasing dose from of 0.05 to 300 mg/kg bw. (Figure. 7B) shows a 1.25-fold dose dependent
increase in the percentage formation of 1′-hydroxymyristicin glucuronide, 1′-sulfoxymyristicin,
and 1′-oxomyristicin, in human liver with increasing dose from of 0.05 to 300 mg/kg bw.
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Figure 7: PBK model-based prediction of dose-dependent changes in overall formation of (A)
microsomal metabolites of myristicin in human liver and (B) metabolites of 1ʹ-
hydroxymyristicin in human liver. The lines correspond to (A) 5-allyl-2,3-dihydroxyanisole
(●●●●), 3′-hydroxymyristicin (▬ ● ▬ ), 1′-hydroxymyristicin (▬▬), and 2′,3′-
dihydroxymyristicin (▬  ▬), and (B) 1′-hydroxymyristicin glucuronide (▬ ▬), 1′-
sulfoxymyristicin (▬▬), and 1′-oxomyristicin (●●●●).
Comparison of the relative extent of bioactivation of myristicin by rat and human liver revealed
that formation of 1′-hydroxymyristicin (expressed as nmol/g liver) is comparable in rat and
human liver at the low dose of 0.05 mg/kg bw and 1.8-fold higher in rat liver than in human
liver at a dose of 300 mg/kg bw (Figure. 8A). Formation of 1′-sulfoxymyristicin (expressed as
nmol/g liver) is 4-fold higher in human liver than in rat liver at a low dose of 0.05 mg/kg bw
and 2.8-fold lower in rat liver than in human liver at a dose of 300 mg/kg bw (Figure. 8B).
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Figure 8: PBK model-based prediction of dose-dependent formation (mg/kg bw) of (A) 1′-
hydroxymyristicin and (B) 1′-sulfoxymyristicin in rat and human liver.
Sensitivity Analysis.
A sensitivity analysis was performed to deﬁne model parameters that are capable of inﬂuencing
the formation of 1′-hydroxymyristicin and 1′-sulfoxymyristicin in rat and human liver. For this
purpose, normalized sensitivity coefficients (SCs) were calculated for all parameters at a dose
of 0.05 mg/kg bw myristicin. This sensitivity analysis reveals to what extent small variation in
the respective parameters influences the results. The sensitivity analysis also reveals to which
parameters the predicted outcomes are most sensitive. The results of this analysis are presented
in Figure 9.
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Figure 9: Normalized sensitivity coefficients for the formation from 1′-hydroxymyriticin
(black) and 1′sulfoxymyristicin (grey) in the liver of rat or human.
Figure 9 especially presents the parameters aﬀecting the formation of 1′-hydroxymyristicin
(black) and 1′-sulfoxymyristicin (grey) that have a normalized SC higher than |0.1|. In rat liver,
the formation of ultimate carcinogen metabolite 1′-sylfoxymyristicin is primarily influenced by
the kinetic constants of 1′-hydroxymyristicin formation from myristicin (VmaxHM, KmHM). The
kinetic constants for the formation of 5-allyl-2,3-dihydroxyanisoleand 2′,3′-
dihydroxymyristicin (VmaxDHA, KmDHA, VmaxDHM, KmDHM) were also found to highly inﬂuence
the formation of 1′-hydroxymyristicin in rat and human liver. In rat liver, the formation of the
ultimate carcinogenic metabolite 1′-sulfoxymyristicin is primarily influenced by the kinetic
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constants of 1′-hydroxymyristicin formation from myristicin (VmaxHM, KmHM), the kinetic
constants for the formation of 1′-hydroxymyristicin glucuronide (VmaxHMG, KmHMG), k, the first
order rate constant for the sulfonation of 1′-hydroxymyristicin (kHMS), the kinetic constants for
the formation of 5-allyl-2,3-dihydroxyanisole and 2′,3′-dihydroxymyristicin (VmaxDHA, KmDHA,
VmaxDHM, KmDHM) were also found to highly inﬂuence the formation of 1′-sulfoxymyristicin in
rat liver. In human liver, the formation of the ultimate carcinogenic metabolite 1′-
sulfoxymyristicin is primarily influenced by the kinetic constants of 1′-hydroxymyristicin
formation from myristicin (VmaxHM, KmHM), the kinetic constants for the formation of 1′-
oxomyristicin (VmaxHMO, KmHMO), k, the first order rate constant for the sulfonation of 1′-
hydroxymyristicin (kHMS), and liver microsomal protein yield (MP), the kinetic constants for
the formation of 5-allyl-2,3-dihydroxyanisole and 2′,3′-dihydroxymyristicin (VmaxDHA, KmDHA)
were also found to highly inﬂuence the formation of 1′-sulfoxymyristicin in human liver. The
kinetic constants for the formation of 1′-hydroxymyristicin glucuronide were found to highly
inﬂuence the formation of 1′-sulfoxymyristicin in rat liver and the kinetic constants for
formation of 1′-oxomyristicin were predicted to aﬀect the formation of 1′-sulfoxymyristicin in
human liver to a high extent. These results reflect the fact that glucuronidation of 1′-
hydroxymyristicin in rat and oxidation of 1′-hydroxymyristicin in human are considered as the
most important competitive metabolic pathways to sulfonation.
Comparison of the PBK model-based prediction of bioactivation of myristicin by rat and
human to that of its structurally related compound safrole.
In a next step the mode of action-based PBK models for myristicin metabolism in rat and human
were used to facilitate a read-across from data on safrole (Martati et al., 2011, Martati et al.,
2012). On the basis of the PBK models, a comparison was made for the dose-dependent
formation of the proximate carcinogenic 1′-hydroxy metabolite and of the ultimate carcinogenic
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1′-sulfoxy metabolite of myristicin and safrole in the liver of rats. (Figure 10) shows the dose-
dependent formation of these metabolites in rat liver as predicted by the respective PBK models.
Figure 10: PBK model-based prediction of dose-dependent formation (nmol / g liver) of (A)
1′-hydroxy metabolites and (B) 1′-sulfoxy metabolites of myristicin (▬▬) and safrole (▬
▬) in male rat liver.
The PBK model-based predicted formation of the proximate carcinogenic 1′-hydroxy
metabolites shows that the formation of the 1′-hydroxy metabolite of myristicin and safrole
were predicted to be the same at low dose 0.05 mg/kg bw and 1.4-fold higher for myristicin
than that of safrole at dose level 100mg/kg bw (Figure 10A). The predicted model outcomes
for the formation of the ultimate carcinogenic 1′-sulfoxy metabolites of safrole and myristicin
is in (Figure 10B). The PBK models for rat predict the formation of 1′-sulfoxymyristicin to be
1.5-fold higher for myristicin than safrole at low dose 0.05 mg/kg bw and 2.2-fold higher for
myristicin than for safrole at dose level 100 mg/kg bw (Figure 11) shows the predicted dose-
dependent formation of the 1′-hydroxy metabolites and 1′-sulfoxy metabolites of safrole and
myristicin in human liver.
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Figure 11: PBK model-based prediction of dose-dependent formation (nmol /g liver) of (A)
1′-hydroxy metabolites and (B) 1′-sulfoxy metabolites of myristicin (▬▬), and safrole (▬
▬) in human liver.
In human liver, the predicted formation of 1′-hydroxymyristicin is 7-fold lower than the
formation of 1′-hydroxysafrole at a dose level 0.05 mg/kg bw and 4.5-fold lower for myristicin
than for safrole at high dose 100 mg/kg bw (Figure 11A). The data also reveal that in human
liver the formation of the DNA reactive 1′-sulfoxy metabolite is comparable, 1.35 higher in
safrole at low dose level 0.05 mg/kg bw, and 1.1-fold higher for myristicin at high dose level
100 mg/kg bw (Figure 11B).
Implications for risk assessment
The margin of exposure (MOE) concept was applied to assess the possible risks for human
health resulting from the daily exposure to myristicin (JECFA, 2005, EFSA, 2005, Barlow,
2006, O′Brien, 2006). The MOE is a dimensionless ratio based on a reference point representing
a dose causing a low but measurable cancer incidence in experimental animals (e.g., a
BMDL10), which is divided by the estimated daily intake in humans (EFSA, 2005). When the
MOE is lower than 10000, the compound of interest is considered to be a priority for risk
management actions and a concern for human health (EFSA, 2005). To date, tumor data for
myristicin, from which a BMDL10 can be derived, are absent in the available literature,
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hampering the application of the MOE approach in the risk assessment of myristicin.
Nevertheless, the results of the PBK model predictions presented above indicate that at dose
levels in the range of the BMDL10 values, the formation of 1′-sulfoxy metabolites of myristicin
in human liver is comparable (1.1-fold higher) to that of the structurally related safrole. On the
basis of these considerations, and the limited difference in 1′-sulfoxy metabolite formation for
myristicin and safrole in rat and human liver, it was concluded that the BMDL10 values of
safrole could be used to perform an initial MOE based risk assessment for myristicin. Using the
BMDL10 for safrole of 1.9-5.1 mg/kg bw per day (van den Berg, 2011  ) and an estimated daily
intake of myristicin of 0.0019 mg/kg bw per day (WHO, 2009) from use of herbs and spices,
the MOE for myristicin would amount to 1000-2684. The estimated daily intake of safrole from
spice and spice oil in USA that amounts to 0.001 mg/kg bw per day (WHO, 2009). These data
result in an MOE for safrole of 1900-5100 indicating a priority for risk management that is
somewhat lower than for myristicin.
Discussion
In the presented paper, the recently developed mode of action based PBK models for
detoxification and bioactivation of the alkenylbenzene safrole (Martati et al., 2011, Martati et
al., 2012) in male rat and human were extended to the structurally related alkenylbenzene
myristicin. The newly developed PBK models combine biochemical and physico-chemical
information on myristicin and on the physiology of the organism of interest (i.e., rat and
human), enabling the quantification of detoxification and bioactivation in rat and human at
realistic low exposure levels. The development of these models facilitates a risk assessment
based on read-across from data on safrole, for which in vivo chronic toxicity studies are
available, to myristicin, a compound for which toxicity data are limited.
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The PBK models for myristicin defined in the present paper were able to predict the overall
formation of the reactive 1′-sulfoxymyristicin metabolite in the liver of rat and human thus
enabling comparison to the overall formation of the 1′-sulfoxy metabolite of the corresponding
alkenylbenzene safrole. Comparison of the rat and human PBK model predictions indicated an
only limited species dependent difference in the overall metabolic activation of myristicin. The
difference observed were within the default factor of 4, which is generally used to describe
kinetic differences between species (IPCS, 2010). The newly developed PBK model for
myristicin was also used to compare the levels of metabolic activation of myristicin to those
predicted previously for safrole in male rat and human liver (Martati et al., 2011, Martati et al.,
2012). Results reveal that the formation of the proximate and ultimate carcinogenic metabolites
of myristicin and safrole in rat liver appear to be comparable varying about 1.4-fold and 2.2-
fold, respectively, with rat liver bioactivation of myristicin predicted to be somewhat higher
than that of safrole for both metabolites. In humans, the formation of especially the 1′-sulfoxy
metabolites of the two alkenylbenzenes is predicted to be comparable (1.1-fold difference). The
PBK model outcomes obtained for the formation of reactive 1′-sulfoxy metabolites of
myristicin and safrole, can be compared to the relative bioactivation of these two
alkenylbenzenes observed in other studies. In an in vitro study with cultured human cells the
ability of myristicin to form DNA adducts upon exposure of the cells to myristicin appeared to
be almost the same as upon exposure to safrole (Zhou et al., 2007b) which is in line with the
relative differences predicted by the PBK models. Data derived from another study in which
mice were exposed to the alkenylbenzenes via intraperitoneal (i.p) injection (Table 1) suggest
that the DNA adduct formation of safrole and myristicin is also not much different with DNA
adduct formation in the liver of safrole being 2.7 times higher than that of myristicin (Randerath
et al., 1984). In a parallel study, Phillips et al. (Table 1) reported that in neonatal mice both
safrole and myristicin were able to form DNA adducts in liver, the DNA binding levels of
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safrole and myristicin were 17.5 and 7.8 pmol/mg DNA, respectively (Phillips et al., 1984). It
is important to note that in these mice studies DNA adduct levels were quantified by 32P post
labeling which is known to be less accurate than for example LC-MS in quantification of DNA
adduct levels (Randerath et al., 1984). On the basis of the results now available, it can be
concluded that using data on safrol for a read-across to myristicin is a reasonable approach for
an initial risk assessment on myristicin. Such a risk assessment for myristicin can be based on
the MOE approach. Because data on tumor formation are currently not available for myristicin,
risk assessment for myristicin was performed using the BMDL10 values for tumor formation by
safrole, given the comparable bioactivation in human liver predicted by the newly developed
PBK models, where the difference in the bioactivation of myristicin and safrole was predicted
to be only 1.1-fold.
Using the BMDL10 for safrole of 1.9-5.1 mg/kg bw per day (van den Berg, 2011  ) and an
estimated daily intake of myristicin of 0.0019 mg/kg bw per day (WHO, 2009) from use of
herbs and spices, the MOE for myristicin would amount to 1000 -2684. For comparison, the
MOE values of safrole can be given, obtained at the estimated daily intake of safrole from spice
and spice oil in USA that amounts to 0.001 mg/kg bw per day (WHO, 2009), and a BMDL10 of
safrole of 1.9-5.1 mg/kg bw per day (van den Berg, 2011  ). These data result in an MOE for
safrole of 1900-5100 indicating a priority for risk management that is lower than for myristicin.
Altogether, the results obtained indicate that PBK modelling provides an important insight in
the limited species differences between male rat and human in the metabolic activation of
myristicin, and that in human liver formation of the ultimate carcinogenic 1′-sulfoxy
metabolites is almost the same for myristicin and safrole supporting a possibility for risk
assessment for myristicin based on the MOE approach using the BMDL10 for tumor formation
of safrole as a reasonable but careful approximation. The present study provides an example of
how PBK modelling can facilitate a read-across in risk assessment from compounds for which
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in vivo toxicity studies are available to a compound for which only limited toxicity data have
been described, thus contributing to development of alternatives for animal testing.
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Supplementary materials chapter 3
Figure S1 Concentration-dependent rate of myristicin metabolite formation in incubations
with pooled human mixed gender liver microsomes. Curves for formation of four different
phase I metabolites (2′,3′-dihydroxymyristicin, 3′-hydroxymyristicin, 1′-
hydroxymyristicin and 5-allyl-2,3-dihydroxyanisole) are presented.
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Abstract
Risk assessment of parsley and dill based teas that contain alkenylbenzenes was performed. To
this end the estimated daily intake (EDI) of alkenylbenzenes resulting from use of the teas was
quantified. Since most teas appeared to contain more than one alkenylbenzene, a combined risk
assessment was performed based on equal potency of all alkenylbenzenes or using a so-called
toxic equivalency (TEQ) approach through defining toxic equivalency factors (TEFs) for the
different alkenylbenzenes. The EDI values resulting from consuming one cup of tea a day were
0.2–10.1 μg/kg bw for the individual alkenylbenzenes, 0.6–13.1 μg/kg bw for the sum of the
alkenylbenzenes, and 0.3–10.7 μg safrole equiv/kg bw for the sum of alkenylbenzenes when
expressed in safrole equivalents. The margin of exposure (MOE) values obtained were generally
<10000, indicating a concern if the teas would be consumed on a daily basis over longer periods of
time.
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Introduction
At present there seems to be a growing interest for use of botanicals and botanical preparations in
medicines, as food flavors and spices, drugs, food supplements and/or teas (Rietjens et al., 2008).
This development is in part related to the fact that consumers consider natural products to be safe
(Rietjens et al., 2008, EFSA, 2009a). However, botanicals and botanical products are well known
to possibly contain a variety of natural toxins including chemicals like alkenylbenzenes,
aristolochic acids, or pyrrolizidine alkaloids that are known to be genotoxic carcinogens (EFSA,
2009b, WHO, 2009, Van den Berg et al., 2011a). The present paper focuses on exposure to
alkenylbenzenes as a result of use of parsley (Petroselinum crispum) and dill (Anethum
graveolens) in teas. Parsley is available almost worldwide and is presently cultivated as an annual
for its aromatic and attractive leaves (Simon and Quinn, 1988). Parsley has been used globally for
many years as a diuretic and a medicine for treatment of kidney health problems (Kreydiyyeh and
Usta, 2002, Bisset, 1994). In addition, many other medicinal claims have been associated with this
botanical and its preparations, including stomach, carminative, and abortifacient effects (Farzaei et
al., 2013, Kreydiyyeh and Usta, 2002). Dill is used as a medicinal herb for many purposes. For
example, for treatment of gastrointestinal colic, for antispasmodic effects on the smooth muscle of
the gastrointestinal tract, for treatment of disturbed nights, and for strengthening the brain
(Heamalatha et al., 2011). Given all these possible effects the use of parsley and dill in food
supplements and as teas becomes of increasing interest.
Parsley and dill based teas are available over the counter although they are known to contain the
alkenylbenzenes apiol and myristicin (WHO, 2009, EFSA, 2009b).
Apiol and myristicin are structurally related to other alkenylbenzenes like safrole, methyleugenol,
elemicin, and estragole reported to be of concern because of their potential to induce liver cancer
in experimental rodents at high levels of exposure (Miller et al., 1983, Phillips et al., 1984). The
alkenylbenzenes are rapidly absorbed after ingestion and transferred to the liver. In the liver one of
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the metabolic pathways of these compounds leads to formation of a reactive 1′-sulfoxy metabolite
that can form adducts with cellular macromolecules including proteins and DNA, the latter
contributing to the mode of action underlying the carcinogenicity (Borchert et al., 1973, Wiseman
et al., 1985, Alajlouni et al., 2016). Thus, alkenylbenzenes are considered to be genotoxic and
carcinogenic, and the risks associated with the levels of these alkenylbenzenes in a variety of
botanicals and botanical preparations remains to be evaluated. To evaluate the risk of genotoxic
and carcinogenic compounds, the so-called Margin of Exposure (MOE) approach was
recommended by expert groups of EFSA, the Joint FAO/WHO expert committee on Food
Additives (JECFA) and the International Life Sciences Institute (ILSI) (Barlow et al., 2006, EFSA,
2005, WHO, 2009, O'Brien et al., 2006). The MOE is a dimensionless ratio based on a reference
point obtained from epidemiologic or experimental data on tumor incidence which is divided by
the estimated daily intake in humans. The preferred reference point used in MOE calculations is
the Benchmark Dose Lower confidence limit for 10% tumor incidence (BMDL10). An MOE >
10000 is considered as a low priority for risk management actions (EFSA, 2005). The value of
10000 was defined based on considering various factors that cause uncertainties in the MOE
including 1) a factor 100 for species differences and human variability in toxicokinetics and
toxicodynamics, 2) a factor 10 for interindividual human variability in cell cycle control and DNA
repair, and 3) a factor 10 for the reason that the BMDL10 when used as a reference point is not
identical to a NOAEL (EFSA, 2005). The aim of the present study was to assess the risk of
exposure to alkenylbenzenes as a result of drinking parsley and dill based teas. This was done for
parsley and dill based tea samples available on the local Dutch market and via the internet, using
the MOE approach (EFSA, 2005). Given that chemical analysis of the collected samples revealed
the presence of more than one alkenylbenzene in several of the parsley and dill based teas,
combined exposure to different alkenylbenzenes was also taken into account.
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Materials and Methods:
Chemicals and materials:
Nineteen parsley or dill containing tea samples were purchased from the Dutch market and online.
The products were provided as tea bags, seeds or leaves. Some products were present as a mixture
with other herbs. Product characteristics are summarized in Table S1. Estragole (purity  98% w/w
(as indicated by the manufacturer)), methyleugenol (purity 99% w/w), safrole (purity >97% w/w),
and myristicin (purity >97% w/w) were obtained from Sigma Aldrich (Zwijdrecht, Netherland).
Apiol (purity >99%) and dill apiol (purity >99%) were obtained from Extrasynthese (Genay
Cedex, France). Elemicin was obtained from Synchem OHG (Felsberg, Germany). Acetonitrile
(ACN) (ULC/MS gradient), trifluoroacetic acid (TFA) and methanol (HPLC supra gradient) were
acquired from Sigma Aldrich. Nanopure water was obtained from an Arium pro UF/VF water
purification system (Sartorius Weighting Technology GmbH, Goettingen, Germany). Dimethyl
sulfoxide (DMSO) was acquired from Acros Organics (Geel, Belgium).
Methanolic extraction:
Methanolic extraction was applied to completely extract and quantify the amount of different
alkenylbenzenes present in the tea samples. The extraction was performed by adding 50 ml
methanol to 0.5 g of tea followed by sonication for 15 minutes. Upon sonication the extract was
filtered using a 0.45 µm syringe filter and the filtrate was stored at -20 °C until Ultra Performance
Liquid Chromatography (UPLC) analysis.  The method was based on the method described by
Gursale et al. (Gursale et al., 2010). A recovery analysis for the different alkenylbenzenes was
performed to account for possible losses during the extraction process if needed. To this end tea
sample number nine (Table S1) was spiked with all alkenylbenzenes under study providing two
spiked samples, one containing methyleugenol, myristicin, and apiol while the other contained
Chapter 4
122
safrole, estragole, and elemicin. These spiked samples were analyzed by the same procedure as
described above. The average percentage recoveries were found to equal 85.3% ± 2.9% for
estragole, 96.2% ± 6.0% for methyleugenol, 101.1% ± 5.4% for myristicin, and for apiol this was
94.5% ± 7.6%. Based on these outcomes the levels of the alkenylbenzenes detected in the different
teas were corrected for sample recovery. The limit of detection values were 8.6 µg/g for
myristicin, 9.3 µg/g for estragole, 6.4 µg/g for apiol and 7.9 µg/g for methyleugenol and limit of
quantification values were 28.8 µg/g for myristicin, 30.9 µg/g for estragole, 21.5 µg/g for apiol
and 26.4 µg/g for methyleugenol. The extraction procedure was shown to be linear with the
amount of dry tea sample and water used up to 2% weight of tea/volume of water (data not
shown).
Hot water extraction:
In order to mimic the way of preparation of homemade tea, hot water extraction was performed for
the tea samples essentially as described before (Raffo et al., 2011, Van den Berg et al., 2014). As a
first approximation, the weight of a parsley tea bag was taken to contain 2g of dry tea material
(Table S1) and a cup of tea was assumed to contain 200 ml hot boiling water. To mimic this
preparation method for the hot water extraction, 50 ml of boiling water were added to 0.5 g of each
tea sample in a covered beaker and the mixture was incubated for 7 minutes. During this period the
incubation was stirred three times.  Subsequently the extract was centrifuged at 16,000 g for 5
minutes and the supernatant obtained was stored at -20 °C until UPLC analysis.
UPLC analysis:
For analysis of the methanolic tea extracts the samples were analysed both in undiluted form and
also diluted 10 times with methanol because the amount of the alkenylbenzenes was expected to be
high, while hot water extracts were analyzed undiluted. UPLC analysis was performed using a
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Waters (Waters, Milford, MA) Acquity solvent manager, sample manager, and diode array
detector, equipped with a Water Acquity C18 1.7 µm column, 2.1 x 50 mm. The gradient was
made with a mixture of ACN and ultrapure water containing 0.1% (v/v) TFA. The flow rate was
0.6 ml/min. After equilibrating the column at starting conditions of 31% ACN, the % ACN was
kept at this level for 5 minutes and then increased to 80% over 4 minutes and kept at 80% for 1
minute, then decreased to 0% over 1.5 minutes and kept at 0% for 1 minute after which the % of
ACN was returned to the starting conditions. Identification and quantification of the different
alkenylbenzenes was done by comparison of the retention time, UV spectrum and peak areas
obtained at 209 nm for apiol and myristicin and at 201 nm for methyleugenol and estragole to the
retention time, UV spectrum and calibration curve of commercially available standards. In the
present study no difference was made between parsley apiol and dill apiol since they co-eluted on
the UPLC column. It appeared that due to the limited difference in their chemical structure,
reflected by a different position of one of the methoxy substituents, parsley and dill apiol elute at
the same retention time and could not be separated under the conditions applied. Their
identification was based on the nature of the botanical ingredients listed to be part of the respective
tea sample (Table S1).
Estimation of daily intakes of alkenylbenzenes resulting from the use of teas.
For estimation of the alkenylbenzene exposure resulting from use of the teas, the concentration of
the alkenylbenzene quantified in the hot water extract was corrected by a factor that accounted for
the amount of tea likely to be used to make a cup of tea. If possible this amount was derived from
the amount present in the tea bags, or specified on the label. For those samples where this
information was not available it was assumed that 2 grams of dry tea is used to prepare a cup (200
ml) of tea following the assumptions made by the ESCO working group, that 1.5 – 2.5 g of tea
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material will be used to prepare a cup of tea of bitter fennel (EFSA, 2009a) and also based on the
fact that most of the parsley tea bags appeared to contain 2g of dry tea material (Table S1).
Intake estimates for combined exposure to different alkenylbenzenes.
Since several of the tea samples appeared to contain more than one alkenylbenzene (see Result
section), a combined exposure assessment and subsequent risk assessment were also performed. A
first issue to solve for such a combined risk assessment is how to combine the levels of the
different alkenylbenzenes when defining an estimated daily intakes (EDI). To this end it is of
importance to take into account that there is high similarity between the different alkenylbenzenes;
in structure, target organ, type of adverse effects, and mode of action through formation of a DNA
reactive 1′-sulfoxy metabolite contributing to formation of liver tumors. Based on this similar
mode of action and similar target organ and end point the effect of combined exposure to different
alkenylbenzenes present in the teas is assumed to be adequately described by dose addition. Based
on these considerations two approaches were applied for the combined risk assessment. The first
one was based on adding the levels of the different alkenylbenzenes as such, and the second
approach was based on the use of a so-called Toxic Equivalency (TEQ) approach. For the latter
approach, Toxic Equivalency Factors (TEFs) for the different alkenylbenzenes need to be defined,
in order to allow expression of the EDIs of the combined exposure to the alkenylbenzenes in toxic
equivalents. In the present study TEF values for the different alkenylbenzenes were defined taking
safrole as the reference (TEF safrole = 1.00) enabling expression of the overall alkenylbenzene
concentration and EDI in safrole equivalents. The TEF values for the different alkenylbenzenes
were defined by taking the average of three approaches. In the first approach TEF values were
defined based on data for DNA adduct formation by the different alkenylbenzenes in CD-1 mice as
reported by Randearath et al. (Randerath et al., 1984). Based on these data the TEF values could be
derived from the slopes of dose-response curves for DNA adduct formation in the liver for the
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different alkenylbenzenes. The second approach for definition of TEF values was based on data
obtained from human physiologically-based kinetic (PBK) models that allow prediction of the
dose-dependent relative formation of the ultimate carcinogenic 1′-sulfoxy metabolite representing
the relative importance of the bioactivation route. This approach was feasible since for all
alkenylbenzenes of interest PBK models to predict their relative bioactivation have been
developed (Al-Subeihi et al., 2011, Martati et al., 2011, Punt et al., 2008, Van den Berg et al.,
2012, Alajlouni et al., 2016). The third approach was based on the benchmark dose lower
confidence limit for 10% tumor incidence above background (BMDL10) values of alkenylbenzenes
calculated based on carcinogenicity data reported by Miller et al. (Miller et al., 1983). For safrole,
methyleugenol, and estragole such BMDL10 values have been derived previously based on
available in vivo tumor data (Van den Berg et al., 2011b).  For apiol, elemicin and myristicin in
vivo animal tumor data are not available and as a result BMDL10 values cannot be defined from
available tumor data but only estimated based on read-across from the structurally related
alkenylbenzenes estragole and methyleugenol for elemicin (Van den Berg et al., 2012) or from
safrole for myristicin (Al-Malahmeh et al., 2016) and apiol (Alajlouni et al., 2016). The average
TEF of the three approaches above were used to calculate the EDI of the alkenylbenzenes
extracted from the tea samples expressed in µg safrole equivalents/kg bw.
Calculation of the MOE
The MOE values were calculated in three ways; first the MOE values were calculated for the
individual alkenylbenzenes using their respective BMDL10 values, then the MOE values were
calculated using a combined exposure assessment assuming equal potency of all alkenylbenzenes
and the BMDL10 for the major alkenylbenzene in each mixture, and finally MOE values were
calculated based on the TEQ approach calculating the combined exposure in safrole equivalents
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and using the BMDL10 of safrole. BMDL10 values were obtained from literature (Alajlouni et al.,
2016, Van den Berg et al., 2011b, Al-Malahmeh et al., 2016).
Results:
Chemical analysis of samples:
Table 1 presents the level of different alkenylbenzenes found in the dry tea samples when using
the methanol extraction method as well as the concentrations determined in the hot water extracts.
The amounts of alkenylbenzenes extracted using hot water were significantly lower than the
amounts extracted by methanol, the latter assumed to result in optimal extraction efficiency.  The
amount of alkenylbenzenes extracted into the hot water samples amounted to 10 to 62 % of the
amount extracted using methanol. This indicates that there was wide variation in the hot water
extraction efficiency which might be related to the actual form in which the dry sample was
provided; whole fruits or fine cut (Table S1). Samples containing fine cut material resulted in
extraction efficiencies of 15-62 % while samples containing whole fruits gave rise to extraction
efficiencies of 10-18 %. The results obtained also revealed that 15 out of the 19 samples appeared
to contain alkenylbenzenes with 7 out of the 15 samples containing alkenylbenzenes actually
containing more than one alkenylbenzene. It was of interest to note that 10 samples appeared to
contain apiol. Given the co-elution of apiol from parsley and dill, the nature of the apiol present
can best be derived from the plant species present in the tea samples. Given the nature of the plant
species present in the different tea samples (Table S1), it was likely that several apiol containing
teas (3, 10, 11, 12, 16, 18 and 19) contained parsley apiol while 3 out of the apiol containing teas
(4, 6 and 14) would contain dill apiol. Other alkenylbenzenes detected were myristicin, estragole,
and methyleugenol.
Level of alkenylbenzenes in parsley and dill based teas and associated risk assessment
127
EDI of individual alkenylbenzenes resulting from tea consumption.
Daily intake of different alkenylbenzenes was estimated based on the concentration of the
alkenylbenzenes in the hot water extracts assuming a body weight of 70 kg (Table 1).
Table 1: Level of alkenylbenzenes found in the methanol and hot water extracts of different tea
samples and the calculated extraction efficiency into hot water extractsa.
tea
sampl
e
alkenylbenzene
s detected
alkenylbenzene level in
the dry tea sample
Average ± SD
(in µg /g dry tea
preparation)
alkenylbenzene in the
hot water extract
(µg /50 ml infusion
extracted from 1 g
sample material ± SD)
extraction
efficiency
into hot
water
infusion (%)
EDI based
on
consumptio
n of one cup
of tea
(μg/kg bw)
01 NDb ND ND ND -
02 methyleugenol 575.4 ± 19.5 354.9± 60.2 62 10.1
estragole 302.6 ± 20.3 66.3±7.2 22 1.9
03 apiol 51.2± 5.0 31.3 ± 3.0 61 0.9
04 apiol 18.5 ± 2.1 ND ND -
05 methyleugenol 288.6 ± 13.6 155.8± 29.9 54 4.5
06 apiol 392.7 ±13.8 228.6± 8.9 58 6.5
07 ND ND ND ND -
08 methyleugenol 235.3 ± 30.7 131.6± 26.6 56 3.8
09 myristicin 1269.8± 68.3 125.7± 17.8 10 3.6
10 myristicin 726.3± 30.4 103.2± 8.2 14 3.0
apiol 226.4± 9.0 75.6± 5.9 33 2.2
11 myristicin 992.8± 75.5 98.2± 13.1 10 2.8
apiol 381.8± 24.8 124.4± 10.6 33 3.6
12 myristicin 980.0 ± 81.3 148.0± 21.4 15 4.2
apiol 576.4 ± 44.7 290.9± 39.8 50 8.3
13 methyleugenol 33.2± 1.4 19.4± 1.8 58 0.6
14 apiol 356.6 ± 26.9 64.3 ± 7.1 18 1.8
15 ND ND ND ND
-
16 myristicin 64.6 ±11.3 21.4 ± 1.8 33 0.6
apiol 195.4 ±15.1 93.6 ± 6.1 48 2.7
17 ND ND ND ND
-
18 myristicin 1171.5 ± 160.0 180.9 ± 21.5 15 5.2
apiol 667.9 ± 33.5 276.3± 24.8 41 7.9
19 myristicin 1055.6 ± 34.5 150.1 ±13.1 14 4.3
apiol 19.9 ± 1.5 6.5 ± 0.2 33 0.2
aLevels presented were calculated back to original dry weight for the dry tea sample and presented
as the amount per ml hot water extract. From these values the EDI’s were calculated assuming
intake of one cup of tea and a body weight of 70kg.
bND: Not Detected.
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EDI for combined exposure to alkenylbenzenes resulting from tea consumption:
Combined exposure was determined by adding up the individual levels and by using TEQ
approach (table 2). TEF values for the different alkenylbenzenes were determined by three
different approaches as explained in the Materials and method section. The detailed outcomes for
the three methods are presented in Tables S2, S3 and S4 while Table 2 presents an overview of the
TEF values thus obtained calculating the average of the TEF values obtained by the three methods.
Table 2: Overview and average of the TEF estimates obtained using the different protocols as
presented in Table S2-S4.
compound
TEF derived from
in vivo DNA
adduct formation
(Table S2)
TEF derived from
human PBK model
based prediction of 1′-
sulfoxy metabolites
formation
(Table S3)
TEF derived from
the BMDL10 for
liver tumor
formation
(Table S4)
average
TEF value +
SD
safrole 1.00 1.00 1.00 1.00
myristicin 0.23 0.74 1.00 0.66 ± 0.39
apiol 0.07 0.49 0.33 0.30 ± 0.21
estragole 1.48 4.28 0.72 2.16 ± 1.87
methyleugenol 0.95 0.92 0.14 0.67 ± 0.46
elemicin 0.08 0.36 0.07 0.17 ± 0.16
These average TEF values were used to determine the EDI of the combined exposure to
alkenylbenzenes extracted from the tea samples expressed in safrole equivalents. The EDI values
thus obtained are presented in Table 3.
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Table 3: EDIs resulting from combined intake assessment of alkenylbenzenes assuming use of
one cup of tea a day and 70 kg bw.
tea
sample
alkenylbenzenes
detected
EDI of the
individual
alkenylbenzenes
based on
consumption of one
cup of tea (µg/kg
bw) as taken from
Table 1
combined EDI of
the individual
alkenylbenzenes
based on
consumption of
one cup of tea
(µg/kg bw)
assuming similar
potency
EDI for the
individual
alkenylbenzenes
expressed in µg
safrole
equivalents/kg bw
using the average
TEF values
resulting from 1
cup of tea
combined
EDI in µg
safrole
equivalents
per kg bw
resulting
from 1 cup of
teaa
2
methyleugenol 10.1
12
6.7
10.7
estragole 1.9 4
3 apiol 0.9 0.9 0.3 0.3
5 methyleugenol 4.5 4.5 2.7 2.7
6 apiol 6.5 6.5 2 2
8 methyleugenol 3.8 3.8 2.2 2.2
9 myristicin 3.6 3.6 2.4 2.4
10
myristicin 2.9
5.1
2
2.7
apiol 2.2 0.7
11
myristicin 2.8
6.4
1.9
3
apiol 3.6 1.1
12 myristicin 4.2 12.5 2.8 5.3
apiol 8.3 2.5
13 methyleugenol 0.6 0.6 0.3 0.3
14 apiol 1.8 1.8 0.6 0.6
16 myristicin 0.6 3.3 0.4 1.2
apiol 2.7 0.8
18 myristicin 5.2 13.1 3.4 5.8
apiol 7.9 2.4
19 myristicin 4.3 4.5 2.8 2.9
apiol 0.2 0.1
a calculated as Σ (EDI of each alkenylbenzenes × TEF (safrole equivalent))
Combined risk assessment of tea consumption using the Margin of Exposure (MOE).
Figure 1A presents the MOE values calculated for individual alkenylbenzenes using BMDL10
values taken from literature (Alajlouni et al., 2016, Al-Malahmeh et al., 2016, Van den Berg et al.,
2011b).  The results obtained reveal MOE values generally below 10000 except for 2 values
(samples T13 and T19) for which the MOE value was > 10000 for a minor alkenylbenzene in the
mixture (Figure 1A).
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Based on combined risk assessment, the MOE values for consumption of one cup of tea first were
calculated by dividing the BMDL10 of the major alkenylbenzene in the hot water extract by the
EDI for the respective tea sample expressed as total alkenylbenzenes assuming equal potency.
Second, the MOE values obtained by dividing the BMDL10 of 1.9 mg/kg bw per day for safrole
(Van den Berg et al., 2011b) by the EDI for the respective tea samples expressed in safrole
equivalents (Figure 1B and 1C). The results obtained reveal MOE values that are all lower than
10000 for both approaches for the combined risk assessment except for sample number 13
calculated by the first approach for which the MOE is higher than 10000 (Figure 1B and 1C). The
results also revealed that the MOE values obtained using the two methods for combined risk
assessment do not vary substantially, with the final conclusion on the need for risk management
for samples with MOE < 10000 being similar for both methods except for sample 13.
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Figure 1: MOE values based on the three approaches used: A) MOE values for the individual
alkenylbenzenes using their BMDL10 values (apiol (5.7 mg/kg bw/day) (Alajlouni et al., 2016),
myristicin (1.9 mg/kg bw/day ) (Al-Malahmeh et al., 2016), methyleugenol (15.3 mg/kgbw/day)
(Van den Berg et al., 2011b) and estragole (3.3 mg/kg bw/day ) (Van den Berg et al., 2011b): B)
MOE values for the combined exposure assuming equal potency of all alkenylbenzenes and using
the BMDL10 value of the major alkenylbenzenes in the mixture. MOE values for combined
exposure using the TEQ approach based on safrole equivalents and using the BMDL10 value of
safrole (1.9 mg/kg bw/day) (Van den Berg et al., 2011b). The grey line represents the limit of
MOE of 10000 with MOE values <10000 pointing at a priority for risk management.
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Discussion:
The aim of the present study was to assess the risk of exposure to alkenylbenzenes as a result of
drinking parsley and dill based teas. Chemical analysis of the overall levels of alkenylbenzenes in
the different teas as derived from the methanol extractions revealed that 15 out of 19 tea samples
analysed contained alkenylbenzenes, with 7 out of these 15 samples containing more than one
alkenylbenzene. When making the hot water extracts it turned out that 14 out of 19 tea samples
contained alkenylbenzenes at quantifiable levels while 7 out of these 14 contained more than one
alkenylbenzene. This result points at the need for a combined risk assessment given the similar
critical effect and target organ for the different alkenylbenzenes, being hepatocarcinogenicity
induced via a genotoxic mode of action (Borchert et al., 1973, Wiseman et al., 1985, Kobets et al.,
2016). The tea samples that contained more than one alkenylbenzenes were generally teas that did
not contain only parsley or dill but were made of a combination of a wide variety of herbs including
also parsley and/or dill. Apiol was detected in 10 out of 15 alkenylbenzene containing teas which
is in line with the fact that the teas were selected based on having parsley or dill as a basic material,
and parsley and dill are known to generaly contain high levels of apiol (Semenov et al., 2007).
The total content of alkenylbenzenes in the dry tea samples ranged from 18-1269 µg/g dry
preparation. Different factors may cause this high variation of alkenylbenzene levels in the tea
samples including genetic factors, geographical influences in cultivation, harvesting time,
processing and manufacturing conditions, and the method of drying, which can all influence the
concentrations of alkenylbenzenes (Smith et al., 2002).
To mimic the way of preparing of a cup of tea at home, and estimate the expected exposure to
akenylbenzenes when drinking tea made from the different samples, hot water extraction of the
teas was perfomed. The hot water extraction efficiency for the alkenylbenzenes appeared to vary
from 10-62%, reflecting that upon hot water extraction not all alkenylbenzenes present in the dry
tea sample and detected in the methanolic extract will eventually end up in the tea as consumed.
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This lower bioaccessability of the alkenylbenzenes from the tea samples upon extraction with hot
water than with methanol can be explained by the fact that alkenylbenzenes have higher ability to
disssolve in methanol than in water and may also be related to the ability of methanol to break
down the cell walls thereby increasing the extraction efficiency. In addition the methanolic
extraction method included ultrasonification that facilitates degradation of cell walls and release of
cellular contents (Ebringerová and Hromádková, 1997). Finally also the form of tea sample may
play role in extraction efficiency with extraction form fine cut material showing higher efficiency
than that from whole fruit samples. Our results are comparable to those reported by Zeller and
Rychilk reporting that hot water extraction of alkenylbenzenes from fennel is 45% (Zeller et al.,
2009). On the other hand our results showed high hot water extraction efficiency compared to
results reported by Van den Berg et al. (Van den Berg et al., 2014) for extraction of
alkenylbenzenes from fennel teas, which was much lower, amounting to 0.1-2.3% perhaps related
to the different herbal species involved.
Based on the chemical analysis of the hot water extracts, the EDI of alkenylbenzenes when
actually consuming tea prepared from the different tea samples was determined. Based on
consumption of one cup of tea the EDI values of the individual alkenylbenzenes ranged from 0.2-
10.1 µg/kg bw assuming a body weight of 70 kg. These EDI values resulted in MOE values that
were generally below 10000, except for sample 13 and 19. Previosuly Van den Berg et al. (2014)
evaluated the hazards and risk of the presence of the alkenylbenzene estragole in fennel based teas
and found a similar result for especially children for which the MOE values for estragole exposure
upon intake of one cup of fennel tea were generally < 10000. For adults, however, especially upon
intake of only one cup of tea, MOEs pointed at a low pritoriy for risk assessment, being > 10000
(Van den Berg et al., 2014). MOEs for exposure to methyleugenol from other sources than tea
were also provided. Grosch et al. (2013) reported a study in which levels of methyleugenol were
quantified in various food items including samples of basil, estragon, pimento, nutmeg, several
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teas, alcoholic beverages, and pesto. Based on the levels detected the authors estimated the
exposure to methyleugenol to be below 1 µg/kg bw/day for the average German population. As a
worst case example they calculated an MOE of 3084 resulting from intake of 29 g of sauces and
flavour ingredients per day using the methyleugenol level detected in pesto sauce of 5.3 mg/kg and
a 60 kg bw (Grosch et al., 2013). And Smith et al. (2010) reported MOEs for exposure to
methyleugenol from all food sources that ranged from 100-800 depending on the assumptions used
in the exposure estimate (Smith et al., 2010).
By using the additive effect of alkenylbenzenes the combined EDI values obtained ranged from
0.6-13.1 µg/kg bw. Based on this and using the BMDL10 of the major alkenylbenzene present in
the sample, MOE values below 10000 were obtained for all samples except sample 13 (Figure
1B).
Use of the average TEF values resulted in combined EDI values that ranged from 0.3-10.7 µg/kg
bw. These values were generaly 35-84 % of the combined EDI values obtained by just summing
up the levels, which is mainly due to the fact that the TEF values for the different alkenylbenzenes
are generally lower than 1.00 the value for the reference compound safrole (Table. 2). The MOE
values obtained using these EDI values expressed in safrole equivalents and the BMDL10 of
safrole of 1.9 mg/kg bw by were <10000 for all samples (Figure 1C).
Thus, all approaches chosen for estimating the EDI result in MOE values below 10000 for
consumption of one cup of tea for 14 out of the 19 tea samples. The results also reveal that the
MOE values obtained using the two methods for combined risk assessment do not vary
substantially, with the final conclusion on the need for risk management for samples with MOE <
10000 being similar for both methods except for sample 13.
The overall conclusion did not change with the method used to estimate the MOE: in all three
cases MOE values resulting from consumption of already one cup of tea per day were below
10000.
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It is important however that these MOE values assume daily use of the herbal teas over longer
periods of time and even lifelong while in reality some of these teas may be consumed for
relatively shorter time periods especially when they would be used for medicinal purposes.
Assuming use of the teas for periods of only a few weeks instead of during a whole life (70 years
52 weeks a year), would increase MOE values by two to three orders of magnitude indicating a far
lower priority for risk management. Taking into account this consideration it is concluded that the
present study shows that use of parsley and dill based teas is a concern especially for people who
frequently drink large quantities of these herbal teas.
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Table S1: Parsley and dill tea products used in the present study and their major characteristics.
Information provided was derived from the label of the preparation unless stated otherwise.
tea
sample origin form how to use ingredients
01 Canada fine cut
one tea bag in boiling water
for 3-5 or 7-12 minutes parsley leaf
02 USA fine cut
one tea bag in boiling water
for 5-10 minutes and 1 to 3
cups a day
fennel seed, ginger root,
cinnamon bark, chamomile
flower, raspberry leaf, anise seed,
dong quai root extract, chaste tree
berry extract, Juniper berry
extract, parsley leaf
03 Canada fine cut one tea bag in boiling waterfor 2-4  minutes parsley
04 Canada fine cut One tea bag in boiling
water for 2-4  minutes dill seed
05 Hamburg,Germany fine cut
one tea bag in boiling water
for 5-10 minutes
liquorice, cinnamon, burdock
root, ginger, dandelion, fennel,
anise, Juniper berries,
coriander, cardamom, black
pepper, parsley, sage, cloves,
turmeric root
06 TheNetherlands fine cut no information provided
Aniseed, fennel, dill, caraway,
fenugreek, liquorice, mustard
seed
07 TheNetherlands fine cut
one tea bag (2 g) in boiling
water for 5-10 minutes
aniseed, dill seed, caraway seed,
mustard seeds, fennel seeds,
fenugreek seeds, liquorice
08 TheNetherlands fine cut
one tea bag (2 g) in boiling
water for 5-10 minutes
liquorice, cinnamon, burdock,
dandelion, fennel, anise,
coriander, Juniper, cardamom,
black pepper, sage, parsley,
cloves
09 TheNetherlands
whole
fruits
2 tablespoons of herbs on a
pint of boiling water. 10
minutes infusion
parsley seed, stable herbs,
liquorice, lovage, Juniper,
aniseed
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10 TheNetherlands powder no information provided chopped parsley leaf
11 TheNetherlands fine cut no information provided chopped parsley
12 TheNetherlands fine cut no information provided chopped parsley
13 TheNetherlands fine cut no information provided
nettle, liquorice, yarrow,
lungwort, malva leaf, knotgrass,
elderflower, lady’s mantle,
bedstraw, plantain, basil, savory,
dill, tarragon leaf, caraway seed,
chervil, coriander, lovage,
marjoram, lemon balm, parsley,
rosemary, celery, thyme, fennel,
strawberry leaves, blood root,
blackberry leaves, rupturewort,
pansy, speedwell, raspberry leaf,
marigold, grass root, goldenrod,
oat straw, clover honey, lime
blossom, eyebright, pelargonium,
rose, rosehip, verbena
14 TheNetherlands
whole
fruits
2 tablespoons of herbs on a
pint of boiling water. 10
minutes infusion (indicated
on internet)
dill, caraway, anise and cumin
15 TheNetherlands
whole
fruits
1 tablespoon in 500 ml
boiling water for 10 min
fennel seed, dill seed, fenugreek,
liquorice and anise
16 Canada fine cut one tea bag (1 g) in boiling
water for 3-6 minutes parsley leaf
17 Lithuania fine cut one tea bag (1.5 g) inboiling water for 5-7
minutes
chokeberry fruits, lavender
flowers, parsley leaves, lemon-
balm leaves, oregano herb, Java
tea leaves
18 USA fine cut one tea bag (2 g) in boiling
water for 10 minutes; 3
times daily
parsley leaves
19 USA fine cut
one tea bag (1.5 g) in
boiling water for 3 minutes
and press the bag before
removing
parsley leaves
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Table S2: TEF values for the different alkenylbenzenes as derived from data reported for the dose-
dependent level of DNA adduct formation in the liver of alkenylbenzene exposed CD-1 mice
(Randerath et al., 1984).
compound
dose of
alkenylbenzene
(mg/kg.bw)
total Relative Adduct
Labelling (RAL) (1
adduct in 107
nucleotides) X107 + SD
slope of the curve for
formation of DNA adduct in
107 nucleotides versus dose
(mg / kg.bw)
TEF
safrole
0 0
1.68 1.0080 153 + 27
400 678 + 151
myristicin
0 0
0.39 0.2380 56 + 6.4
400 165 + 30
apiol
0 0
0.11 0.0780 12 + 3.5
400 46 + 9.5
estragole
0 0
2.48 1.4880 109 + 8.2
400 963 + 51
methyleugenol
0 0
1.6 0.9580 150 + 15
400 646 + 88
elemicin
0 0
0.14 0.0880 6.2 + 0.7
400 54 + 5.3
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Table S3: TEF values for the different alkenylbenzenes as derived from the formation of the
proximate carcinogenic 1′-sulfoxy metabolites in liver in µmol/kg bw as predicted by the available
PBK models at a dose level of 0.01 mg/kg bw.
compound
1′-sulfoxy metabolite
concentration
µmol/kg bw
reference for the PBK model TEF (safrole
equivalent)
safrole 3.28E-05 (Martati et al., 2012) 1.00
myristicin 2.44E-05 (Al-Malahmeh et al., 2016) 0.74
apiol 1.62E-05 (Alajlouni et al., 2016) 0.49
estragole 1.41E-04 (Punt et al., 2009) 4.28
methyleugenol 3.05E-05 (Al-Subeihi et al., 2012) 0.92
elemicin 1.20E-05 (Van den Berg et al., 2012) 0.36
Table S4: TEF values for the different alkenylbenzenes as derived from BMDL10 values reported
in the literature.
compound BMDL10
(mg/kg bw.day)
reference TEF (safrole
equivalent)a
safrole 1.9-5.1 (Van den Berg et al., 2011b) 1.00
myristicin 1.9-5.1 (Al-Malahmeh et al., 2016) 1.00
apiol 5.7-15.3 (Alajlouni et al., 2016) 0.33
estragole 3.3-6.5 (Van den Berg et al., 2011b) 0.72
methyleugenol 15.3-34 (Van den Berg et al., 2011b) 0.14
elemicin 30.6-68 (Van den Berg et al., 2012) 0.07
a calculated using average BMDL10 value.
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Abstract
A risk assessment of parsley and dill based plant food supplements (PFS) containing apiol and
related alkenylbenzenes was performed. First the levels of the alkenylbenzenes in the PFS and the
resulting estimated daily intake (EDI) resulting from use of the PFS were quantified. Since most
PFS appeared to contain more than one alkenylbenzene a combined risk assessment was performed
based on equal potency or using a so-called Toxic Equivalency (TEQ) approach based on Toxic
Equivalency Factors (TEFs) for the different alkenylbenzenes. The EDI values resulting from daily
PFS consumption amount to 0.74 to 125 µg/kg bw for the individual alkenylbenzenes, 0.74 to 160
alkenylbenzenes when expressed in safrole equivalents. The Margin of Exposure (MOE) values
be consumed on daily basis. Considering short term use of the PFS, MOE values would increase
above 10000 indicating low priority for risk management. It is concluded that alkenylbenzene
intake through consumption of parsley and dill based PFS is only of concern when these PFS are
used for long periods of time.
obtained were generally below 10000 indicating a priority for risk management if the PFS would
µg/kg bw for the sum of the alkenylbenzenes and 0.40  to 60 µg/kg bw for the sum of
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Introduction
Parsley (Petroselinum crispum) and dill (Anethum graveolens) just like many other botanical and
botanical preparations have been used for medicinal and edible purposes around the world because
of their many active ingredients (Popovic et al., 2007, Heamalatha et al., 2011). Because people
tend to assume that natural products are safe, use of botanicals and botanical preparations as plant
food supplements (PFS) is increasing rapidly all over the world (Rietjens et al., 2008, EFSA,
2009a). Parsley and dill are widely used as flavoring agents in food or as medicinal drugs since
many health claims suggest that use of these botanicals may promote health or cure a disease
(Leung and Foster, 1996). Parsley is for example used as a curing agent in kidney health issues
(Bisset, 1994, Blumenthal, 1999) and as a diuretic agent for treatment of some gastrointestinal tract
problems (Kreydiyyeh and Usta, 2002). Dill is used for the treatment of gastrointestinal problems
such as flatulence, indigestion, stomachache and colic, because of its antispasmodic effect on the
smooth muscle of the gastrointestinal tract. In addition, dill has been used to stimulate and
strengthen the brain and alleviate tiredness from disturbed nights (Heamalatha et al., 2011, Kaur
and Arora, 2010). However, botanicals and PFS derived from parsley and dill may also contain
harmful compounds such as the alkenylbenzenes apiol and myristicin (EFSA, 2009b, FAO/WHO,
2009). These two compounds are structurally related to alkenylbenzenes like safrole, estragole,
methyleugenol, and elemicin (Figure 1) (FAO/WHO, 2009, EFSA, 2009b).
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Figure 1: Structures of myristicin and apiol and related alkenylbenzenes
These alkenylbenzenes are of concern because they have been shown to be carcinogenic and
genotoxic (Borchert et al., 1973, Miller et al., 1983, Wiseman et al., 1985, Randerath et al., 1984,
FAO/WHO, 2009). Miller et al., for example, found that injection of high doses of safrole,
methyleugenol, or estragole to mice over a 12 months period led to significant formation of hepatic
tumors (Miller et al., 1983). Other alkenylbenzenes such as apiol and myristicin may be less potent
carcinogens but still have the ability to induce hepatic tumors by a similar mode of action (Phillips
et al., 1984, Randerath et al., 1984, Zhou et al., 2007). The mode of action underlying the ability of
these compounds to induce cancer is considered to be the formation of DNA adducts upon
formation of 1′-sulfoxy metabolites (Figure 2) (Alajlouni et al., 2016b, Al-Malahmeh et al., 2016,
Al-Subeihi et al., 2012, Van den Berg et al., 2012, Martati et al., 2012, Punt et al., 2009). The 1′-
sulfoxy metabolites of alkenylbenzenes have the ability to bind to cellular macromolecules
including DNA.
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Figure 2: Metabolic pathways of apiol.
Because of their genotoxic and carcinogenic properties, the European Commission has prohibited
the use of safrole, methyleugenol and estragole as pure substances in foodstuffs since September
2008 with exceptions for some specific products (European Commission (EC), 2008). Given that,
there is currently no EU legislation specifically for botanicals other than the general food
law Regulation 178/2002 (EFSA, 2009a) and the general food low provides the general basis for
the assurance of a high level of protection of human health (European Commission (EC), 2002)
and botanical based PFS do not fall under these regulations, it is of interest to characterize the
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levels and accompanying hazards and risks of alkenylbenzene containing PFS. Some studies
recently focused on PFS containing estragole, myristicin and safrole (Van den Berg et al., 2011)
but so far parsley and dill based PFS potentially containing apiol and/or myristicin were not
studied. A study on parsley and dill based teas showed that most of the examined samples
contained alkenylbenzenes at levels that result in estimated intakes that would pose a priority for
risk management assuming daily use of those teas (Alajlouni et al., 2016a). Therefore, the aim of
the present study was to assess the risk of exposure to alkenylbenzenes as a result of consumption
of PFS containing parsley and dill. To this end levels of alkenylbenzenes in parsley and dill
containing PFS obtained on the market were quantified to facilitate a combined exposure
assessment and a subsequent risk assessment by the so-called Margin of Exposure (MOE)
approach which is the preferred method for risk assessment of compounds that are both
carcinogenic and genotoxic (EFSA, 2005).
Materials and Methods
PFS and Chemicals
PFS based parsley and dill products were purchased from the local Dutch market and online. The
products were in the form of capsules and pills. According to the information on the respective
labels some products contained more than parsley or dill. Product information is summarized in
Table 1. Estragole (purity 98% w/w (as indicated by the manufacturer)), methyleugenol (purity
99% w/w), safrole (purity >97% w/w), and myristicin (purity >97% w/w) were obtained from
Sigma Aldrich (Zwijdrecht, Netherland). Apiol (purity >99%) and dill apiol (purity >99%) were
obtained from Extrasynthese (Genay Cedex, France). Elemicin was obtained from Synchem OHG
(Felsberg, Germany). Acetonitrile (ACN) (UPLC/MS gradient), trifluoroacetic acid (TFA) and
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methanol (HPLC supra gradient) were acquired from Sigma Aldrich. Nano pure water was
obtained from an Arium pro UF/VF water purification system (Sartorius Weighting Technology
GmbH, Goettingen, Germany). Dimethyl sulfoxide (DMSO) was acquired from Acros Organics
(Geel, Belgium).
Table 1: Parsley and dill based PFS used in the present study and their major characteristics.
PFS
Product name
and type of
supplement
Origin PFS characteristics and recommended
daily dose
Health claim
1 Vocht Support.
Parsley
containing
dietary
supplement
capsules for a
balanced diet.
Netherlands Supplement consisting of
80 mg parsley, 80 mg ponytail
(Beaucarnea recurvate), 80 mg
bearberry (Arctostaphylos uva-ursi), 80
mg juniper (Juniperus), 80 mg
goldenrod (Solidago), 30 mg calcium
chloride / capsule.
Recommended daily dose: 3 capsules
per day.
Proper moisture balance.
2 Parsley Leaf.
Parsley
containing
dietary
supplement
capsules.
USA Supplement consisting of
450 mg parsley / capsule.
Recommended daily dose:
6 capsules daily.
Treatment of anemia,
high content in vitamin
C. Protects breath from
smelling.
3 Parsley Leaves
Herbal dietary
supplement
capsules.
USA Supplement consisting of
335 mg parsley / capsule.
Recommended daily dose:
2 capsules per day.
Herbalists use the leaves
to nutritionally support
the kidneys and urinary
system, but the whole
plant can be used for
general nutritional
needs.
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4 Liver Complex
powder-Red
beet,
Horseradish,
Dandelion and
more. Dietary
supplement
powder.
Canada Supplement consisting of a mixture of
powdered plant material.
Supplement consisting of 450 mg
parsley, 450 mg barberry (Berberis
vulgaris), 450 mg dandelion
(Taraxacum), 450 mg fennel
(Foeniculum vulgare) , 450 mg horse
radish (Armoracia rusticana), 450 mg
rosehip (Rosa canina), and 450 mg  beet
root (Beta vulgaris) / ¼ teaspoon.
Recommended daily dose:
¼ (1 g) teaspoon 3 times a day.
Diuretic and has been
shown to have bacteria-
killing and fungicide
effects in vitro.
5 Dill seed
containing
dietary
supplement
capsules.
Canada Supplement consisting of
450 mg dill seed / capsule.
Recommended daily dose:
3 capsules per day.
(-)
6 Dr.Clark Purity.
Parsley
containing
dietary
supplement
capsules.
USA Supplement consisting of
385 mg freeze dried parsley / capsule.
Recommended daily dose:
2 capsules daily.
Supports kidney
function, aids in
detoxification, anti-
inflammatory properties.
7 Interfresh.
Parsley
containing food
supplement oil
capsules.
UK Supplement consisting of
15 mg parsley seed oil / capsule.
Recommended daily dose:
2 capsules up to 3 times a day.
Bad breath remedy.
8 New care
Parsley
containing
Netherlands Supplement consisting of
80 mg parsley, 80 mg ponytail, 80 mg
bearberry, 80 mg juniper, 80 mg
Proper moisture balance.
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dietary
supplement
capsules.
goldenrod, 30 mg calcium chloride /
capsule.
Recommended daily dose: 3 capsules
per day.
9 B-50 Vitamin
complex tablets
containing
parsley.
Netherlands Supplement consists of a mixture of 2.5
mg powdered plant material.
Recommended daily dose: 1 tablet per
day
Supports central nervous
system.
10 Mountain fresh
Dill weed
containing
dietary
supplement
capsules.
UK Supplement consisting of
500 mg dill / capsule.
Recommended daily dose : 2-3 capsules
daily
(-)
11 Mountain fresh
Parsley Root
containing
dietary
supplement
capsules.
UK Supplement consisting of
1000 mg parsley / capsule.
Recommended daily dose : 1 capsule
daily
(-)
12 Godon natural
Garlic and
Parsley
USA Supplement consisting of
150 mg garlic (Allium sativum) and
parsley / capsule.
Recommended daily dose : 2 capsules
daily
Cholesterol support,
promotes cardiovascular
health.
13 Nature’s plus
Garlic and
Parsley oil
USA Supplement consisting of
550 mg garlic and parsley / capsule
Recommended daily dose : 2 capsules
daily
(-)
14 SOLARAY USA Supplement consisting of (-)
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Parsley leaves 430 mg parsley/ capsule.
Recommended daily dose : 4-8 capsules
daily
15 Pure healthland
Garlic and
Parsley
USA Supplement consisting of
150 mg garlic and parsley / capsule.
Recommended daily dose : 1-3 capsules
daily
Support heart health
Breathe freshening.
16 Gl Nutrition
Garlic and
Parsley
Canada Supplement consisting of
150 mg garlic and parsley / capsule.
One Capsule daily
Immune and cholesterol
support, powerful
antioxidant.
17 Kroeger Herb
Black Radish
and Parsley
USA Supplement consisting of
450 mg black radish (Raphanus sativus)
and parsley / capsule.
Recommended daily dose : 6 Capsule
daily
Support the immune
system and throat health.
18 Natures design
Garlic complex
including
parsley
USA Supplement consisting of
150 mg garlic and parsley / capsule.
Recommended daily dose : 1-3 capsule
daily
Lower cholesterol level,
promotes health blood
circulation and
cardiovascular health.
19 Solgar
Garlic Parsley
USA Supplement consisting of
670 mg garlic and parsley / tablet.
Recommended daily dose : 6 tablets
daily
(-)
Quantification of alkenylbenzenes levels:
Methanolic extraction was applied to extract and quantify the amount of different alkenylbenzenes
presents in the PFS samples. The method was based on the method described by Gursale et al.
(Gursale et al., 2010). The extraction was performed by adding 50 ml methanol to 0.5 g of PFS
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material followed by sonication for 15 minutes. Upon sonication, the extract was filtered using a
0.45 um syringe filter and the filtrate was stored at -20 °C until Ultra Performance Liquid
Chromatography (UPLC) analysis. To determine the accuracy of the method a recovery analysis for
apiol, myristicin and estragole was performed to account for possible losses during the extraction
process if needed. To this end, PFS sample number four (Table 1) was spiked with apiol,
myristicin and estragole. The spiked sample was analysed by the same procedure as described
above. The average percentages for recovery were found to equal 85.3% ± 2.9% for estragole,
101.1% ± 5.4% for myristicin, and 94.5% ± 7.6% for apiol. Based on these outcomes the levels of
the alkenylbenzenes detected in the different PFS were corrected for sample recovery. To
determine the linearity of the extraction method, solutions of sample number four were prepared as
follows: 0.5 g/200 ml, 0.5 g/100 ml, 0.5 g/50 ml, 0.5 g/25 ml, and 1 g/25ml. The results were shown
to be linear up to the amount of 0.5 g PFS in 25 ml methanol.
UPLC analysis.
For analysis of the methanolic PFS extracts, the samples were analysed both in undiluted form and
also diluted 10 times with ACN because the amount of the alkenylbenzenes was expected to be
high. UPLC analysis was performed using a Waters (Waters, Milford, MA) Acquity solvent
manager, sample manager, and diode array detector, equipped with a Water Acquity C18 1.7 µm
column, 2.1 x 50 mm. The gradient was made with a mixture of ACN and ultrapure water
containing 0.1% (v/v) TFA. The flow rate was 0.6 ml/min. After equilibrating the column at the
starting conditions of 31% ACN, the % ACN was kept at this level for 5 minutes and then
increased to 80% over 4 minutes and kept at 80% for 1 min, then decreased to 0% over 1.5 minutes
and kept at 0% for 1 minute after which the % ACN was returned to the starting conditions.
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Identification and quantification of the different alkenylbenzenes were done by comparison of the
retention time, UV spectra and peak areas obtained at 209 nm for apiol and myristicin and at 201
nm for estragole to the retention time, UV spectra and calibration curve of commercially available
standards. It appeared that due to the limited difference in their chemical structure, reflected by a
different position of one of the methoxy substituents, parsley and dill apiol elute at the same
retention time and could not be separated under the conditions applied. Their identification was
based on the nature of the botanical ingredients listed to be part of the respective PFS sample
(Table 1).
Estimation of daily intakes of alkenylbenzenes resulting from the consumption of PFS.
For estimation of the alkenylbenzene exposure resulting from consumption of the PFS, the
concentration of the alkenylbenzene quantified in the methanolic extract was multiplied by a factor
taking the daily use of the PFS as recommended by the supplier (Table 1) into account.
Intake estimates for combined exposure to different alkenylbenzenes.
Based on the results (see results section), most of the PFS samples contained two alkenylbenzenes.
Because of that a combined exposure assessment was applied. The effect of combined exposure to
different alkenylbenzenes present in the PFS is assumed to be adequately described by dose
addition, because all alkenylbenzenes share high similarity in structure, target organ, type of
adverse effects and mode of action through formation of a DNA reactive 1′-sulfoxy metabolite
contributing to the formation of liver tumors. Based on these considerations two approaches were
applied for the combined risk assessment. The first one was based on adding the levels of the
different alkenylbenzenes as such assuming equal potency of each one.  The second approach was
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based on the use of a so-called Toxic Equivalency (TEQ) approach through defining Toxic
Equivalency Factors (TEFs) for apiol, myristicin and estragole. The TEF values used for apiol,
myristicin and estragole amounted to 0.30, 0.66 and 2.16 as compared to safrole as the reference
(TEF=1.00) respectively, and were derived previously (Alajlouni et al., 2016a) based on i) data for
DNA adduct formation by the different alkenylbenzenes in CD-1 mice as reported by Randerath et
al. (Randerath et al., 1984), ii) data obtained from human physiologically-based kinetic (PBK)
models that allow prediction of the dose-dependent relative formation of the ultimate carcinogenic
1′-sulfoxy metabolite representing the relative importance of the bioactivation route, and iii) the
benchmark dose lower confidence limit for 10% tumor incidence above background (BMDL10)
values of the alkenylbenzenes calculated based on carcinogenicity data reported by Miller et al.
(Van den Berg et al., 2011) or by read-across (Alajlouni et al., 2016b, Al-Malahmeh et al., 2016,
Van den Berg et al., 2012). The average TEF of the three approaches provided the TEF values
mentioned above and these were used to calculate the estimated daily intake (EDI) of the
alkenylbenzenes extracted from the PFS samples expressed in µg safrole equivalents/kg bw.
Calculation of the MOE
Risk assessment was performed using the MOE approach. The MOE values were obtained using
EDI values and calculated in three ways; first the MOE values were calculated for the individual
alkenylbenzenes using their respective BMDL10 values amounting to respectively 5.7 mg/kg bw
for apiol (Alajlouni et al., 2016b), 1.9 mg/kg bw for myristicin (Al-Malahmeh et al., 2016) and 3.3
mg/kg bw for estragole (Van den Berg et al., 2011). Second, the MOE values were calculated using
a combined exposure assessment assuming equal potency of all alkenylbenzenes and the BMDL10
for the major alkenylbenzene in the mixture. Finally MOE values were calculated based on the
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TEQ approach calculating the combined exposure in safrole equivalents and using the BMDL10 of
safrole 1.9 mg/kg bw (Van den Berg et al., 2011) .
Results
Concentrations of alkenylbenzenes in the PFS
Table 2 presents the concentrations of the different alkenylbenzenes found in the PFS samples
varying from 17 to 6487 µg/g. The results obtained revealed that 16 out of the 19 samples
contained alkenylbenzenes with 11 out of these 16 samples containing both apiol and myristicin.
One sample contained only estragole, two samples contained only apiol and two samples contained
only myristicin.
Risk assessment of combined exposure to alkenylbenzenes
159
Table 2: The concentrations and EDI of different alkenylbenzenes found in the PFS samples.
PFS
sample
alkenylbenzenes
detected
alkenylbenzene
level in the PFS
sample (ug/g)
EDI of the individual
alkenylbenzenes (µg/kg
bw) based on
consumption of the PFS
as recommended by the
supplier (Table 1)
combined EDI of the
alkenylbenzenes
(µg/kg bw) based on
consumption of the
PFS as recommended
by the supplier (Table
1) assuming similar
potency
combined
EDI in µg
safrole
equivalents
per kg bwa
resulting
from
consumption
of the PFS as
recommended
by the
supplier
(Table 1)
S2 myristicin 284.45 6.10
8.12 4.63
apiol 94.54 2.03
S3 myristicin 171.27 1.63 9.26 3.37
apiol 800.99 7.63
S4 estragole 17.17 0.74 0.74 1.59
S5 myristicin 1804.48 34.80
159.90 60.05
apiol 6486.63 125.10
S6 apiol 184.58 2.03 2.03 0.61
S7 myristicin 745.8 0.96 0.96 0.63
S10 apiol 93.04 1.33 1.33 0.40
S11 myristicin 331.83 4.74 4.74 3.13
S12 myristicin 375.70 1.61
2.86 1.44
apiol 290.94 1.25
S13 myristicin 716.20 11.25
14.66 8.45
apiol 216.42 3.40
S14 myristicin 127.80 4.71
16.01 6.50
apiol 306.46 11.30
S15 myristicin 329.70 1.41
2.32 1.21
apiol 212.79 0.91
S16 myristicin 323.40 1.39
2.24 1.16
apiol 199.82 0.86
S17 myristicin 71.20 2.75 9.52 3.85
apiol 175.73 6.78
S18 myristicin 323.60 1.39
2.20 1.16
apiol 190.15 0.81
S19 myristicin 26.00 1.49
9.02 3.24
apiol 131.04 7.53
a calculated as Σ (EDI of each alkenylbenzenes × TEF (safrole equivalents))
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EDI of the individual alkenylbenzenes.
The EDI of the individual alkenylbenzenes resulting from consumption of the PFS as
recommended by the supplier (Table 1) was estimated based on the concentration of the different
alkenylbenzenes in the PFS, the supplier recommendations for daily use and assuming a body
weight of 70 kg. Table 2 presents the EDI values thus obtained. For individual alkenylbenzenes the
equal potency or based on TEF values expressed in safrole equivalents, are also presented in Table
2. The EDI values obtained when assuming equal potency amounted to 0.74 to 159 µg/kg bw day
approach generally results in lower values than the approach assuming equal potency because the
major alkenylbenzenes present in the PFS have TEF values lower than 1.00.
Combined risk assessment of PFS consumption using the MOE.
Figure 3A presents the MOE values for the individual alkenylbenzenes obtained using the EDI
values presented in table 2 and their BMDL10 values taken from literature (Alajlouni et al., 2016b,
Al-Malahmeh et al., 2016, Van den Berg et al., 2011).  MOE values for the combined risk
assessment, obtained by dividing the BMDL10 of the major alkenylbenzene present in the PFS by
the EDI for the respective PFS sample expressed as total alkenylbenzenes assuming equal potency,
are presented in Figure 3B. MOE values obtained by dividing the BMDL10 of 1.9 mg/kg bw per
day for safrole (Van den Berg et al., 2011) by the EDI for the respective PFS samples expressed in
safrole equivalents are presented in Figure 3C. The results obtained reveal MOE values that are all
lower than 10000 by using any method to calculate the MOE. Based on the combined risk
assessment more than half of the samples are even below 1000 (Figure 3).
EDI values amounted to 0.74 to 125 µg/kg bw day. The combined EDI values calculated assuming
and those obtained using the TEQ approach amounted to 0.40 to 60 µg/kg bw day. The TEQ
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Figure 3: MOE values based on the three approaches used: A) MOE values for the individual
alkenylbenzenes using their BMDL10 values, B) MOE values for the combined exposure
assuming equal potency of all alkenylbenzenes and using the BMDL10 value of the major
alkenylbenzene in the mixture, and C) MOE values for combined exposure using the TEQ
approach based on safrole equivalents and using the BMDL10 value of safrole. The black and grey
horizontal lines represent an MOE value of 10000 and 1000 respectively.
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It is important to note that this risk assessment based on the MOE as presented in figure 3, assumes
long term exposure during a whole lifetime while the consumption of PFS may occur just for a
short period of time of one or only a few weeks. The consequences of such a different exposure
regimen may be estimated based on Haber’s rule k=C×T where (k) is the toxic outcome, (C) is the
concentration (or dose) of the toxic chemical and T is the time of exposure (Felter et al., 2011).
This implies that the response upon lifetime exposure (75 years) to a certain dose level may be
equivalent to an exposure during shorter than lifetime to a higher dose level according to the
equation (C1×T1 = C2×T2) (Felter et al., 2011, Van den Berg et al., 2014). Based on this assumption
the relation between the total level of alkenylbenzenes detected in the PFS samples assuming equal
potency and the amount of PFS consumed that would result in MOE values of 10000 was
calculated for different frequencies of intake including lifetime, 4, 2 and 1 week. To present a
worst case approach the BMDL10 of myristicin was used to calculate the MOE values. The results
thus obtained are presented in Figure 4. From the results presented it can be derived that a daily
PFS consumption during lifetime of a PFS containing 8000 µg alkenylbenzenes/g PFS, would be of
low concern only if the PFS would contain only 1.7 mg of the respective preparation. This is far
less than the amount generally found in PFS samples (Table 1).
priority for risk management.
To further illustrate how short term exposure would affect the MOE values the data presented in
Figure 3 for lifetime exposure are presented in Figure 5 assuming four week exposure. From these
1600 to 119700, 3200 to 256500 and 6400 to 513000 mg of PFS upon lifetime, 4 weeks, two weeks
Figure 4  also  reveals  that the levels of  alkenylbenzenes  detected in the PFS  samples within  the
present  study, which vary  between 100  and  8000 µg/g, would  allow consumption of 1.7  to 133,
and one  week intake, respectively,  to achieve  MOE values  above the 10000  safety limit for low
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results it follows that assuming four week exposure the MOE values of all PFS are higher than
10000 indicating they would be of low priority for risk management.
Figure 4: Relation between the total alkenylbenzenes level in a PFS, calculated based on equal
potency (µg/g), and the amount of PFS consumption (mg) that would result in an MOE of 10000
upon lifetime intake (insert), one week intake (∙∙∙∙), two weeks intake (----), and four weeks intake
(— —). Combinations of alkenylbenzenes levels and PFS intake that result in values below the
respective curves result in MOE values above 10000 and would be of low priority for risk
management.
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Figure 5: MOE values assuming 4 weeks intake and based on the three approaches used: A) MOE
values for the individual alkenylbenzenes using their BMDL10 values, B) MOE values for the
combined exposure assuming equal potency of all alkenylbenzenes and using the BMDL10 value of
the major alkenylbenzenes in the mixture, and C) MOE values for combined exposure using the
TEQ approach based on safrole equivalents and using the BMDL10 value of safrole. The grey
horizontal lines represent an MOE value of 10000 and all samples MOE values are above it.
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Discussion
The objective of the current paper was to assess the risk of exposure to alkenylbenzenes as a result
of consumption of parsley and dill based PFS. Based on chemical analysis of 19 PFS samples
containing parsley or dill, 16 samples appeared to contain one or more alkenylbenzenes. One
sample contained mainly estragole and this is probably because this PFS contained fennel in
addition to parsley, and estragole is known to be the major alkenylbenzene in fennel (Foeniculum
vulgare) (Van den Berg et al., 2014, Van den Berg et al., 2011). Two samples contained only
myristicin. Two samples contained only apiol and 11 samples contained both apiol and myristicin.
The results obtained also revealed wide variation in the level of the alkenylbenzenes present in the
PFS which may be ascribed to various reasons including the type and amount of each herb within
the PFS, genetic factors of these herbs, geographical influences during cultivation, harvesting time,
processing and manufacturing conditions of the herbs, and the method of drying which can all
influence the amount of alkenylbenzenes within the botanical and thus the PFS (Smith et al., 2002,
Van den Berg et al., 2011, Rainer and L., 1983). In line with this variation, Vokk et al. (Vokk et
al., 2011), for example, showed that myristicin within dill from Estonia makes up 1.67 % of the
essential oil in summer while this level increased up to 28.15% of the essential oil during winter,
while in parsley, myristicin appeared to be higher in summer amounting to 42.65% of the essential
oil and lower in winter amounting to 30.67% of the essential oil. Apiol levels in dill were reported
to vary from 0.05% of the essential oil in summer increasing up to 0.62 % of the essential oil in
winter (Vokk et al., 2011). While in parsley apiol levels amounted to 0.11% of the essential oil in
summer and increase up to 1.76 % of the essential oil in winter (Vokk et al., 2011). In addition to
that the oil content in the dill seeds is around 7 times more than that of leaves (Vokk et al., 2011).
Furthermore, depending on the stage of maturity of dill the apiol content was reported to range
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from 0.7 to 4.35% of the essential oil while the myristicin content was reported to range from 0.0
to 7.63% (Huopalahti and Linko, 1983). In another study the effects of parsley source, type, size
and color were studied for 104 different parsley plants, showing that apiol levels ranged from 0.1
to 22 % of the essential oil and myristicin levels from 0.1 to 68% (Simon and Quinn, 1988). These
observations can explain the wide range of alkenylbenzene levels detected in the parsley and dill
containing PFS of the present study.
Based on the chemical analysis of the PFS samples, the EDI of the alkenylbenzenes resulting from
consuming these PFS could be determined. Based on consumption of the PFS as recommended by
the suppliers, the EDI values of the individual alkenylbenzenes ranged from 0.74 to 125 µg/kg bw
assuming a body weight of 70 kg. These EDI values resulted in MOE values that were generally
below 10000. Previosuly Van den Berg et al. (Van den Berg et al., 2011) evaluated the hazards and
risks of the presence of the alkenylbenzenes estragole, methyleugenol, β-asaron and safrol in basil
(Occimum basilicum), nutmeg (Myristica fragrans), fennel, sassafras (Sassafras albidum), calamus
(Acorus calamus) and cinnamon (Cinnamomum zeylanicum) based PFS and found a similar result
with MOE values for exposure to these related alkenylbenzenes as a result of intake of these PFS
also often < 10000, also some PFS gave rise to MOE values far above this limit.
Since most of the PFS samples included in the present study contained two alkenylbenzenes, apiol
and myristicin, a combined exposure and risk assessment was performed. The combined EDI
values obtained assuming equal potency of the different alkenylbenzenes ranged from  0.74 to 160
µg/kg bw. Based on this and using the BMDL10 of the major alkenylbenzene present in the sample
MOE values below 10000 were obtained for all samples. Use of the average TEF values to expres
safrole equivalents/kg bw. These values were generaly 40 to 64 % of the combined EDI values
the EDI in safrole equivalents resulted in combined EDI values that ranged from 0.40 to 60 µg
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obtained by summing up the levels, which is mainly due to the fact that the TEF values for the
major alkenylbenzenes in the mixtures are lower than 1.00, the value for the reference compound
safrole. In spite of this the MOE values obtained using these EDI values expressed in safrole
equivalents and the BMDL10 of safrole of 1.9 mg/kg bw were still <10000 for all samples.
Thus, it can be concluded that the overall conclusion did not change with the method used to
estimate the MOE: in all three approaches MOE values resulting from consumption of the PFS as
recommended by the provider per day were below 10000, and for many of the PFS even below
1000.
It is of interest to note that these MOE values refer to regular daily and lifetime consumption of the
PFS which may be an overestimation of realistic human consumption. Based on Haber’s rule,
levels of alkenylbenzenes in PFS samples and consumption frequency of PFS directly impact the
EDI and the resulting possible toxic effect presented by their MOE values.
Considering short term use of the PFS MOE values would increase above 10000 indicating low
priority for risk management. It is concluded that intake of alkenylbenzenes through consumption
of parsley and dill based PFS is only of concern when these PFS are used for longer periods of
time.
Taking into account this consideration it is concluded that the present study shows that use of
parsley and dill based PFS is a concern especially for people who use those PFS for a long period
of time.
Finally, it is important to acknowledge that the targeted sampling strategy applied to collect the
parsley and dill based food supplements, was focused on preparations available on the Dutch
market and available via internet. Given the results of the present study it would be of interest to
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extent the risk assessment to include samples all over Europe. In addition, one might consider the
sample types to be extended to include other parsley and dill based food products such as
smoothies, detox, breath refreshers or any other sources of exposure. In a previous study, we
already investigated dill and parsley based teas obtained on the Dutch market and online and
showed that the MOE values obtained were generally < 10000 indicating a concern if the teas
would be consumed on a daily basis over longer periods of time (Alajlouni et al., 2016a).
Risk assessment of combined exposure to alkenylbenzenes
169
References
1. Al-Malahmeh, A. J., Al-Ajlouni, A. M., Wesseling, S., Soffers, A. E., Al-Subeihi, A., Kiwamoto, R.,
Vervoort, J. & Rietjens, I. M. C. M. 2016. Physiologically based kinetic modeling of the bioactivation
of myristicin. Archives of toxicology.
2. Al-Subeihi, A. A., Spenkelink, B., Punt, A., Boersma, M. G., van Bladeren, P. J. & Rietjens, I. M. C. M.
2012. Physiologically based kinetic modeling of bioactivation and detoxification of the
alkenylbenzene methyleugenol in human as compared with rat. Toxicology and applied
pharmacology, 260, 271-84.
3. Alajlouni, A. M., Al-Malahmeh, A. J., Isnaeni, F. N., Wesseling, S., Vervoort, J. & Rietjens, I. M.
2016a. Level of Alkenylbenzenes in Parsley and Dill Based Teas and Associated Risk Assessment
Using the Margin of Exposure Approach. Journal of agricultural and food chemistry.
4. Alajlouni, A. M., Al Malahmeh, A. J., Kiwamoto, R., Wesseling, S., Soffers, A. E., Al-Subeihi, A. A.,
Vervoort, J. & Rietjens, I. M. C. M. 2016b. Mode of action based risk assessment of the botanical
food-borne alkenylbenzene apiol from parsley using physiologically based kinetic (PBK) modelling
and read-across from safrole. Food Chem Toxicol, 89, 138-50.
5. Bisset, N. G. 1994. Herbal Drugs and Phytotherapeuticals, Medpharm Scientific Publishers.
6. Blumenthal, M. 1999. The Complete German Commission E Monographs. , American Botanical
Council: Austin.
7. Borchert, P., Miller, J. A., Miller, E. C. & Shires, T. K. 1973. 1'-Hydroxysafrole, a proximate
carcinogenic metabolite of safrole in the rat and mouse. Cancer research, 33, 590-600.
8. Cousyn, G., Dalfrà, S., Scarpa, B., Geelen, J., Anton, R., Serafini, M. & Delmulle, L. 2013. Project
BELFRIT: Harmonizing the Use of Plants in Food Supplements in the European Union: Belgium,
France and Italy - A first Step. European Food and Feed Law Review, 8, 187-196.
9. EFSA 2005. European Food Safety Authority. Opinion of the scientific committee on a request from
EFSA related to a harmonised approach for risk assessment of substances which are both
genotoxic and carcinogenic. The EFSA Journal, 282, 1-31.
10. EFSA 2009a. Advice on the EFSA guidance Document for the Safety Assessment of Botanicals and
Botanical Preparations Intended for Use as Food Supplement, based on Real Case Study. EFSA
Journal, 7, 280.
11. EFSA 2009b. Compendium of Botanicals That Have Been Reported to Contain Toxic, Ad-dictive,
Psychotropic or Other Substances of Concern on Request of EFSA. EFSA Journal, 9, 1-100.
12. EFSA 2012. Compendium of botanicals reported to contain naturally occuring substances of
possible concern for human health when used in food and food supplements. EFSA Journal, 10.
13. European Commission (EC) 2002. Regulation (EC) No 178/2002 of the Europian Parliament and of
the Council of 26 January 2002 laying down the general principles and requirments of food law,
establishing the european food safety  authority and laying down procedures in matters of food
safety.
14. European Commission (EC) 2008. Regulation (EC) No 1334/2008 of the Europian Parliament and of
the Council of 16 December 2008 on flavourings and certain food ingredients with flavouring
properties for use in and on foods and amending Council Regulation (EEC) No 1601/91,
Regulations (EC) No 2232/96 and (EC) No 110/2008 and Directive 2000/13/EC.
15. FAO/WHO 2009. Safety evaluation of certain food additives. Sixty-ninth meeting of the Joint
FAO/WHO Expert Committee on Food Additives (JECFA), 642.
16. Felter, S. P., Conolly, R. B., Bercu, J. P., Bolger, P. M., Boobis, A. R., Bos, P. M., Carthew, P., Doerrer,
N. G., Goodman, J. I., Harrouk, W. A., Kirkland, D. J., Lau, S. S., Llewellyn, G. C., Preston, R. J.,
Schoeny, R., Schnatter, A. R., Tritscher, A., van Velsen, F. & Williams, G. M. 2011. A proposed
Chapter 5
170
framework for assessing risk from less-than-lifetime exposures to carcinogens. Critical Reviews in
Toxicology, 41, 507-44.
17. Gursale, A., Dighe, V. & Parekh, G. 2010. Simultaneous quantitative determination of
cinnamaldehyde and methyl eugenol from stem bark of Cinnamomum zeylanicum Blume using RP-
HPLC. Journal of Chromatographic Science, 48, 59-62.
18. Heamalatha, S., Swarnalatha, S., Divya, M., Gandhi Lakshmi, R., Ganga Devi, A. & Gomathi, E. 2011.
Pharmacognostical, Pharmacological, Investigation on Anethum Graveolens. Research Journal of
Pharmaceutical, Biological and Chemical Sciences, 2, 564-574.
19. Huopalahti, R. & Linko, R. R. 1983. Composition and Content of Aroma Compounds in Dill,
Anethum-Graveolens L, at 3 Different Growth-Stages. Journal of Agricultural and Food Chemistry,
31, 331-333.
20. Kaur, G. J. & Arora, D. S. 2010. Bioactivation potential of Anethum graveolens. Foeniculum and
trachyspermum ammi belonging to the family umbelliferar-current status. medicinal plants
research, 4, 087-094.
21. Kreydiyyeh, S. I. & Usta, J. 2002. Diuretic effect and mechanism of action of parsley. Journal of
Ethnopharmacology, 79, 353-7.
22. Leung, A. & Foster, S. 1996. Encyclopedia of Common Natural Ingredients Used in Food, Drugs and
Cosmetics, New York, John Wiley & Sons.
23. Martati, E., Boersma, M. G., Spenkelink, A., Khadka, D. B., van Bladeren, P. J., Rietjens, I. M. C. M.
& Punt, A. 2012. Physiologically based biokinetic (PBBK) modeling of safrole bioactivation and
detoxification in humans as compared with rats. Toxicological Sciences
24. Miller, E. C., Swanson, A. B., Phillips, D. H., Fletcher, T. L., Liem, A. & Miller, J. A. 1983. Structure-
activity studies of the carcinogenicities in the mouse and rat of some naturally occurring and
synthetic alkenylbenzene derivatives related to safrole and estragole. Cancer research, 43, 1124-
34.
25. Phillips, D. H., Reddy, M. V. & Randerath, K. 1984. 32P-post-labelling analysis of DNA adducts
formed in the livers of animals treated with safrole, estragole and other naturally-occurring
alkenylbenzenes. II. Newborn male B6C3F1 mice. Carcinogenesis, 5, 1623-8.
26. Popovic, M., Kaurinovic, B., Jakovljevic, V., Mimica-Dukic, N. & Bursac, M. 2007. Effect of parsley
(Petroselinum crispum (Mill.) Nym. ex A.W. Hill, Apiaceae) extracts on some biochemical
parameters of oxidative stress in mice treated with CCl(4). Phytother Res, 21, 717-23.
27. Punt, A., Paini, A., Boersma, M. G., Freidig, A. P., Delatour, T., Scholz, G., Schilter, B., van Bladeren,
P. J. & Rietjens, I. M. C. M. 2009. Use of physiologically based biokinetic (PBBK) modeling to study
estragole bioactivation and detoxification in humans as compared with male rats. Toxicological
sciences : an official journal of the Society of Toxicology, 110, 255-69.
28. Rainer, H. & L., R. R. 1983. Composition and Content of Aroma Compounds in Dill, Anethum
graveolens L., at Three Different Growth Stages. Journal of agricultural and food chemistry, 31,
331-333.
29. Randerath, K., Haglund, R. E., Phillips, D. H. & Reddy, M. V. 1984. 32P-post-labelling analysis of
DNA adducts formed in the livers of animals treated with safrole, estragole and other naturally-
occurring alkenylbenzenes. I. Adult female CD-1 mice. Carcinogenesis, 5, 1613-22.
30. Rietjens, I. M. C. M., Slob, W., Galli, C. & Silano, V. 2008. Risk assessment of botanicals and
botanical preparations intended for use in food and food supplements: emerging issues.
Toxicology letters, 180, 131-6.
31. Simon, J. E. & Quinn, J. 1988. Characterization of essential oil of parsley. Journal of Agricultural and
Food Chemistry, 36, 467-472.
Risk assessment of combined exposure to alkenylbenzenes
171
32. Smith, R. L., Adams, T. B., Doull, J., Feron, V. J., Goodman, J. I., Marnett, L. J., Portoghese, P. S.,
Waddell, W. J., Wagner, B. M., Rogers, A. E., Caldwell, J. & Sipes, I. G. 2002. Safety assessment of
allylalkoxybenzene derivatives used as flavouring substances - methyl eugenol and estragole. Food
Chem Toxicol, 40, 851-70.
33. Van den Berg, S. J., Punt, A., Soffers, A. E., Vervoort, J., Ngeleja, S., Spenkelink, B. & Rietjens, I. M.
C. M. 2012. Physiologically based kinetic models for the alkenylbenzene elemicin in rat and human
and possible implications for risk assessment. Chemical research in toxicology, 25, 2352-67.
34. van den Berg, S. J. P. L., Alhusainy, W., Restani, P. & Rietjens, I. M. C. M. 2014. Chemical analysis of
estragole in fennel based teas and associated safety assessment using the Margin of Exposure
(MOE) approach. Food and Chemical Toxicology, 65, 147-154.
35. Van den Berg, S. J. P. L., Restani, P., Boersma, M. G., Delmulle, L. & Rietjens, I. M. C. M. 2011.
Levels of Genotoxic and Carcinogenic Compounds in Plant Food Supplements and Associated Risk
Assessment. Food and Nutrition Sciences, 989-1010.
36. Vokk, R., Lougas, T., Mets, K. & Karvets, M. 2011. Dill (Anethum graveolens L.) and Parsley
(Petroselinum crispum (Mill.) Fuss) from Estonia: Seasonal Differences in Essential Oil
Composition. Agronomy research, 9, 515-520.
37. Wiseman, R. W., Fennell, T. R., Miller, J. A. & Miller, E. C. 1985. Further characterization of the DNA
adducts formed by electrophilic esters of the hepatocarcinogens 1'-hydroxysafrole and 1'-
hydroxyestragole in vitro and in mouse liver in vivo, including new adducts at C-8 and N-7 of
guanine residues. Cancer research, 45, 3096-105.
38. Zhou, G. D., Moorthy, B., Bi, J., Donnelly, K. C. & Randerath, K. 2007. DNA adducts from
alkoxyallylbenzene herb and spice constituents in cultured human (HepG2) cells. Environ Mol
Mutagen, 48, 715-21.

Chapter 6
General discussion, future perspectives and
conclusion
Chapter 6
174
General discussion
Apiol and myristicin belong to the group of alkenylbenzenes. Alkenylbenzenes are found in several
herbs and spices including for example parsley, dill, basil, tarragon, fennel and nutmeg (Kreydiyyeh
and Usta, 2002, Semenov et al., 2007, Smith et al., 2002). Alkenylbenzenes also occur in the
essential oils of these herbs and spices (Smith et al., 2002). Human exposure to apiol and myristicin
mainly occurs through the consumption of parsley and dill containing preparations including teas,
spices and/or plant food supplements (PFS).
The Estimated Daily Intake (EDI) of myristicin due to daily consumption of spices has been
estimated to be in the range of 684 ug/person per day (Gavin et al., 2007).
The EDI of apiol compared to other alkenylbenzenes is considered to be low. In the USA, the mean
intake of apiol from spice and spice oils is estimated to be 2.84 ug/person per day while for other
alkenylbenzenes like safrole, estragole, methyleugenol and myristicin, exposure may be at least 10
times higher (Gavin et al., 2007).
The alkenylbenzenes including apiol and myristicin have a similar molecular structure consisting of
an allylbenzene nucleus containing one or more alkoxy ring substituents. Because of this structural
similarity these compounds share similar metabolism, mode of action and biological effects (WHO,
2009, Van den Berg et al., 2012). Safrole, estragole and methyleugenol were shown to induce liver
tumors at high dose levels in rodents via a metabolic pathway that includes formation of DNA
adducts (Boberg et al., 1986, Boberg et al., 1983, Phillips et al., 1984, Randerath et al., 1984,
Wiseman et al., 1985, Wislocki et al., 1976, Miller et al., 1983). For myristicin and apiol, long term
carcinogenicity studies are not available (WHO, 2009), but in the present thesis, based on the
similarities in the molecular structure and metabolic pathways between these two compounds and
safrole, a mode of action based approach for their risk assessment was undertaken using
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physiologically based kinetic (PBK) modelling and read-across from safrole for which adequate
rodent tumor data are available.
PBK models are models established based on different parameters including physiological
parameters, physico-chemical parameters, and metabolic parameters. The models describe the
absorption, distribution, metabolism and excretion (ADME) of a chemical of interest (Krewski et al.,
1994, Chiu et al., 2007, Rietjens et al., 2011). The use of PBK models allows the study of possible
time and dose-dependent variations in metabolism, the prediction of the concentrations of the
chemical and its metabolites within tissues and blood (Rietjens et al., 2011), and the study of
interspecies differences through use of parameters of the species of interest (Andersen and Krishnan,
1994). In the present thesis PBK models were used to support a read-across from a compound for
which adequate tumor data are available to compounds for which such data are absent.
The currently preferred risk assessment approach used to assess the risk of exposure to compounds
that are both genotoxic and carcinogenic is the so-called margin of exposure (MOE) approach
(EFSA, 2005). The MOE is calculated as the ratio between a dose level derived from human
epidemiological data or from in vivo carcinogenicity data obtained in experimental animals, and the
EDI. The preferred point of departure derived from the in vivo data to calculate the MOE is the
lower confidence limit of the dose level that results in 10% extra cancer incidence above background
levels, the so-called BMDL10 (O'Brien et al., 2006, EFSA, 2005). BMDL10 values can be defined for
estragole, methyleugenol and safrole, since tumor data from rodent bioassays are available, while for
the two related alkenylbenzenes, apiol and myristicin, such data do not exist so BMDL10 values
cannot be derived from experimental tumor data.
The present PhD project aimed to establish a mode of action based risk assessment of exposure to
low doses of apiol and myristicin by using PBK modelling based read-across from safrole and to use
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the results obtained to perform a risk assessment of consumption of PFS and teas containing parsley
and dill.
In chapter 2 a PBK model for apiol was developed for rat and human in order to facilitate read-
across from the related alkenylbenzene safrole. The models were developed based on in vitro
metabolic parameters determined using relevant tissue fractions, in silico derived partition
coefficients, and physiological parameters derived from the literature. The models were based on the
models previously developed for the related alkenylbenzene safrole (Martati et al., 2012) and
consisted of six compartments including liver as metabolizing compartment, and separate
compartments for fat, arterial blood, venous blood, richly perfused and slowly perfused tissues. With
the model obtained the relative extent of bioactivation and detoxification of apiol at different oral
doses was examined. At low doses, formation of 4-allyl-3,6-dimethoxy benzene-1,2-diol (ADD) and
2′,3′-dihydroxyapiol (DHA) leading to detoxification appeared to be the major metabolic pathways,
occurring in the liver. At high doses, the rat model revealed a relative increase in the formation
percentage of the proximate carcinogenic metabolite 1′- hydroxyapiol from 4% to about 7% of the
dose at low and high dose levels respectively, occurring in the liver. This relative increase in
formation of 1′- hydroxyapiol leads to a relative increase in formation of 1′-hydroxyapiol
glucuronide, 1′-oxoapiol, and 1′-sulfooxyapiol with increasing dose levels, the latter metabolite
being the ultimate carcinogenic metabolite of apiol. These results indicate that the relative
importance of different metabolic pathways of apiol may vary in a dose-dependent way, leading to a
relative increase in bioactivation of apiol at higher doses. In rat liver the percentage of the dose
converted to the ultimate carcinogenic metabolite 1′-sulfooxyapiol was predicted to increase from
0.003% of the dose at 0.05 mg/kg bw/day to 0.005% of the dose at a dose level of 300 mg/kg
bw/day. This reflects a change of only 1.67-fold over the dose range of interest, which is expected to
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only marginally influence the cancer risk estimate as compared to the effect of increasing the dose
itself from 0.05 to 300 mg/kg bw/day. The human model revealed a slight decrease in the relative
formation of the proximate carcinogenic metabolite 1′- hydroxyapiol from 6.7% to about 6.3% of the
dose at low and high dose levels respectively, occurring in the liver. The formation of the ultimate
carcinogen 1ʹ-sulfoxyapiol amounted to 0.036% to 0.035% of the dose at low and high dose levels
respectively. By comparing the PBK model based predicted 1′-sulfoxy metabolite formation of apiol
with that for safrole, it appeared that at similar dose levels the formation of the 1ʹ-sulfoxy metabolite
for apiol is predicted to be about 3-fold lower than for safrole in rat liver and 2- fold lower in human
liver. Based on these PBK modelling results, assuming the same mode of action for these two
compounds, one could use the BMDL10 for liver tumor formation in rat by safrole for risk
assessment of the related compound apiol making a correction for the expected 3-fold lower
formation of the ultimate carcinogenic 1ʹ-sulfoxy metabolite at similar dose levels. Thus the
BMDL10 of safrole which amounts to 1.9-5.1 mg/kg bw per day (Van den Berg et al., 2011) was
multiplied by factor of 3 resulting in a BMDL10 of 5.7-15.3 mg/kg bw per day. Using the EDI of
apiol resulting from intake from spice and spice oil in the USA that amounts to 4×10-5 mg/kg bw per
day (Gavin et al., 2007), and a BMDL10 of 5.7-15.3 mg/kg bw per day, the MOE would amount to
In chapter 3 a PBK model for myristicin was developed in rat and human in order to facilitate risk
assessment based on read-across from the related alkenylbenzene safrole. The models were
developed using the same parameters and compartments as for the apiol model in Chapter 2. In
incubations of myristicin with rat and human liver microsomes the formed metabolites were 2′,3′-
dihydroxymyristicin (DHM), 3′-hydroxymyristicin (3HM), 1′-hydroxymyristicin (HM), and 5-allyl-
2,3-dihydroxyanisole (DHA). At high doses, the rat and human model revealed a relative increase in
140000 -385000. This value is > 10000 indicating a low priority for risk management.
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the formation of the proximate carcinogenic metabolite 1′- hydroxymyristicin. This relative increase
in formation of 1′-hydroxymyristicin leads to a relative increase in formation of 1′-
hydroxymyristicin glucuronide, 1′-oxomyristicin, and 1′-sulfooxymyristicin with increasing dose
levels, the latter metabolite being the ultimate carcinogenic metabolite of myristicin. As with apiol
these results indicate that the relative importance of different metabolic pathways of myristicin may
vary in a dose-dependent way, leading to a relative increase in bioactivation of myristicin at higher
doses. In rat liver, the percentage of the dose converted to the ultimate carcinogenic metabolite 1′-
sulfooxymyristicin increases from 0.015% of the dose at 0.05 mg/kg bw/day to 0.027% of the dose
at a dose level of 300 mg/kg bw/day. This reflects a change of only 1.8-fold over the dose range of
interest, which is a change that would be expected to only marginally influence the cancer risk
estimate as compared to the effect of increasing the dose itself from 0.05 to 300 mg/kg bw/day. Also
the human model revealed an increase in the formation percentage of the proximate carcinogenic
metabolite 1′- hydroxymyristicin from 6.5% to about 8.0% of the dose at low and high dose levels
respectively, occurring in the liver. The formation of the ultimate carcinogen 1ʹ-sulfoxymyristicin
amounted to 0.047% of the dose at 0.05 mg/kg bw/day and to 0.059% of the dose at a dose level of
300 mg/kg bw/day. By comparing the values predicted by the myristicin PBK models with values
predicted for safrole by the safrole PBK models at similar dose levels, the formation of the 1ʹ-
sulfoxy metabolite is predicted to be about 2-fold lower for myristicin than for safrole in rat liver and
almost the same in human liver. Based on this it can be concluded that at dose levels in the range of
BMDL10 values, the formation of the 1′-sulfoxy metabolites of myristicin in liver is comparable to
that of the 1′-sulfoxy metabolites of the structurally related safrole. Based on that, and assuming the
same mode of action for these two compounds, the PBK modelling results can support the use of the
BMDL10 values for tumor formation by safrole (1.9-5.1 mg/kg bw per day) for risk assessment of the
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related compound myristicin. Based on the theoretical EDI of myristicin from spice and spice oil in
USA that amounts to 0.0019 mg/kg bw per day, and a BMDL10 of 1.9-5.1 mg/kg bw per day, the
MOE would amount to 1000-2700, indicating a priority for risk management.
In chapter 4 a risk assessment of parsley and dill based teas that contain alkenylbenzenes was
performed using the BMDL10 values obtained in chapter 2 and 3 for apiol and myristicin. To this
end, parsley and dill based tea samples were collected from the local Dutch market and via internet.
To quantify the possible maximum concentrations of the alkenylbenzenes, the samples were
extracted by applying a methanol extraction followed by alkenylbenzene quantification using UPLC.
To obtain the EDI of the alkenylbenzenes resulting from use of the teas, the concentration of the
alkenylbenzenes was also quantified in a hot water extract and the values thus obtained were
corrected by a factor that accounted for the amount of tea likely to be used to make a cup of tea.
Chemical analysis of the alkenylbenzenes present in the teas and their hot water extracts revealed the
presence of more than one alkenylbenzene within most of the samples. Because of that a risk
assessment for combined exposure to the alkenylbenzenes was also performed. Because the
molecular structures and mode of action of these alkenylbenzenes are similar (JECFA, 2009), a dose
addition approach can be used to calculate the combined exposure (van den Berg et al., 2006). For
this combined risk assessment, the EDIs were calculated assuming equal potency of the
alkenylbenzenes and also based on use of the so-called Toxic Equivalency (TEQ) approach. The
Toxic Equivalency Factors (TEFs) for the different alkenylbenzenes were defined using safrole as
the reference compound (TEF=1). The TEF values for the other compounds were defined using
different sets of literature data, also including the PBK model based predictions for formation of the
ultimate carcinogenic 1′-sulfoxy metabolites and the BMDL10 values obtained by read-across from
safrole as defined for apiol and myristicin in Chapter 2 and Chapter 3 of the thesis. Risk assessment
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for the exposure to the alkenylbenzenes via use of the selected teas was applied using the MOE
approach. MOE values were calculated in three different ways; first the MOE values were calculated
for the individual alkenylbenzenes using their respective BMDL10 values amounting to respectively
5.7 mg/kg bw for apiol as obtained in Chapter 2 of the thesis (Alajlouni et al., 2016), 1.9 mg/kg bw
for myristicin as obtained in Chapter 3 of the thesis (Al-Malahmeh et al., 2016),  and 3.3 mg/kg bw
for estragole and 15.3 mg/kg bw for methyleugenol (Van den Berg et al., 2011). Then the MOE
values were calculated using a combined exposure assessment assuming equal potency of all
alkenylbenzenes and using the BMDL10 for the major alkenylbenzene in each mixture. Finally MOE
values were calculated based on the TEQ approach calculating the combined exposure in safrole
equivalents and using the BMDL10 of safrole. MOE values obtained were generally < 10000,
indicating a priority for risk management, especially for people who frequently drink large quantities
of these herbal teas. Drinking of these herbal teas for shorter periods instead of during a whole
lifetime will increase the MOE values above 10000 indicating a low priority for risk management.
Chapter 5 describes a risk assessment of consumption of parsley and dill based PFS. The PFS
samples were collected from the local Dutch market and via internet. The PFS sample selection was
based on the presence of dill or parsley within the PFS. The samples were extracted by methanol and
analyzed using UPLC. The EDIs of the alkenylbenzenes were quantified and corrected based on the
recommended dose of the PFS as indicated on the labels of the preparations. The results showed that
most samples contain more than one alkenylbenzene, mainly apiol and myristicin. This is in line
with the fact that a targeted sampling was applied collecting samples containing dill and/or parsley
known to contain especially these alkenylbenzenes (Simon and Quinn, 1988, Vokk et al., 2011). As
for the tea samples in Chapter 4 a combined exposure to alkenylbenzenes was included in the
assessment. The EDI and MOE values were calculated based on the same approach used for tea
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samples in Chapter 4. The results revealed that the MOE values of the PFS samples under study
obtained using all three methods for risk assessment resulted in MOE values that were generally <
10000, indicating a need for risk management if the PFS would be consumed on a daily basis during
a whole lifetime. However, since intake of PFS is not likely to occur daily during a whole lifetime,
but rather for a short period of time, Haber’s rule (k=C×T where (k) is the toxic outcome, (C) is the
concentration (or dose) of the toxic chemical and T is the time of exposure), was applied to obtain
insight in the consequences for the associated risks (Felter et al., 2011). Assuming shorter periods of
exposure of for example one or two week or a month, using Haber’s rule to correct for this shorter
exposure, resulted in MOE values generally > 10000 indicating low priority for risk management. It
was concluded that risks associated to use of these PFS would be negligible provided intake is
limited to only a few weeks during a lifetime.
Future perspectives:
This thesis studied the risk assessment of parsley and dill based teas and PFS products that contain
especially the alkenylbenzenes apiol and myristicin. To enable this risk assessment first read-across
from tumor data on safrole was performed using PBK model based analysis. Previously, several
studies focused on the adverse effects of safrole, estragole and methyleugenol, alkenylbenzenes that
are known to be carcinogenic and genotoxic, but there are only a few studies focusing on adverse
effects of apiol and myristicin. Therefore, this thesis focused on these two alkenylbenzenes. Future
research on these food borne-compounds and their structural analogues may consider including some
additional aspects that are discussed hereafter.
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Improving PBK models for extrapolation in risk assessment of botanicals preparations.
The MOE approach needs carcinogenicity data to define the BMDL10, whereas such data may be not
present for many botanical ingredients. So, Chapter 2 and Chapter 3 present the development of a
mode of action based PBK model approach to perform a read-across from a compound for which
rodent tumor data are available (safrole) to compounds for which such data are missing (apiol and
myristicin). Van den Berg et al. studied the risk assessment of the alkenylbenzene elemicin by using
PBK model based read-across from estragole and methyleugenol (Van den Berg et al., 2012). The
developed PBK models allow studying effects at low dose levels relevant for the human situation.
This implies that the PBK models can study the (non-) linear effects at low doses that cannot be
detected in animal experiments since they use high dose levels. A major advantage of the PBK
models is that they allow quantification of the dose-dependent formation of the unstable reactive
carcinogenic 1′-sulfoxy metabolite thereby facilitating the read-across based on predictions of
relative bioactivation. But still there are limitations for this PBK model based approach that may
provide topics for future research. One disadvantage is the fact that PBK models need to be
described for each single compound and that definition of these models is time consuming, because
they require a large set of parameters. Although the time and costs of developing the PBK models
for bioactivation and detoxification of genotoxic carcinogens is small compared to time and costs
associated with performing a two year in vivo rodent carcinogenicity study, it may be of use to work
on the development of generic PBK models. So, development of generic PBK models for a group of
compounds will be more efficient for future risk assessment on genotoxic carcinogens for which
rodent tumor data are not available and will save time and costs (Bessems et al., 2014).  The
sensitivity analyses presented in this thesis could be of help to define the most influential parameters
that should be included in such generic PBK models. A next step would be to take such models,
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developed now for the alkenylbenzenes, to other botanical ingredients that are genotoxic and
carcinogenic such as for example pyrrolizidine alkaloids for which rodent tumor data are also not
widely available (Chen et al., 2017).
Extending of PBK models to Physiologically Based Dynamic (PBD) models
In Chapter 2 and Chapter 3 PBK models for apiol and myristicin were developed enabling prediction
of bioactivation and detoxification of apiol and myristicin. However, the ultimate adverse effect,
liver tumor induction, is a multistep process which depends not only on kinetic but also on dynamic
processes that include in addition to bioactivation also DNA-adduct formation, DNA repair,
mutation modulation, gene and protein expression and tumor formation. Therefore, for an even
better read-across, these dynamic processes should be considered as well and might be describes in
so-called physiologically based dynamic (PBD) models. Development of PBD models needs the
description of dynamic characteristics in addition to the kinetic characteristics used in a PBK model.
This can be achieved by extending the PBK models of apiol and myristicin to PBD models to predict
the tumor incidences occurring at low realistic intake levels. A first step in this process would be
extending of the PBK models to PBD models that describe the dose dependent formation of DNA
adducts. Such PBD models have been described before for estragole and used to evaluate the
interindividual human variation in bioactivation and DNA adduct formation resulting from estragole
exposure (Paini et al., 2010, Punt et al., 2016).  Another example is the use of physiologically based
kinetic/dynamic (PBK/D) modelling  to compare dose-dependent DNA adduct formation by
cinnamaldehyde and 18 acyclic food-borne α,β-unsaturated aldehydes showing that at doses relevant
for human dietary exposure there was no concern for DNA adduct formation (Kiwamoto et al.,
2016). So developing valid generic PBK models and extending these models to PBD models for
Chapter 6
184
compounds of interest may help in developing even better approaches for read-across in risk
assessment of genotoxic carcinogens. It is of interest to note that developing such  PBD models,
predicting in vivo DNA adduct formation by adding data on concentration dependent DNA adduct
formation in primary hepatocytes to the PBK/D model, will at the same time take into account DNA
adduct stability and DNA repair. DNA adduct stability and repair may turn out to be important
factors in determining the ultimate mutagenic and carcinogenic potential of the alkenylbenzenes.
Cut off value for the MOE based risk assessment; Compound specific uncertainty factors.
Many approaches -qualitative and quantitative- can be used to assess the risk of genotoxic
carcinogenic compounds. Data used in these approaches are mainly obtained from rodent bioassays
performed at high dose levels. This implies that extrapolation to lower exposure levels is required in
order to judge the risks at realistic human daily exposure levels. Several mathematical models have
been proposed to perform this high to low dose extrapolation, with linear extrapolation being the
simplest form. However, it is not known if and/or to what extent these mathematical models reflect
the underlying biological processes. As a result the extrapolation from high dose to low dose
exposure has been debated (Barlow et al., 2006, EFSA, 2005). In addition linear extrapolation of
tumor data from animal studies to the human situation does not take into account species differences.
Because of that, as an alternative to linear extrapolation, the MOE approach was developed to be
used for risk assessment of compounds that are both carcinogenic and genotoxic (EFSA, 2005). In
the present thesis, this MOE approach was the method of choice for the risk assessment of
consumption of different herbal teas and PFS. The MOE approach uses a default cut-off value of
10000; above this value an exposure is considered as a low priority for risk management actions
(EFSA, 2005). The value of 10000 was considered to include all possible uncertainties that may be
involved and affect the risk assessment. The value of 10000 includes a factor of 100 for kinetic and
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dynamic differences between species and within humans, a factor of 10 that presents the variability
in cell cycle control and DNA repair within humans, and a factor of 10 that takes into account that
the BMDL10 represents a 10% Bench Mark Response (BMR) (EFSA, 2005, O'Brien et al., 2006).
The results of the present thesis show some insight into whether for apiol and myristicin the
interspecies factor of 10, including a factor of 4 for differences in toxicokinetics and a factor 2.5 for
differences in toxicodynamics (IPCS, 2010) would be adequate. The PBK model based predictions
for the formation of the ultimate carcinogen for apiol in rat and human showed that at low dose in
human the formation of the ultimate carcinogenic metabolite is 15 times higher than in rat, while for
myristicin the difference was 4-fold. This suggests that a factor of 4 to take into account species
differences in toxicokinetics may be sufficient for myristicin but not for apiol. There is no formal
way to include this consideration in the MOE value used as the cut-off in making a risk management
decision, but if the factor 4 for toxicokinetics would be increased to 15, the default cut-off value may
increase accordingly and more samples could result in MOE values that might be of concern. This
result also illustrates how these PBK model based results may assist the development of compound
specific uncertainty factors and other default values in risk assessment.
Correction for less-than lifetime exposure.
The MOE is based on BMDL10 data that are obtained in long term rodent carcinogenicity studies,
and using EDI values also assuming lifetime exposure. However, exposure to the compounds under
study as indicated in Chapters 4 and 5 may be for only a few weeks and not for a lifetime. In the
present thesis, a framework was applied for assessing the risk to human health resulting from short
time exposures that was proposed by Felter et al. for assessing the risk from less-than lifetime
exposures to carcinogens (Felter et al., 2011). This was done by using the principle of Haber’s Rule.
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Haber’s Rule states that k=C×T where (k) is the toxic outcome, (C) is the concentration (or dose) of
the toxic chemical and T is the time of exposure. Chapter 5 of this thesis describes the application of
Haber’s Rule in the MOE approach to assess the potential risk for exposure to alkenylbenzenes form
use of PFS for short periods of time instead of during a whole lifetime. Assuming a lifetime
exposure to parsley and dill based PFS, MOE values for all samples were below 10000 indicating a
priority for risk management, but when applying Haber’s Rule and assuming consumption of these
PFS for 4 weeks, all MOE values would be above 10000 suggesting a low priority for risk
management. Use of Haber’s Rule for products consumed for shorter periods of time may prevent
overestimation of the actual risk to human health that may occur if MOE values are calculated
assuming lifetime exposure. Applying Haber’s Rule however is not a generally accepted approach
when using the MOE for risk assessment of exposure to genotoxic carcinogens. Felter et al. (Felter et
al., 2011) were the first to propose use of Haber’s Rule for assessing the risk from less-than lifetime
exposure to carcinogens. It is important to acknowledge the assumptions underlying this
methodology, which include the fact that chemical-specific carcinogenicity data should be available
and that the data support a linear dose-response relationship (Felter et al., 2011). Whether such a
linear dose-response relationship would apply to the dose dependent induction of liver tumors by the
alkenylbenzenes remains to be established and is actually a matter for considerable debate in the
field of risk assessment of genotoxic carcinogens that is not yet resolved (EFSA, 2005). The linear
dose-response relationship may depend on the mode of action underlying the carcinogenicity. The
formation of the 1′-sulfoxy metabolite and subsequently formed DNA adducts play an important role
in the alkenylbenzene-induced carcinogenicity. In previous PBK based studies on detoxification and
bioactivation of alkenylbenzenes it was shown that the bioactivation of alkenylbenzenes to their
ultimate carcinogenic 1′-sulfoxy metabolites is linear with the dose, from dose levels as low as levels
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of realistic human dietary intake up to dose levels as high as the BMDL10 inducing liver tumors in
rodent bioassays (Rietjens et al., 2010, Punt et al., 2009, Al-Subeihi et al., 2012). Whether this
linearity in alkenylbenzene bioactivation will also be reflected in linearity of mutagenicity remains
to be established since the mutagenic potential of alkenylbenzene 1′-sulfoxy metabolites has not
been extensively quantified so far. Herrmann et al. (2012) investigated the mutagenic potential of
sulfate conjugates of 1′-hydroxymethyleugenol and showed that different isomeric hydroxylated
metabolites of methyleugenol are mutagenic in an Ames test using Salmonella typhimurium TA100
strains expressing different sulfotransferase enzymes (Herrmann et al., 2012). This suggests that the
formation of the 1′-sulfoxy metabolite and subsequently formed DNA adducts play an important role
in the alkenylbenzene-induced carcinogenicity, and that knowledge of the levels of DNA adduct
formation in human livers at relevant dietary intake levels would be of use to facilitate risk
assessment for low-dose alkenylbenzenes intake. In this respect it is of interest to note that
Herrmann et al. 2013 reported formation of methyleugenol DNA adducts in 29 out of 30 human liver
samples at levels that amounted for the maximal and median levels to 37 and 13 adducts per 108
nucleosides respectively (Herrmann et al., 2013). The results of the present thesis imply that it would
be of interest to look for also other alkenylbenzene DNA adducts in human liver samples. This
possible formation of DNA adducts in human liver may also be investigated by   combining the PBK
models with data on alkenylbenzene concentration-dependent DNA adduct formation in isolated
human hepatocytes to build PBD models as done for rat hepatocytes exposed to estragole previously
(Paini et al., 2010). This study also revealed that not only bioactivation to the reactive 1′-sulfoxy
metabolite but also DNA adduct formation in rat liver was linear with the dose of estragole (Paini et
al., 2012). Such studies in primary hepatocytes are likely to also account for possible repair and
stability of the alkenylbenzene adducts and would thus provide insight in whether formation of
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adducts even during a short period, could have irreversible effects and thus be deleterious, or
whether they are likely to be repaired, thereby decreasing the risk. However, given that linear
extrapolation from tumor data at high dose level to low dose level is generally considered the worst-
case approach for this extrapolation (EFSA, 2005, COC, 2012, Edler et al., 2002) it may equally well
be considered a conservative approach for extrapolation from high to low duration of exposure.
Banding of the MOE cut-off value
The results of the present thesis revealed that MOE values obtained for the different teas and PFS
may vary orders of magnitude, and that MOE values lower than 10000 may vary from being close to
10000 to less than 1000 or even less than 100. At the current state-of-the-art there is no proposal on
how to deal with an MOE of just below or just above 10000. So if use of a preparation results in an
MOE value of 10500 its use would be a low priority for risk management while a sample with an
MOE value of 9500 would be a high priority for risk management. In addition, there is no difference
in the conclusion for a preparation with an MOE of just below 10000 and one that is close to 1 so for
which exposure would be in the range of the doses that induce tumor formation in experimental
animals. Discriminating between these situations to a further extent by banding the MOE cut-off
value might help the risk managers in better defining risk management actions. The Committee of
Carcinogenicity of chemicals in food, consumer products and the environment (COC) proposed a
system of MOE banding as follow: MOE <10,000: May be a concern, MOE 10000-1000000:
Unlikely to be a concern, MOE >1000000 Highly unlikely to be a concern (COC, 2012). But still
this proposal groups all values below the 10000.  One could consider further banding of MOE cut-
off values that are < 10000 as follows: MOE < 1000: Very high concern, MOE = 1000-5000: High
concern, MOE = 5000- 10000: Moderate concern.
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All together it is concluded that an internationally scientific framework to assess and refine the MOE
approach, taking into account shorter than life time exposures and banding of MOE cut-off values
would be of use, and improve the potential of the MOE approach for risk assessment.
Combined exposure to alkenylbenzenes
In the present study chemical analysis revealed that the parsley and dill based products can contain
more than one alkenylbenzene. Therefore combined exposure to these alkenylbenzenes was taken
into account in the risk assessment (Meek et al., 2011, EFSA, 2013, Pose-Juan et al., 2016). In this
combined risk assessment, equal potencies but also different potency of the different
alkenylbenzenes was considered, the latter resulting in definition of so-celled TEF values. In an ideal
situation such TEF values should be based on the endpoint under consideration, i.e. tumor formation.
The carcinogenic potency of alkenylbenzenes was shown in previous studies (Miller et al., 1983,
Phillips et al., 1984, Randerath et al., 1984, Zhou et al., 2007), but these studies focused on only a
few of the alkenylbenzenes under study and did not provide data for myristicin and apiol that could
be compared to those of safrole, estragole and myristicin to set TEF values. Therefore in the present
thesis TEF values were determined using an alternative approach using BMDL10 values obtained via
read-across form safrole but also surrogate endpoints including relative formation of the ultimate
carcinogenic 1′-sulfoxy metabolite and DNA adduct formation upon in vivo exposure. Use of such
surrogate endpoints for definition of TEF values is in line with what has been done for definition of
such relative potencies for other groups of chemicals including for example pyrrolizidine alkaloids
(Merz and Schrenk, 2016) for which interim relative potency factors were defined based on available
literature data on in vitro cytotoxicity, genotoxicity in Drosophila, and acute toxicity in rodents
(LD50) (Merz and Schrenk, 2016). In another study, Botana et al. calculated the relative potency
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factors for a group of marine biotoxins, the so-called diarrhetic shellfish toxins, indicating a priority
for the type of data to be used when defining these potencies: 1)data from human intoxications, 2)
acute toxicity data upon oral administration to animals, 3) acute toxicity data upon intraperitoneal
administration to animals and 4) in vitro data, indicating that use of other data than the ultimate
endpoint relevant for human risk assessment would be feasible (Botana et al., 2017). Another
example can be found in the TEF values derived for dioxins. Van den berg et al. (van den Berg et al.,
2006) defined TEF values for dioxin like compounds based primarily on in vivo experiments but
indicated that if in vivo data were limited, data from the in vitro experiments can be used as long as
there is a structural relationship between the compounds, and they have the same mode of action and
adverse response.
In the present thesis we defined TEF values for the different alkenylbenzene compounds based on
the average of three methods; DNA adduct formation in CD-1mice (Randerath et al., 1984),
(Alajlouni et al., 2016, Al-Malahmeh et al., 2016, Van den Berg et al., 2012, Al-Subeihi et al., 2012,
Punt et al., 2009, Martati et al., 2012) and BMDL10 values for tumor formation in rodent bioassays
(Alajlouni et al., 2016, Al-Malahmeh et al., 2016, Van den Berg et al., 2012). The first method
represents the potency of the compounds to bind to DNA while the second one presents the
formation of the ultimate carcinogenic metabolite at levels representing human intake, while the last
method is based on rodent carcinogenicity data from long term exposure with high dose and/or read-
across from these data. Thus, we used some surrogate endpoints in addition to an endpoint that really
refers to potency for tumor formation, the BMDL10. However, it should be acknowledged that by
using read-across from tumor data on safrole, the BMDL10 values for apiol and myristicin were
actually also in part surrogate endpoints that were not based on experimental tumor data for the
formation of the ultimate carcinogenic 1′-sulfoxy metabolite as predicted by the PBK models
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compounds under consideration. On the other hand, the approach reveals a useful application of
PBK modelling in defining differences in relative potencies for tumor formation without the need for
further animal testing and thus contributing to the 3Rs in safety testing.
Matrix effects in risk assessment of botanicals products
In the present thesis, PBK models that were used to quantify the formation of the ultimate
carcinogenic metabolites were defined for pure compounds. It is of interest to note that teas and PFS
appeared to contain one or more botanicals and their extracts may represent a complex mixture of
bioactive compounds that may interact and thereby increase or decrease the toxicity of the
compound under study. Schilter et al. described that the use of single pure compounds might not
represent a sufficient starting point for risk assessment of botanicals or botanical preparations,
because other compounds found within the matrix may affect the kinetic or dynamic processes of the
compound of interest (Schilter et al., 2003). For example, the bioavailability of β-carotene when
consumed within a matrix of mixed vegetables is about 14% of the bioavailability observed when it
is consumed as pure β-carotene (van het Hof et al., 1999). Jeurissen et al. 2008 studied the effect of
the matrix from basil on estragole bioactivation and DNA adduct formation by using a methanolic
basil extract and found that co-incubation with the extract reduced the level of estragole
bioactivation and DNA adduct formation both in incubations with isolated DNA as well as in HepG2
human hepatoma cells (Jeurissen et al., 2008). Subsequently, Alhusainy et al. identified the
responsible compound that caused the decrease of estragole bioactivation as the flavonoid
nevadensin (Alhusainy et al., 2010). In similar studies it was shown that safrole bioactivation was
inhibited by malabaricone C a compound present in mace together with safrole (Martati et al., 2014).
The inhibition of bioactivation of estragole and safrole was shown to mainly occur through
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inhibition of sulfotransferase mediated bioactivation of these compounds and could be even
demonstrated to occur in an in vivo rodent bioassays using relatively high dose levels (Alhusainy et
al., 2010, Martati et al., 2014). However, subsequent PBK modelling of the effect revealed that at
low doses that represent realistic human intake, the inhibition of the bioactivation as described above
may not occur and the matrix effect on the bioactivation of the compound of interest may be absent
because at such low dose levels the concentrations of the inhibitors in the liver may not reach the Ki
values required for SULT inhibition (Rietjens et al., 2015). Based on this example it appears that for
some compounds use of a pure compound will give a better starting point for the risk assessment at
low dose levels, than using the whole extract. So the study of matrix effects should be done on a
case-by-case basis using approaches that take the mode of action   and the dose dependency of the
interaction into account (Rietjens et al., 2015). Obviously, many compounds present in the matrix of
botanicals and botanical preparations may affect the absorption, distribution, metabolism and/or
excretion of botanical ingredients of interest thereby causing deviations as compared to what would
be observed when testing the pure compound. Given the complexity of such matrix effects the EFSA
working group already has indicated that such matrix effects should be studied on a case by case
basis (EFSA, 2013). Development of mode of action based PBK analysis of such possible matrix
effects can help to investigate whether interactions observed in rodent bioassays at high dose levels
may still be valid at realistic human exposure levels.
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Botanical products quality control
A final issue to consider that may affect the risk assessment of the different herbal products are the
data about the finished product and the quality of the botanical used to produce the product and how
to document such information correctly on the product label (Walker, 2004). Since the herbal
extracts contain many compounds that may not all have a biological activity it is not possible to
name all these compounds on the product label. Instead it would be of use to at least list the active
ingredients and their actual levels in the preparation of interest. This would be of use for both the
beneficial ingredients as well as for the ingredients of concern, the first to not mislead the consumer
and the latter to guarantee the safety of the proposed use and levels of intake. Levels of such marker
ingredients would at the same time be of use for quality control of the respective preparation and at
least reflect adequate quality during the whole production process, including the growing conditions,
storage conditions, details of the extraction procedure, type of final products and any other herbs
used during the production (Sanzini et al., 2011). Applying of such a quality control and labeling of
levels of ingredients of concern will aid the risk assessors and facilitate the risk assessment of these
products. This would also require   validation of analytical methods and reference standards to
identify the active compounds. Adequate chemical characterization of the botanicals and botanical
preparations would also  prevent botanical adulterants and contaminants (Swanson, 2002). Applying
of a good quality control during botanical product preparation with establishment of validated
analytical methods to identify the bioactive compound within these products will facilitate risk
assessment and quality control of the final product. Based on that integrated monitoring plans should
be applied from farming to marketing of botanical products to make sure that all will be performed
under good quality measures and that labeling includes all the required information.
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Conclusion
This thesis examined the risk assessment of parsley and dill based products that contain
alkenylbenzenes using read-across through building of PBK models for two alkenylbenzenes (apiol
and myristicin). This facilitated the estimation of a BMDL10 for apiol and myristicin without the
need for a rodent bioassay. These BMDL10 values were subsequently of use in the risk assessment of
exposure to these two alkenylbenzenes via use of parsley and dill based teas and PFS.  The overall
conclusion of the risk assessment of consumption of parsley and dill based teas and PFS revealed
that daily lifetime consumption of most of these products would be a priority for risk management.
On the other hand, exposure to those products for shorter periods of time will increase the MOE
values to levels > 100000 indicating a low priority for risk management. Thus, it can be concluded
that the risks associated with the use of these teas and PFS would be limited, provided intake is for
only a few weeks during a lifetime. The thesis also provided new proofs of principle of how PBK
model based approaches can facilitate novel non-animal based studies in risk assessment
contributing to the development of alternatives for animal testing.
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Summary
Alkenylbenzenes including estragole, methyleugenol, safrole, elemicin, apiol, and myristicin are
naturally occurring in many herbs such as parsley, dill, basil, tarragon, fennel and nutmeg
(Kreydiyyeh and Usta, 2002, Smith et al., 2002, Semenov et al., 2007). Estragole, methyleugenol
and safrole are genotoxic and carcinogenic in rodent bioassays inducing liver tumors (Boberg et
al., 1986, Boberg et al., 1983, Drinkwater et al., 1976, Miller et al., 1983, Swanson et al., 1981,
Wiseman et al., 1985, Wiseman et al., 1987, Wislocki et al., 1977). Because of that, the use of
methyleugenol, safrole and estragole as pure substances in foodstuff has been prohibited in the EU
from September 2008 onwards (European Commission (EC), 2008). For apiol and myristicin data
for their risk assessment are limited and more research is needed to support the evaluation of the
risk resulting from  consumption of products containing these compounds (WHO, 2009). The aim
of the current thesis was to perform a mode of action based risk assessment of exposure to low
doses of apiol and myristicin by using physiologically based kinetic (PBK) modelling based read-
across from other alkenylbenzenes and to use the results obtained for risk assessment of
consumption of plant food supplements (PFS) and other botanical products containing parsley and
dill.
Chapter 1 provides general background information to alkenylbenzenes especially apiol and
myristicin, a description of the chemical, metabolic and toxicity characteristics of apiol and
myristicin and other structurally related alkenylbenzenes, a brief outline of the method used for
their risk assessment and a short introduction to PBK modelling. Besides that, Chapter 1 include
the aim of the current thesis. In Chapter 2 and Chapter 3, PBK models for respectively apiol and
myristicin in male rat and human were defined, enabling prediction of dose-dependent effects in
bioactivation and detoxification of these alkenylbenzenes. The PBK model based predictions were
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subsequently compared to those for safrole enabling estimation of a BMDL10 for apiol and
myristicin from read-across from the BMDL10 available for safrole, thereby enabling risk
assessment of current dietary exposure to apiol. In Chapter 4 and 5, the risk assessment of exposure
to apiol and related alkenylbenzenes through drinking of parsley and dill based herbal teas and
consumption of parsley and dill containing PFS was performed using the BMDL10 values derived
in Chapter 2 and 3. The results showed that consumption of parsley and dill based herbal teas and
PFS would be a   priority for risk management if consumed for longer periods of time. Chapter 6
includes a general discussion of the thesis results obtained and the future perspectives that describe
the needs to further research, based on alternatives for animals testing, to improve the risk
assessment approaches for different botanical preparations.
Altogether, the results obtained through different thesis chapters show that integration of different
approaches provides the basis for a mode of action and PBK modelling based read-across from
compounds for which tumor data are available to related compounds for which such data are
lacking. This can contribute to the development of alternatives for animal testing and will facilitate
the risk assessment of compounds for which in vivo toxicity studies on tumor formation data are
unavailable.
Chapter 7
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